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ABSTRACT 
 
Objectives  
The objectives were to 1) examine adherence to multiple medications prescribed for a 
chronic disease (intra-disease multiple medication adherence) and that of multiple chronic 
diseases (inter-disease multiple medication adherence); 2) determine appropriate measurement 
paradigm from different intra-disease multiple medication adherence measurement approaches; 
3) identify optimal cut-point for a dichotomized composite measure.   
 
Methods 
A retrospective study design was used.  The subjects came from the MarketScan® 
Commercial Claims and Encounters data 2002-2003 and filled both sulfonylurea (SU) and 
thiazolidinedione (TZD).  Adherence was measured by proportion of days covered (PDC) over 
each period of 30 or 90 days and cumulatively.  Random components from multivariate 
multilevel models were analyzed to examine multiple medication adherence relationships, 
including associations of evolutions of adherence.  Survival analysis was performed on any-
cause or diabetes-related emergency services (ER) utilization.  Concordance statistics were 
computed to compare different measurement approaches.   
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Results 
Intra-disease multiple medication analysis demonstrated strong and significant (p<0.05) 
relationships between overall adherence estimates for SU and TZD and changes in adherence 
estimates over time.  Patients who were receiving lipid or hypertension medications, or both in 
addition to SU and TZD showed strong and significant (p<0.05) relationships between overall 
adherence to cross-disease medications or cross-disease adherence slope estimates.  However, 
such results were not observed in diabetic subjects who were prescribed nitrates for angina.   
Each of six composite measures of intra-disease multiple medication adherence 
significantly predicted hazard (hazard ratio <1.0) of all-cause or any diabetes-related ER 
utilization.  Although each concordance statistic was significant (p<0.05), there were no 
differences among concordance statistics produced by these measurement approaches.  The 
average and all approach showed some superiority.  The optimality of cut-point for categorizing 
adherence based on a composite measure of intra-disease multiple medication adherence ranged 
from 75-85%.   
 
Conclusion  
The study population demonstrated good but not optimal levels of adherence to multiple 
chronic disease medications.  Factors that affect adherence to individual medications appear to 
be related and should be targeted for intervention.  Efficacy of a composite measure of intra-
disease multiple medications may depend on intervention goals.  Further research needs to 
identify a composite measurement approach that demonstrates superiority in predictive and 
discriminatory power consistently.    
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CHAPTER 1 
INTRODUCTION 
Chronic Diseases and Its Implication 
The disease-related pharmaceutical market landscape has been evolving for the last few 
decades.  This evolution is characterized primarily by marked changes in incidence and 
prevalence, and thus importance, of chronic diseases. According to the Centers for Disease 
Control and Prevention (CDC), chronic diseases such as cancer, diabetes, heart disorders, stroke, 
and arthritis are among the most common, expensive, and preventable of all health problems in 
the U.S.  The number of patients with at least one chronic disease is growing in America and 
projected to rise to 164 million by 2025 (Wu and Green, 2000).  Chronic diseases have 
associated with them significant implications.  For example, seven out of 10 deaths annually 
among Americans occur from chronic diseases; heart disease, cancer, and stroke account for 
more than 50% of all deaths each year (Kung et al., 2008).  Moreover, chronic disease patients 
are likely to consume health care resources frequently because of the nature of care they require.   
 
Chronic comorbidities 
It is undeniable that the situation facing the healthcare system today is dire because of the 
increasing prevalence of chronic diseases in the U.S. population.  However, the chronic disease 
crisis looms even larger for tomorrow.  It is imperative that chronic diseases be managed 
2 
appropriately.  Additionally, the challenge associated with the management of chronic disease is 
compounded because many of these patients experience two or more chronic diseases 
simultaneously (multiple comorbidities).  In fact, a consistent pattern has been found currently 
such that many individuals present to the healthcare system with multiple coexisting diseases 
(Starfield, 2006). In the U.S., the number of patients with multiple comorbidities has been 
estimated to increase from 60 million in 2000 to 81 million by 2020 (Mollica and Gillespie, 
2003).  This growth in comorbidities is not confined to any specific segment of population or 
geographic region.  The National Center for Health Statistics (NCHS) reported that 7% of adults 
of 45–54 years of age, 30% of low income adults of 55–64 years of age, and 37% of adults of 75 
years of age and over had three or more chronic conditions in 2005 (NCHS, 2007).  Moreover, 
not all chronic disease necessarily have symptoms associated with them and they may remain 
undiagnosed.  Approximately 10% and 8% of U.S. adults of 20–64 years of age were reported to 
have undiagnosed high cholesterol and elevated blood pressure, respectively in 1999–2004 
(NCHS, 2007).  Thus, it is possible that many chronic disease patients, at some point in time, 
may be suffering from comorbidities the number of which may exceed current estimates.   
The impact of chronic disease and multiple morbidities on the U.S. healthcare system is 
not trivial.  This is so partly because of an increase in number of the elderly population apart 
from some of the reasons discussed above.  In the U.S., about 80% of Medicare spending is 
devoted to patients with four or more chronic conditions and costs increase exponentially as 
number of chronic conditions increases (Wolff, Starfield, and Anderson, 2002).  Health care 
managers increasingly have had to deploy additional resources toward the management of 
chronic diseases and specifically, multiple comorbidities.  This confluence of events has led to a 
growing interest on the part of researchers and practitioners in the impact of comorbidity on 
3 
health outcomes, including mortality, health-related quality of life, and quality of health care 
(Fortin et al., 2007; Ritchie, 2007). 
 
Chronic Disease Treatment and Outcomes 
Treatment Trend 
Prescription drug utilization in the U.S. has experienced a significant change over the last 
decade.  Lundy (2010) reported that from 1999 to 2009, the number of prescriptions dispensed 
increased by 39% compared to a U.S. population growth of only 9%.In addition, the average 
number of retail prescriptions per capita grew by approximately 25% during the same period.  
These findings, at a minimum, suggest that prescription medications are being utilized for the 
treatment of diseases at an increasing rate.   
In addition to an overall increase in medication use, the pattern of medication use unfolds 
an interesting trend.  Physicians frequently recommend multiple therapies for the treatment of 
chronic disease.  This trend – oftentimes described by treatment intensification or therapy 
augmentation – is prevalent largely in chronic disease management and has been facilitated by 
the availability of new products and product classes.  Until the early 1990s, U.S. prescribers had 
only two anti-diabetic drug classes (i.e., insulins and sulfonylureas (SU)) to treat hyperglycemia 
associated with type 2 diabetes.  Several new classes of oral anti-diabetic medications (OAD) 
such as metformin, acarbose, thiazolidinediones (TZD) (pioglitazone and rosiglitazone)were 
introduced to the U.S. market from 1995 to 1999.  The availability of multiple therapeutic 
options gave physicians the opportunity to manage diabetes in ways that directly influenced 
glycemic control and the underlying disease pathophysiology.  The CDC estimated that 14% of 
adult diabetes patients were using insulin and at least one oral medication for diabetes (CDC 
4 
National Diabetes Fact Sheet 2011).  Other anti-diabetic medications that were introduced 
relatively recently, including glucagon-like peptide-1 (GLP-1) analogues, dipeptidyl peptidase-4 
(DPP-4) inhibitors, and lispro insulin are gaining in popularity and more importantly, many 
products including new product classes are currently under development (Nguyen et al., 2011).  
Thus, it is not surprising that antihyperglycemic prescription patterns in the U.S. have changed in 
the last decade.  The trend has included an increasing use of multiple medication regimens 
(Cohen et al., 2003). 
The practice of intensive treatment is advocated in other chronic diseases.  For example, 
an aggressive management of hypertension has been recommended for some patients in the U.S 
(Leeper 2005; Mustone-Alexander, 2006).  As a result, multiple medication regimens are 
prescribed initially or in response to poor outcomes.  This practice may have provided the 
impetus for two-medication combination products; in fact, a combination product of three anti-
hypertensive drugs exists in the market (e.g., Exforge HCT).  Interestingly, the use of 
combination of antihypertensive therapies (i.e., use of ≥2 antihypertensive medication classes) 
was higher in the U.S. when compared against European countries (Wang et al., 2007).  
Similarly, multiple medication regimens are the treatment norm in other chronic conditions 
including those in which multiple classes of medications are prescribed.  For example, a number 
of pharmacological agents are prescribed to treat the underlying causal factors, including 
hypertension, coronary artery disease, and dyslipidemia in patients with heart failure.  Wong et 
al. (2011a) reported that there has been a significant change in heart failure patient characteristics 
over the last two decades; along with an increasing number of comorbidities, the mean number 
of prescription medications has grown from 4.1 to 6.4 prescriptions.  Similarly, a U.K. study of 
patients suffering from diabetes, hypertension, and lipid disorder reported that approximately 
5 
50%, 20%, and 30% of subjects were receiving 3, 4-5, and 6 or more medications, respectively 
(Stack et al., 2010). 
 
Medication Adherence and Its Implications  
Appropriate medication consumption behavior is critical to chronic disease management.  
In general, rates of adherence to medication regimens are low in patients with chronic conditions.  
An estimated 33-50% of all patients do not take their medications as prescribed (Horne, 1999; 
Osterberg and Blaschke, 2005).  Likewise, persistence with chronic disease medications is also 
low as many patients with chronic conditions oftentimes discontinue treatment within a few 
months of initiation.  One study found that while adherence was approximately 80% in the first 3 
months of treatment, the adherence rate to anti-hyperlidemic medications reduced to 56% within 
6 months and only one in four patients showed an adherence level of 80% or more after 5 years 
(Benner et al., 2002).  Among a large cohort of patients who were suffering from coronary artery 
disease, over 25% of patients discontinued their medication within 6 months and only 74% of 
patients were adherent to all prescribed medications just 120 days after an acute myocardial 
infarction (MI) (Jackevicius, Mamdani, and Tu, 2002). In spite of evidence supporting the use of 
pharmacotherapy, patients do not appear to demonstrate appropriate medication use behaviors.   
Large-scale studies have confirmed repeatedly that pharmacological treatment can reduce 
adverse outcomes associated with chronic diseases.  However, the reduction of the occurrence of 
potential adverse outcomes depends on patients’ ability to follow their prescribed medication 
regimens.  The relationships between poor adherence and desirable treatment outcomes have 
been examined.  Various outcomes that have been studied include clinical parameters (e.g., 
systolic or diastolic blood pressure, HbA1c, or lipid profile) or adverse events (e.g., 
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hospitalizations or emergency room visits).  Patients who were highly adherent to 
antihypertensive therapy (AHT) were more likely to achieve blood pressure control than those 
with medium or low adherence (Chapman et al., 2005).  Similarly, ‘good’ adherence to 
pharmacotherapy was associated with a host of positive health outcomes.  A study investigating 
the relationship between antihypertensive therapy use and the risk of MI/stroke reported that 
patients who stayed with the therapy were at significantly lower risk of myocardial infarction 
(MI) or stroke than who did not (Charles et al., 2003).  Additionally, adherence to medication 
regimens has been shown to reduce the risk of hospitalization or emergency room (ER) visits.  
Sokol et al. (2005) examined the relationship between adverse health outcomes and poor 
adherence in patients with diabetes, hypertension, high cholesterol, and congestive heart failure 
to examine the relationship between poor adherence and adverse health outcomes.  In all four 
conditions, hospitalization rates were significantly higher for patients with low medication 
adherence and there were 26% and 18% reductions in hospitalization or ER visits over a 2-3 year 
period among diabetes patients and hypertension patients, respectively, who were adherent to 
treatment.  A negative association between adherence and mortality has also been reported (Ho 
et al., 2006a; Rasmussen, Chong, and Alter, 2007; Simpson et al., 2006).  For example, one-year 
mortality was significantly higher in patients who were taking only some of their medications 
compared to those adherent to all medications (Jackevicius, Li, and Tu, 2008).  More 
importantly, similar associations, including those against all-cause mortality, hold for different 
medication classes (e.g., statins and β-blockers) (Rasmussen, Chong, and Alter, 2007; Wei et al., 
2002).   
In spite of the strong association of adherence with positive outcomes, nonadherence to 
medication remains a significant public health problem.  A report by the World Health 
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Organization (WHO) states that nonadherence to medications for chronic disorders such as 
hypertension, dyslipidemia, and diabetes leads to reduced health benefits and serious economic 
consequences in terms of wasted resources including time and money (WHO, 2003).  Poor 
medication adherence is a source of waste in health care systems or avoidable medical spending 
in the U.S. because it gives rise to unnecessary health risks, particularly for patients with chronic 
illnesses (New England Healthcare Institute (NEHI), 2009).For a typical, mid-sized employer 
that spends $10 million in medical claims, poor adherence is associated with avoidable 
healthcare expenditures of about $1 million annually (NEHI, 2009).  Poor adherence or 
nonadherence has been shown to result in $100 billion each year in excess hospitalizations alone 
(Osterberg and Blaschke, 2005).  In addition to poor health outcomes that translate into societal 
costs, overall health care costs are much higher for patients with poor adherence.  The annual 
healthcare costs were estimated to be $8,886 for diabetes patients with high levels of adherence 
as compared to $16,498 for those with low levels of adherence (Sokol et al., 2005).  
Additionally, a 10% increase in adherence was associated with 2% and 4% decrease in total 
health care costs and diabetes-related medical care costs respectively (Shenolikar et al., 2006).  
However, the association between costs and adherence is not clear. Medication adherence was 
positively associated with lower disease-related medical costs in chronic conditions such as 
diabetes and hypercholesterolemia (Sokol et al., 2005); however, evidence contrary to what 
mentioned above exists also (e.g., Karve et al., 2008).  Because 75% of U.S. health care spending 
is used for the treatment of chronic disease (CDC, 2009), the role of adherence in chronic disease 
management, improving the efficiency in the health care system, and achieving desired health 
outcomes cannot be overemphasized.   
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Need for the Project 
Decades of research has advanced our understanding of patient adherence to medication.  
A range of perspectives including medicine, pharmacology, psychology, and nursing (Russell et 
al., 2003) have been employed to examine adherence behavior.  A host of factors, both internal 
(e.g., personality) and external (e.g., socio-cultural), (see Cameron, 1996 for a review) have been 
implicated.  Some of these factors offer a simplistic but, to some extent, successful model 
explaining patient adherence.  Other approaches emphasize the complex, dynamic, and 
reciprocal nature of relationships among the factors affecting adherence including how patients 
cognitively interpret and act on their illness and associated symptoms (Bishop, 1991; Leventhal, 
Diefenbach, and Leventhal, 1992).  In spite of these effects, several questions related to 
adherence remain unanswered.  Specifically, there is a dearth of understanding about the 
consistency of adherence behavior within a disease and across diseases and the state of change of 
such behaviors in patients over time.  
Multiple therapies are often prescribed for patients suffering from chronic diseases.  
Indeed, treatment intensification is advocated and advised earlier in the patient’s treatment for a 
chronic condition (Grant et al., 2011). Thus, multiple medication regimens may occur because of 
multiple medications intended to treat a single disease or because of the need to treat 
comorbidities.  While treatment intensification and treatment of comorbidities have become the 
norm, new issues arise as a result of such practices.  Further examination of intra-disease and 
inter-disease multiple medication adherence are warranted.  Another important issue is the 
measurement of intra-disease multiple medication adherence, including the selection of right 
measure.  These issues seem relevant and merit empirical exploration.  
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Study Aims: 
The present study has several aims.  The hypotheses and objectives associated with these 
aims are discussed in Chapter 2. Specifically, this study:  
1. examined adherence to multiple medications prescribed for the treatment of a chronic 
disease (intra-disease multiple medication adherence behavior); 
2. examined adherence to multiple medications prescribed for the treatment of different but 
related chronic diseases (inter-disease multiple medication adherence behavior); 
3. proposed a composite measure for the estimation of adherence to multiple medications 
prescribed for the treatment of a chronic disease; 
4. compared the existing methods and the proposed method of estimating adherence to 
multiple medications prescribed for the treatment of a chronic disease; 
5. calibrated the intra-disease multiple medication adherence measurement approaches 
including the composite measure.  
 
Significance 
The rising prevalence of chronic disease, including diabetes, hypertension, and 
hyperlipidemia is a recognized public health concern.  For patients on intensified treatment 
regimens or multiple medications, the concern is increased due to the risk of adverse 
consequences associated with inadequately controlled or uncontrolled disease.  The practice of 
prescribing multiple medications for a chronic disorder has increased recently and is expected to 
continue in the future due to the aging U.S. population, increase in knowledge of disease, and the 
availability of newer classes of medications.  Although chronic disease patients may be managed 
with a single fixed-dose combination medication, this option is not always available for all 
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patients.  Thus, the importance of understanding multiple medication adherence within a disease 
or across diseases is and remains an important issue facing the healthcare system.  It is believed 
that this information on multiple medication adherence may act as trigger to providers and will 
guide clinicians, pharmacists, healthcare managers, and policy makers to formulate strategies to 
improve medication adherence and design interventions to promote health behaviors.  As various 
suggestions (e.g., synchronization and scheduling) (Agarwal et al., 2009) have been made to 
improve medication adherence, the applicability of these strategies will be strengthened by the 
knowledge about intra-disease and inter-disease multiple medication adherence behavior.  
Indeed, profiling patients based on adherence patterns will help with designing subsequent 
interventions.   
Assessing or measuring medication adherence is the first step in order to understand 
nonadherence and lay the groundwork for interventions for improving adherence (Morisky et al., 
2008).  Although many measures of adherence exist (see McCaffrey, 2011 for a review), most 
were developed to evaluate adherence to individual medications or medication classes.  Thus, an 
examination of these measures in situations where patients are prescribed multiple medications 
for a disease is important.  In a market where implementation of quality initiatives and 
performance-based incentives are increasingly advocated and emphasized (Lee, 2007), the 
question about measuring multiple medication adherence occupies a central position.  The lack 
of informed thought, as it is now, is going to constrain the appropriate assessment of adherence 
to multiple medications and hamper the quality of patient care.  Moreover, the effect of metric 
choice must be known in order to provide guidance and consistency in the adherence literature.  
In particular, an empirical rationale about measure choice while examining multiple medication 
adherence is needed for practitioners, researchers, and policy makers alike.   
11 
 
 
 
 
 
CHAPTER 2 
LITERATURE REVIEW 
Adherence Research  
Adherence to medication has been a focus of much research for, at least, the last five 
decades.  Apart from a nearly uncountable number of primary studies that have been conducted 
on adherence/compliance, the number of reviews and meta-analyses of studies on the same topic 
is not small.  The breadth and depth of past research on adherence is extremely large and a 
thorough discussion is beyond the scope and objective of this chapter.  It is well known that 
many factors affect adherence.  Researchers have attempted to categorize these factors into 
different dimensions deemed to be most important.  For example, the WHO (2003) describes five 
sets of factors as being influential on medication-taking behaviors of patients.  These are 
socioeconomic, patient-related, therapy-related, condition-related, and healthcare team-related 
factors of adherence.  However, there is little consensus regarding the optimal categorization of 
factors that influence adherence.   
 
Adherence to Chronic Disease 
Given the prevalence and overarching impact of chronic diseases, adherence to chronic 
disease medications has been extensively investigated empirically.  In general, these studies are 
conducted within a disease category such as diabetes (Adams et al., 2008), hypertension (Morrell 
et al. 1997), dyslipidemia (Huser, Evans, Berger, and 2005), heart failure (Dunlay et al., 2011), 
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ischemia (Carney et al., 1998), myocardial infarction (Maio et al., 2011), stroke (Khan et al., 
2010), and so on.  While some studies focused on a single class of medications or a single 
product within a disease (e.g., Kogut et al., 2004; Pladevall et al., 2004; Shenolikar et al., 2006), 
others focused on multiple medications, including multiple therapeutic classes within a disease 
(e.g., Alvarez Guisasola et al., 2008; Dunlay et al., 2011; Guillausseau, 2003) or on a single 
medication across diseases (e.g., Thavendiranathan et al., 2006).   
On average, there is not much difference in adherence estimates among different chronic 
disease categories. A meta-analysis concluded that adherence rates, measured by 12-month 
medication possession ratio (MPR), in antihypertensive, anti-diabetic, and anti-hyperlipidemic 
medication(LIP) categories varied between 67% and 76% and were not significantly different 
(Cramer et al., 2008).  However, it is not uncommon to find individual studies reporting lower 
rates of adherence to pharmacotherapy.  For example, one U.S. study reported that the average 
antihypertensive adherence was 49% among elderly patients initiating therapy (Monane et al., 
1996).  Likewise, a systematic review of studies reported that adherence rates in diabetes varied 
widely among oral agent-only (36%-87%) versus concomitant or insulin-only (54%-81%) 
regimens (Lee et al., 2006).  Adherence within a disease may vary depending on therapeutic 
class or subclass.  For example, Wogen et al. (2003) compared adherence rates of amlodipine, 
lisinopril, or valsartan.  These medications belong to three different pharmaceutical subclasses 
calcium-channel blocker (CCB), angiotensin-converting enzyme inhibitor (ACEI), and 
angiotensin receptor blocker (ARB), respectively and were found to exhibit significantly 
different average MPRs (75% for valsartan, 67% for amlodipine, and 65% for lisinopril).  Other 
studies have examined different measurement approaches to examine adherence.  One such 
method is analyzing dichotomized adherence rates.  Dunlay et al. (2011) investigated 6-month 
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adherence rate among community dwelling heart failure patients; proportions of patients who 
had poor adherence based on medication possession (proportion of days covered (PDC)< 80%) 
to β-blockers, ACEIs/ARBs, and statins were 19%, 19%, and 13%, respectively.  Monane et al. 
(1996) reported only 23% of hypertension patients showed adherence levels of 80% or greater 
measured over a year.   
Alternatively, studies have examined persistence with therapy or duration with therapy 
before discontinuation.  Unlike adherence rates, persistence rates were somewhat similar for 
different product categories.  An analysis of 139 studies that focused on diabetes, hypertension, 
dyslipidemia, and other cardiovascular diseases revealed that only 63% of patients continued 
with their medication for one year (Cramer et al., 2008).  Persistence appears to have strong 
relationship with time; in general, persistence decreases over time.  A systematic review reported 
that treatment persistence with OAD ranged from 16 to 80% in patients who continued their 
treatment for 6-24 months and discontinuation time ranged from 83-300 days (Cramer, 2004).  
Approximately 10-30% of type 2 diabetes patients enrolled in a Medicaid population were found 
to withdraw from SU regimens within one year of diagnosis (Sclar et al., 1999).  Persistence fell 
less sharply from 97% at 1 year to 82% at 4.5 years for patients with established hypertension 
compared to that of 78% and 46% over the same period for those with newly diagnosed disease 
(Caro et al., 1999).  Persistence with anti-hyperlipidemic medications is lower in primary 
prevention than in secondary prevention.  Perreault et al. (2005) observed that persistence with 
statin fell from 71% after 6 months of treatment to 45% after 3 years in the secondary prevention 
cohort, while the corresponding values in the primary prevention cohort were 65% and 35% 
respectively.  Ho et al. (2006b) evaluated the early discontinuation of β-blockers, aspirin, and 
statins among acute myocardial infarction patients.  One month after treatment initiation, the 
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authors reported, 12.1%, 3.7%, and 17.9% of patients discontinued all three drugs, two out of 
three drugs, and one drug, respectively, while approximately 66% of patients continued taking all 
three medications.  Likewise, persistence to medications has been examined across disease 
states.  In elderly patients (≥ 65 years) the two-year adherence rate (measured as medication 
being dispensed at least every 120 days) to statin treatment was about 40% in patients with a 
recent diagnosis of acute coronary syndromes (ACS), 36.1% in patients having chronic coronary 
heart disease (CHD), and 25.4% in primary prevention patients (Jackevicius, Mamdani, and Tu, 
2002).  Interestingly, the average persistence rate across the studies conducted in Europe was 
61.7% over an average observation period of 17 months, while that of the U.S. studies was 
51.1% observed over a mean period of 21 months (Cramer et al., 2008).  Hudson, Richard, and 
Pilote (2007) investigated the patterns of prescription and discontinuation of anti-platelet agents, 
β-blockers, ACE inhibitors and/or ARBs, and statins in all post-AMI (acute myocardial 
infarction) patients; the rates of discontinuation increased significantly during follow-up and had 
a parabolic shape with the youngest and oldest patients having the highest rates.   
Medication adherence in different chronic conditions has been studied together within a 
sample (i.e., within a single study).  Usually, these studies have shown modest variation in 
adherence across different chronic disease categories.  For example, Briesacher et al. (2008) 
compared drug adherence rates among patients with hypercholesterolemia, hypertension, 
hypothyroidism, seizure disorders, and type 2 diabetes mellitus (T2D) in a commercially insured 
population.  Approximately 72% of subjects with hypertension achieved adherence rates of 80% 
or better compared with 68.4%, 65.4%, 60.8%, or 54.6% for those with hypothyroidism, type 2 
diabetes, seizure disorders, and hypercholesterolemia, respectively.  Khanna et al. (2012) 
compared population adherence rates in a Medicaid population across different diseases, 
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including diabetes, hypertension, and dyslipidemia.  On average, adherence rates were poor in 
the population such that approximately 35-42% patients showed adherence rate ≥ 80%.   
 
Adherence and Demography  
Medication adherence is a function of several factors, including individual characteristics.  
Early research on determinants of adherence focused primarily on demographic factors, not to 
say that such studies are not carried out any more.  Indeed, many investigations were conducted 
within specific demographic segments such as age (e.g., Benner et al., 2002), gender (e.g., Khan 
et al., 2010), and race (e.g., Adams et al., 2008).  In the classic review by Sacket and Haynes 
(1976), no clear relationship emerged between adherence and demography, including gender, 
race, ethnicity, education, marital status, and income.  Many studies included specific age groups 
that ranged from a relatively young group of patients of 20-49 years (Okano et al., 1997) to 
elderly cohort aged 65 years or older (Monane et al., 1997).  Patient age has been found to 
predict adherence more consistently than other demographic characteristics.  Yet, some studies 
reported positive association of adherence to medication (e.g., AHTs or OADs) and age (Ren et 
al., 2002; Venturini et al., 1999) while other studies failed to do so (Coons et al., 1994; 
Evangelista et al., 2003).  The relationship between age and adherence, however, may not be 
linear.  Morrell et al. (1997) reported that the younger old, (e.g., 60-70 years), demonstrated the 
highest levels of adherence to AHTs, whereas the adherence levels of those over 75 years were 
the lowest.  Indeed, the study concludes, adherence was problematic for those over 75 years.  In 
light of such finding, it appears that the differential impact of age on medication adherence may 
be affected by some other factors.  Park (1999) argued such effects may be mediated by 
cognitive changes or other age-related factors.   
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Adherence: Trait and Intention  
Researchers have searched for stable characteristics that affect adherence.  Dispositional 
characteristics that affect general behaviors have been examined.  Specifically, associations have 
been examined between personality factors and adherence to medications in chronic diseases, 
including diabetes and hyperlipidemia (Axelsson et al., 2009; Christensen and Smith, 1995; 
Stilley et al., 2004).  Past research has shown that conscientiousness, a personality trait reflecting 
methodical and industrious behavior, is associated with treatment adherence (Christensen and 
Smith, 1995; Stilley et al., 2004).  However, the associations with personality traits have not 
been supported consistently.  Using a medication events monitoring system (MEMS), Insel, 
Reminger, and Hsiao (2006) investigated the association between personality and adherence in 
older community dwelling adults who were using chronic medications, including AHT and LIP.  
The study found no association with conscientiousness but it did found negative associations 
with other personality factors, namely self-reliance and independence.  Recently, an 
observational study found that no personality traits except neuroticism were associated with 
medication nonadherence over 6 years of follow-up in a sample of elderly patients receiving an 
alternative (herbal) medication (Jerant et al., 2011).  It is possible that these characteristics work 
in conjunction with other factors.  For example, the interaction between conscientiousness and 
health beliefs was found to predict adherence among hemodialysis patients (Wiebe and 
Christensen, 1997).  Thus, the influence of personality factors may be less clear or conditional on 
other variables.  In addition, with evidence showing that there may be marked inter-individual 
and intra-individual variation in adherence to different medications or different aspects of 
treatment over time (Cleary et al., 1995; Kruse and Weber, 1990), defining patients by stable 
characteristics, which could be speculated to constitute ‘compliant patient’ or ‘noncompliant 
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patient’ is not practically sensible or theoretically tenable.  At most, as suggested by Horne 
(1998), they can influence some but not others and this has led to exploration of the interaction 
of patients with their disease and treatment.   
A patient may make decision, consciously or subconsciously, about adherence to 
medications.  It has been argued that such decision-making is related broadly to distinct types of 
medication nonadherence – intentional nonadherence and unintentional nonadherence – and 
potentially contribute to observed patterns of adherence behaviors (Clifford, Barber, and Horne, 
2008; Johnson 2002; Morisky, Green, and Levine, 1986; Stack et al., 2010).  While intentional 
nonadherence describes an active process in which the patient makes a conscious decision about 
deviating from a medication regimen, unintentional nonadherence represents a passive process in 
which the patient may deviate from appropriately following the treatment regimen because of 
carelessness or forgetfulness (Morisky, Green, and Levine, 1986).  Past research has examined 
these mechanisms empirically in chronic care management.  Using a self-report measure, Lowry 
et al. (2005) examined adherence to antihypertensive medications among veterans and found that 
approximately 9% of the study subjects reported intentional nonadherence and 31% reported 
unintentional nonadherence.  Stack et al. (2010) measured self-reported intentional and 
unintentional nonadherence to differing numbers of medicines prescribed in type 2 diabetes 
patients and found no difference in intentional nonadherence.  Among patients receiving OADs, 
AHTs, and statins; the authors noted, while intentional nonadherence to statin significantly 
increased with number of medicines prescribed, unintentional nonadherence was higher for some 
medicines than for others (e.g., OAD adherence < AHT or statin).  Similarly, Wroe (2002) found 
that different reasons or beliefs with regard to utility were associated with intentional adherence 
as opposed to unintentional adherence among asthma patients.  Other researchers examined a 
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number of other factors including complexity, type, and knowledge of medication regimens and 
presence of co-morbid conditions (Barr et al., 2002; Horne, 1998; Lehane and McCarthy, 2007) 
to explore the unintentional nonadherence.  Thus, it appears that varying levels of both the 
intentional and the unintentional dimensions of medication taking may occur simultaneously.  It 
is recommended that simultaneous examination of the intentional and unintentional dimensions 
of nonadherence be considered for the sake of comprehensive understanding of the factors of 
nonadherence (Lehane and McCarthy, 2007; Johnson, 2002), although these dimensions may 
have varied motivational or psychosocial factors associated with them.   
 
Psychological Factors in Adherence: Health and Disease Beliefs and Attitudes  
Several theoretical models in social psychology have been adapted to explain variations 
in adherence to treatment.  These theories can be broadly categorized into two groups: Social 
Cognition Models (SCM) and Self-regulatory Theory.  The social cognitive perspectives focus 
on attitudes and beliefs or expectancies as major determinants of health behavior (Conner and 
Norman, 1996).  They assume that patients undertake cost/benefit analyses as a motivating factor 
to act.  Subjective weighting of the benefits, barriers, and consequences of behaviors provide the 
motivation for actions.  Several theoretical models fall under this group(e.g., the Health Belief 
Model (HBM), the Theory of Reasoned Action (TRA), the Theory of Planned Behavior (TPB), 
and the Social Learning Theory).  The HBM has been utilized in studies of medication adherence 
across several diseases including hypertension (Cronin, 1986) and diabetes (Brownlee-Duffeck 
et al., 1987).  The TRA and TPB constructs have been useful in predicting adherence to 
prescription medications (Miller, Wikoff, and Hiatt, 1992; Reid and Christen, 1988).  The 
concept of locus of control - more specifically, multidimensional health locus of control (HLC) 
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(Wallston, Wallston, and Devellis, 1978) - has been applied in the health care context.  The HLC 
beliefs provide inconclusive or inconsistent evidence and remain fairly weak predictors of 
adherence behavior (see Horne and Weinman, 1998 for a discussion).  Disease-specific HLC 
beliefs have also been advanced.  The use of condition-specific HLC measures appears to 
improve the utility of the framework.  For instance, disease-specific locus of control measures 
have been associated with adherence to diabetes care and hypertension (Bradley et al., 1990; 
Kohlman et al., 1993; Stanton, 1987).  Several studies have combined constructs from different 
theories were combined to examine patients’ adherence behavior.  For example, Reid et al. 
(1985) used the HBM and the TRA to examine intention to comply with antihypertensive 
regimens.  Efficacy beliefs (e.g., outcome efficacy and self-efficacy) and HBM constructs were 
examined among patients who were compliant or noncompliant to tuberculosis treatment 
(Barnhoorn and Adriaanse, 1992) or for predicting adherence with an over-the-counter acne 
medication (Flanders and McNamara, 1984).  Wang et al. (2002) used health beliefs based on the 
TRA and LOC beliefs to examine medication nonadherence in hypertension patients.   
Although Social Cognitive Models have been extensively used, they are not devoid of 
criticism.  Rationality of health-related behavior, a fundamental premise of SCMs, is questioned.  
Indeed, some health behaviors appear to be habitual or routine and may not always be 
characterized by rational decision-making.  Moreover, the dynamic nature of health behavior is 
often ignored.  In an attempt to explain the dynamic relationships among cognitions, motivations, 
and behaviors, Leventhal and colleagues developed the Self Regulatory Model (SRM) - a self-
regulatory framework for understanding illness perceptions (Leventhal, Diefenbach, and 
Leventhal, 1992; Leventhal et al., 1997).  The fundamental premise of the SRM is that patients 
are active problem solvers who respond to illness in a dynamic and specific fashion based on 
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their interpretation and evaluation of illness and its symptoms (more discussion follows).  The 
role of illness representation in explaining adherence decisions have been examined empirically 
and illness representations (i.e., patient’s own beliefs about illness) were associated with 
treatment adherence among chronic disease patients (Bane, Hughes, and McElnay, 2006; 
Gonder-Frederick and Cox, 1991; Meyer et al., 1985).   
 
Patient-Provider Interaction and Associated Impacts on Adherence 
Chronic disease care requires a long-standing interaction between a patient and a health 
care provider.  Thus, the patient-provider relationship is important for the success of chronic 
diseases management.  Researchers have recognized factors that characterize the quality of 
patient-provider interactions as important determinants of medication adherence.  Interaction 
quality, including the state of collaboration between a provider and a patient, behaviors and 
attitudes of healthcare professionals, and amount of time spent with patients in a supportive 
environment discussing medications or diseases (Arbuthnott and Sharpe, 2009; Cameron, 1996; 
Kiortsis et al., 2000) have been examined for their effect on medication adherence.  A specific 
aspect of the patient-physician interaction that has been extensively investigated is the role of 
communication.  A meta-analysis of 106 studies found a positive relationship between physician 
communication and adherence (Zolnierek and Dimatteo, 2009).  Piette et al. (2003) examined 
dimensions of communication; both general communication and diabetes-specific 
communication were correlated independently with patients’ self-reported adherence to 
hypoglycemic medications.  Thus, it is believed that an appropriate collaborative relationship 
between a patient and a provider may improve medication adherence.  As may be expected, one 
of the basic communication goals is to improve patient’s knowledge about various aspects of 
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disease or treatment.  Numerous studies have been conducted to examine the effects of 
knowledge of disease and medication on adherence.  Although there is some conflicting 
evidence, in general, a positive correlation has been found between knowledge and adherence to 
chronic disease medications (Cuspidi et al., 2001; McDonald, Garg, and Haynes, 2002).  In 
addition, patient-centered, communication-driven interventions, such as disease management 
programs, are thought to facilitate the management of chronic care and help patients in their 
effort to self-care.  In fact, disease management has been implemented to educate chronic 
disorder patients and support self-management skills and reported to improve adherence to 
treatment recommendations (Fitzner et al., 2005; Thiebaud et al., 2008).  Indeed, disease 
management is widely recommended for patients on multiple medications.   
 
Adherence and Treatment Intensification 
Adherence to medication assumes importance because of its profound role in achieving 
desired therapeutic benefits.  In other words, that nonadherence to medications may potentially 
lead to adverse consequences is of great public health concern and reasons for such concerns 
have been discussed in the previous chapter.  Thus, adherence enhancement occupies a central 
role in chronic disease management in that it helps achieve treatment goals.  Another potential 
way to achieve treatment goals is through intensification of therapy.  Specifically, therapy 
intensification (TI) can occur through an increase in dosage of a medication that is already being 
consumed by the patient for a disease, an addition of a medication or multiple medications to the 
patient’s prescribed regimen intended for the disease, or switching to a new class of medication 
(Rodoni et al., 2006; Schmittdiel et al., 2008).  As such, the relationship between adherence and 
treatment intensity is important for research purposes due to its clinical implications.  A survey 
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of physicians reported that those who intensified therapy in patients with type 2 diabetes were 
more likely to consider issues such as patient adherence and medication costs (Grant et al., 
2009).  Some researchers have addressed whether physicians are likely to increase therapy 
depending on patient adherence (Grant, Singer, and Meigs, 2005; Heisler et al., 2008).  
Nonadherence was not related to the subsequent addition of a second drug in diabetes patients 
(Kogut et al., 2004).  Others suggest that there may be an interaction between adherence and 
disease.  Poor adherence was reported to inhibit intensification of diabetes therapy but not that 
for antihypertensive medications in diabetes patients (Voorham et al., 2011).  The extent of lack 
of therapy intensification among adherent patients has also been investigated.  Among diabetes 
patients with no evidence of poor adherence, the lack of treatment intensification was found in 
30% , 47%, and 36% of patients for hyperglycemia, hyperlipidemia, and hypertension treatment, 
respectively (Schmittdiel et al., 2008).  On the contrary, Grant et al. (2007) reported that diabetes 
patients with poor adherence were less likely to have their regimen increased and time to 
intensification was negatively associated with adherence in poorly controlled patients.  
Researchers have examined the relationship between TI and adherence in achieving desired 
control over time.  Rose et al. (2009) observed that treatment intensification was associated with 
improvement in blood pressure regardless of the patient’s level of adherence.  However, other 
researchers have concluded that achieving desired treatment goals is a function of a combination 
of intensification and adherence; therapy intensification must be coupled with interventions to 
improve medication adherence (Ho et al., 2008).  Although no consensus exists regarding the 
role of adherence in intensification of therapy, it can be posited at a minimum that the full benefit 
of therapy intensification cannot be realized without adequate adherence.   
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Adherence to Multiple Chronic Disease Medications 
It has been well established that underutilization of medications is a major problem in 
health care.  In general, studies on medication utilization focus on a single therapeutic class of 
medications.  A meta-analysis undertaken to examine studies related to adherence to diabetes, 
hypertension, and dyslipidemia medications concluded that over 80% of the 139 studies that 
were reviewed investigated only one therapeutic class (Cramer et al 2008).  Although a few 
studies exist that have compared adherence rates across different disease categories in a single 
study (e.g., Khanna et al., 2012), they did not analyze simultaneous adherence to multiple 
medication regimens.  This approach (i.e., considering adherence within a single disease 
category) is not much insightful because it is well known that the presence of multiple chronic 
comorbidities is now more of a norm than an exception. Moreover, this approach is not 
consistent with the recommendation of aggressive treatment of comorbidities.   
Only a few published studies have examined concomitant adherence to medications 
prescribed for multiple chronic diseases.  Chapman et al. (2005) investigated patterns and 
predictors of simultaneous adherence to newly initiated antihypertensive and anti-hyperlipidemic 
therapies.  Using a dichotomized measure of adherence, the researchers concluded that 44.7% 
and 35.8% of the patients were adherent with both antihypertensive (AH) and anti-
hyperlipidemic (LIP) medications at 3 and 12 months after medication initiation respectively; 
however, at each time, approximately an additional 25%-29% of the subjects demonstrated PDC 
≥ 80% to either AHT or LIP.  Concomitant medication consumption behavior has been 
examined, although less explicitly, in other disease conditions.  For example, patients receiving 
long-term dialysis demonstrated higher adherence to antihypertensive and calcitriol therapies 
than their phosphate binder regimens (Cleary et al., 1995).  Preferential or selective adherence 
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was shown to be prevalent in kidney transplant patients.  A cross-sectional study of kidney 
transplant patients compared adherence rates over a month for nonimmunosuppressive 
medications (i.e., AHT, LIP, and anti-diabetic agents) and immunosuppressive medications; 
more patients were reported to be selectively more adherent to immunosuppressive medications 
and nonadherent in the former therapeutic category were more likely to have diabetes (Terebelo 
and Markell, 2010).  A study was conducted to examine medication use in patients who were 
discharged from hospital after acute myocardial infarction with prescriptions for aspirin, statin, 
and β-blockers; while 34% of the patients discontinued at least one medication, 12% stopped all 
three medications within a month of hospital discharge (Ho et al,. 2006b).  A small study with 
diabetes patients who had asthma reported that the pattern of diabetes and asthma medications 
had a similar dispensation interval among 52% of the patients (Krigsman, Nilsson, and Ring, 
2007).  However, the refill adherence rate for diabetes medication was higher than that for 
asthma medication with no correlation between adherence levels.  Adherence to medication for 
one disease has been examined as predictor of adherence for another disease.  Diabetes 
medication adherence, for instance, was associated positively with odds of being adherent to 
statin medication in a university employee population (Kumar and Holiday-Goodman, 2010).  
Simultaneous adherence across therapeutic classes has been examined among patients with 
psychiatric as well as physical comorbidities.  A study with patients who were using medications 
for schizophrenia, diabetes, and hypertension examined differential medication adherence (Piette 
et al., 2007).  Intra-patient adherence rates as measured by MPR across therapeutic classes, the 
authors noted, were correlated modestly; while the correlation of MPRs for hypertension and 
diabetes was the highest, there were weak but significant correlations between MPR for 
antipsychotic medications and MPR for each of the two physical conditions.  MPR for 
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antipsychotic medications explained only 13% and 16% of the variance in that for 
antihypertensive and hypoglycemic medications, respectively.  In addition, patients were more 
likely to show poor adherence for antihyperglycemic and antihypertensive therapies than for 
antipsychotic therapy (Piette et al., 2007).   
Relatively few studies have examined selective adherence over a long period of time.  
Indeed, such research is insightful in that it has the ability to guide in understanding changes 
within an individual.  Nichol et al. (2009) examined the transition probabilities of patients 
receiving both LIP and AHT therapies among different adherence categories (i.e., fully adherent, 
partially adherent (0.2 ≤ PDC < 0.8), and nonadherent) over a period of six years.  The study 
reported that patients showing full adherence to both medications at the beginning were more 
likely to maintain their adherence status and patients who were partially adherent to one and 
fully adherent to the other were more likely to elevate to the adherent status for both 
medications.  The results of the study are interesting in that they suggest the presence of an 
adherence trait.  However, other variables (e.g., comorbidity profile, beliefs, etc.) that were not 
evaluated may explain further the results.  The study found an association between type of 
medication and transition to nonadherence.  Interestingly, this finding is also supported by 
another study despite methodological differences.  Grant et al. (2003) interviewed diabetic 
patients to examine 7-day adherence to multiple medications; patients with overall suboptimal 
adherence appeared to have issues with one specific medication and similar observation was 
made in patients who showed suboptimal adherence and were consuming three or more anti-
diabetic medicines although no association with number of medications was found.   
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Adherence and Burden of Consuming Multiple Medications  
From the above discussion, it is apparent that chronic disease patients are likely to 
experience multiple medication regimens.  As such, the burden may occur because of multiple 
chronic diseases, aggressive treatment (e.g., therapeutic intensification), or a combination 
thereof.  The relationship between number of medications being taken and adherence has been 
the focus of many studies including those of concomitant adherence.  Chapman et al. (2005) 
observed a negative relationship between number of other prescription medications taken in the 
year before initiating concomitant antihypertensive and anti-hyperlipidemic medications and the 
likelihood of adherence with concomitant therapy.  Similar relationships have been observed by 
other studies examining joint adherence (Benner et al., 2009; Terebelo and Markell, 2010).  
Interestingly, Benner et al. (2009) noted a significant curvilinear relationship indicating a decline 
in change in adherence to concomitant AHT and LIP with increase in number of prescriptions.  
The relationship within the context of adherence to a single medication or a class of medications 
has also been examined.  For example, statin adherence in an elderly population was negatively 
associated with number of total prescriptions for other medications (Benner et al., 2002; 
Jackevicius, Mamdani, and Tu, 2002).  However, evidence contradicting the relationship as 
discussed above also exists.  Grant et al. (2004) examined the impact of concurrent medication 
use on statin adherence and refill persistence; number of concurrent medications, including 
statin, measured at initiation of statin therapy as well as at last recorded fill of statin was 
positively associated with statin adherence and persistence.  In a study of predictors of 
suboptimal adherence in diabetes patients, Grant et al. (2003) observed that total number of 
medications prescribed was not associated with self-reported medication adherence measured 
over seven days.  Similarly, Piette et al. (2007) found that number of drug classes was associated 
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with a slight decrease in odds of being nonadherent.  The relationship may vary by disease.  
Briesacher et al. (2008) found that add-on drug therapies enhanced adherence among subjects 
with hypertension, type 2 diabetes, hypothyroidism but not with hyperlipidemia; although burden 
was generally small, the association of comorbidity with adherence varied across disease.  Thus, 
the relationship between the burden of prescription medications and adherence appears to be 
intriguing.  Patients’ overall comorbidity profile and medication beliefs may be the potential 
reasons for the discrepancy.  However, methodological issues (e.g., method to sum up all 
prescriptions) may also explain such results.   
 
Measurement of Adherence 
Precise and appropriate measurement of medication use behavior has been an important 
topic in the realm of adherence research.  Adherence/compliance and persistence are commonly 
chosen to present medication utilization patterns although terminology, definitions, and methods 
of assessment vary widely in the published literature.  Several different ways to measure 
adherence exist (see Fairman and Motheral, 2000 for a review).  A review of studies of patient 
adherence with cardiovascular medications and anti-diabetic medications showed that 
administrative claims data were used in the greatest number of studies, followed by 
questionnaires, MEMS, ‘other’ sources, and pill counts (Cramer et al., 2008).  Retrospective 
pharmacy and medical claims data, although not devoid of limitations, offer several advantages, 
including relative efficiency.  A set of diverse measures of medication adherence (e.g., MPR, 
discontinuations, refill adherence, medication gaps, etc.) have been used in studies using claims 
data; interestingly, variations in operational definition were observed within subgroups (see 
Andrade et al., 2006; Vik, Maxwell, and Hogan, 2004 for a review).  In recent years, there has 
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been an increase in the trend in use of continuous measures of adherence that are based on days’ 
worth of medication dispensed or related measures and this trend seems be driven by the 
propensity to analyze longitudinal observations using pharmacy claims data (Cramer et al., 
2008).   
 
Comparison of Adherence Measurement 
Given that several operationalizations of adherence exist, the interpretation of research 
findings, if required, becomes difficult.  In addition, the disparate use of adherence measures 
creates challenges to researchers about the appropriateness of measures to be used in adherence 
studies.  As such, the task of selecting an appropriate measure is critical.  Fortunately, some 
efforts have been made to compare different measures of adherence.  Hansen et al. (2009) 
assessed the agreement among different adherence measurement methods – patient self-report, 
pharmacy refills, and electronic adherence measures and compared the sensitivity and specificity 
of different cut-off points for classifying nonadherence in a sample of hypertensive or heart 
failure patients. Hess et al. (2006) compared 11 measures of refill adherence that include 
Continuous Measure of Medication Acquisition (CMA); Continuous Multiple Interval Measure 
of Oversupply (CMOS), MPR, Medication Refill Adherence (MRA), Continuous Measure of 
Medication Gaps (CMG), Continuous Single Interval Measure of Medication Acquisition (CSA), 
PDC, Refill Compliance Rate (RCR), Medication Possession Ratio, modified (MPRm), Dates 
Between Fills Adherence Rate (DBR), and Compliance Rate (CR); while six measures(CMA, 
CMOS, MPR, MRA, CMG, and PDC) provided similar values, the others yielded higher values.  
Karve et al. (2008; 2009) compared the abilities of eight different measures of adherence to 
predict all-cause or disease specific hospitalization in a state Medicaid population; PDC and 
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MPR emerged as the best predictors of hospitalization in different disease cohorts such as 
diabetes, hypertension, hyperlipidemia, and congestive heart failure.   
A practice that is common in the adherence literature is the dichotomization of 
continuous adherence estimates to categorize patients as adherent or nonadherent.  Most often, 
the 80% cut-point is used to classify a patient as adherent or nonadherent.  However, different 
cut-points for an operational definition of adherence have been used in past studies; such 
differences exist not only across studies that employed different methods but also across studies 
that used the same method.  Maenpaa et al. (1987) defined good adherence as consuming 85% by 
pill count in a study of adherence in heart disease patients.  Irvine et al. (1999) classified cardiac 
patients as poorly adherent when they had an average pill count below the 20th percentile of the 
pill count distribution in which the 20th percentile point represents those taking lesser than 66% 
of doses dispensed.  Granger et al. (2005) used a complex method of estimation of adherence; the 
proportion of time patients took more than 80% of their study medication by pill count was 
determined first and then those demonstrating proportion of time greater than 80% were 
classified as adherent.  In a study of ambulatory patients with stable coronary heart disease, 
nonadherence was defined as self-reported consumption of medications 75% of the time or less 
(Gehi et al., 2007).  There are many examples of similar variations in the literature (see Vik, 
Maxwell, and Hogan, 2004).   
Apart from using different thresholds for categorization, differences in number of 
categories also exist.  Some studies had grouped patients into multiple categories based on 
adherence.  For example, Bramely et al. (2006) examined the relationship between adherence 
and blood pressure control in patients with essential hypertension and categorized patients into 
three adherence groups: high (80%-100%), medium (50%-79%), and low (< 50%).  In a study 
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exploring the relationship between drug adherence and mortality, adherence estimates, measured 
by PDC, were subdivided a priori into three categories: high (≥ 80%), intermediate (40%-79%), 
and low (< 40%) (Rasmussen, Chong, and Alter, 2007).  Likewise, Nichol et al. (2009) used 
three adherence categories while examining adherence rates in patients who were prescribed 
concomitant AHT and LIP; however, different labels were used with different cut-points: fully 
adherent (PDC ≥ 0.8), partially adherent (0.2 ≤ PDC < 0.8), and nonadherent (PDC < 0.2).  
Furthermore, other researchers have used four categories to classify adherence to chronic 
medications (Mason et al., 2011). 
Classifying patients into different categories according to their adherence behavior may 
be appropriate when it is consistent with the goal of research.  In fact, categorization offers 
efficiency from the perspective of healthcare providers, including practicing pharmacists.  
However, the practice is not without limitations.  Given a lack of uniform method, it becomes 
difficult to compare results, if needed.  Oftentimes, the rationale behind such classification 
schema decisions is not explicitly stated; however, some researchers perform sensitivity analysis 
to examine the susceptibility of results to different classification schema.  Recently, Karve et al. 
(2009) attempted to validate the optimality of cut-points for adherence measure for classifying 
patients as adherent or nonadherent.  Using retrospective claims data for patients in five disease 
cohorts, the authors observed that the optimal cut-point of the PDC measure that predicted 
disease-specific hospitalization varied from 0.58 to 0.85 depending on disease.  However, the 
predictive power of the study models was only modest as was evident from weak c-statistics.  In 
addition, by excluding patients who were prescribed two or more drug classes for a disease the 
study limited its applicability in that the result may not be generalizable to patients on 
concurrently advised multiple medication regimens.   
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Measurement of Adherence to Multiple Medication Regimens 
Measurement of adherence to multiple medications has been and remains a complex 
issue.  The level of complexity may vary in situations in which the issue of measurement of 
adherence arises: multiple medication regimens for a single disease (i.e., therapy 
intensification/augmentation) and multiple medication regimens used to treat two or more 
diseases.  Although adherence to multiple medications has been examined in few studies, the 
question of measurement has not been discussed explicitly.  Indeed, this issue has not received 
the critical deliberation that it deserves.  Currently, there is no consensus or published guideline 
for measuring adherence to multiple medications.  Quite understandably, a set of varied practices 
exists.   
Several approaches are followed for the measurement of adherence to multiple 
medications concurrently consumed for a single disease.  These include 1) average of adherence 
(PDC) to each medication (henceforth, termed as ‘average’), 2) adherent only if ≥ 80% PDC, 
measured separately for each medication, on each concurrent medication (termed as ‘all’), and 3) 
adherent if ≥ 80% PDC measured as proportion of days when at least one medication was 
available, i.e., a patient is adherent on a day if he possesses at least one medication on the day, 
(termed as ‘at least one’) (see Choudhry et al., 2009 for further illustration).  These estimation 
approaches are further complicated depending on the definition of individual intervals, i.e., 
denominators of adherence measures.  Specifically, the interval of individual medications can be 
based on the entire observation period or prescription period for each drug.  However, because 
medications are to be continued, the prescription period-based interval may not be important for 
most chronic disease medications except for situations when physician-recommended switches 
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occur.  Several studies can be cited in which adherence to multiple medications was computed 
based on one of these approaches or some variants of them.  Khanna et al. (2012) adopted the ‘at 
least one’ approach in the study of adherence to medications although the objective was not to 
examine multiple medication adherence.  Yu, Yu, and Nichol (2010) averaged adherence of 
multiple medications for diabetes.  Studies focusing on adherence to multi-disease medications 
adopted one of the above approaches.  Piette et al. (2007) employed a weighted average, 
analogous to the average measure, in the calculation of intra-disease adherence to two 
medications; weight was based on the adjustment (of days supply needed) made in the 
denominator of the MPR estimator and weighted average MPR was then dichotomized.  A 
similar method was employed by Schmittdiel et al. (2008) in which each drug class adherence, 
measured by CMG, was combined into a single estimate for all drugs for a chronic disorder; the 
summary measure was computed by weighting the estimate for each class by the number of days 
from the first to last fill in the observation period and then the single estimate was dichotomized.  
It is not surprising that different measurement methods result in different estimates, at least in 
some cases.  For example, Choudhry et al. (2009) reported concurrent medication adherence 
estimates that ranged from 35% to 95% depending on different measurement approaches 
followed in patients receiving oral hypoglycemic agents.  Martin et al. (2009) used a restricted 
definition of PDC for quarters in which multiple medications were recommended such that a 
patient was considered adherent on a day when he possessed all medications concurrently 
recommended and categorized as adherent if he had 80% or higher PDC as estimated by the 
method during the observation period (herein, termed as ‘both’).  It can be noted here that this 
definition (‘both’) will not yield any estimate greater than that of the all approach as described 
above.  For example, if a patient is prescribed two medications concurrently and he is adherent to 
33 
the first medication for the first 16 days (80%) of a 20-day period but possesses the second 
medication for the last 16 days, then he will be categorized as adherent according to the ‘all’ 
measure (80% on each) but not according to the ‘both’ method (60%).  Because of such 
complexities of estimation of multiple medication adherence, patients taking two or more 
medications for a disease are typically excluded from subsequent analyses (e.g., Karve et al., 
2008; 2009; Piette et al., 2007).   
As discussed above, few studies have examined joint adherence to medications for 
multiple conditions.  While classifying patients as adherent or nonadherent based on joint 
adherence behavior, researchers have followed a dichotomized adherence measurement approach 
that is, in principle, identical to the both approach (e.g., Chapman et al., 2005).  In other words, 
patients were considered adherent with concomitant therapy if 80% or more days are 
simultaneously covered by each therapy.  In contrast, Nichol et al. (2009) defined fully adherent 
to concomitant antihypertensive therapy and anti-hyperlipidemic medications as those 
demonstrating ≥ 80% adherence (PDC) on each medication where adherence was estimated 
separately for each medication (the ‘all’ approach).  Other researchers adopted an average-based 
approach for estimating overall adherence to multiple medications prescribed for different 
diseases.  Ho et al. (2006a) examined the relationship between mortality and overall adherence to 
multiple medications in a cohort of diabetes patients who were prescribed one or more classes of 
medications that included oral hypoglycemics, antihypertensives, and statins; for patients who 
were prescribed medications from multiple categories, a summary PDC measure was calculated 
as the average of PDC of any one or more categories of medications.  The study might have 
applied the same principle while estimating adherence to multiple medications intended to treat a 
single disease although it was not explicitly explained.  Interestingly, different approaches were 
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adopted simultaneously for estimating adherence to multiple medications – one for a disease and 
another for two different diseases.  In the case of estimating adherence to medications for a 
disease, Benner et al. (2009) noted, a patient was considered covered if he was adherent with at 
least one AH medication on a given day; for different diseases, however, patients with a PDC of 
≥ 80% for both AHT and LIP were considered adherent.   
 
Limitations of Research Related to Adherence to Multiple Medications 
Adherence to Multiple Medications  
Patients for whom intensified treatment regimen is advised may be at high risk for 
experiencing adverse consequences if the disease is not adequately controlled.  However, studies 
on adherence have focused largely on understanding consumption of any single medication 
prescribed for a disease or collective consumption patterns in which all medications for a disease 
are considered together.  In addition, failing to establish adherence as a universal trait 
characteristic (Horne, 1998) leaves us with a critical knowledge gap about whether individual 
adherence patterns of a multiple medication regimen for a disease duplicate or closely follow one 
another.  In other words, what happens to adherence behavior for each medication in patients on 
multiple medications for a single disease?  What is the relationship between adherence values 
estimated for different medications taken concurrently for a single disease?  While the roles of 
illness perceptions (Leventhal et al., 1997) may suggest concurrent adherence, the burden of 
taking more medications may attenuate adherence although the effect of prescription burden on 
adherence is not consistent.  Thus, further research is needed to explore adherence to multiple 
medications taken concurrently for a disease or intra-disease multiple medication adherence.  
Specifically, there is much to learn about the covariation of adherence behavior, including the 
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extent of covariation, effect of demography on covariation, and relationships between individual 
change patterns over time. 
Similarly, there is a dearth of empirical knowledge about covariation in adherence among 
medications prescribed for multiple diseases (i.e., inter-disease multiple medication adherence) 
in patients suffering from multiple chronic diseases simultaneously and where fixed combination 
(single) dosage are not available.  Although there have been some attempts to examine cross 
disease adherence behaviors (e.g., Chapman et al., 2005; Stack et al., 2010), several issues, 
including those raised above, however, remain to be solved.  While some studies do not answer 
long term association or change in trends regarding joint adherence behaviors because of the 
study design (cross-sectional), others are limited to specific populations (e.g., newly initiated 
therapy, mental disorder, etc.).  It is known that some patients suffer simultaneously from more 
than two chronic diseases some of which are more symptomatic than others.  In addition, an 
overarching situation arises when therapy intensification occurs in some of these diseases.  It is 
not known how inter-disease and intra-disease adherence covariations emerge, if any, in complex 
therapeutic situations in patients having multiple morbidities. 
 
Measurement of Adherence to Multiple Medications  
Assessing adherence accurately is crucial for many reasons including identifying 
opportunities for intervention.  Although many measures of adherence exist, these measures were 
developed specifically for the measurement of adherence to individual medications or 
medication classes.  The applicability of these measures in a multiple medications situations is 
not known.  Thus, there is a global need to revisit the issue of measuring adherence to multiple 
medications.  Currently, the operationalization of joint adherence to multiple medications is 
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borrowed from the definition of adherence to a single drug.  That is, a patient is adherent if he or 
she is ≥ 80% (in general) on all or some medications simultaneously taken for a disease.  
Empirical work is required to determine the optimality of cut-points or threshold when 
researchers choose to use nominal measure of intra-disease multiple medication adherence, 
including those in which an average-based estimate is dichotomized.  Another important issue, 
particularly because of the absence of evidence for optimal thresholds for joint adherence, is the 
selection of a method (e.g., ‘all’, ‘average’, ‘at least any’ etc.) that results in the best prediction 
of outcomes.  In other words, benchmarking the measurement practices within the domain of 
intra-disease multiple medication adherence has not yet happened.   
Intra-disease multiple medication adherence entails a situation that is conceptually 
distinct form that of single drug adherence.  The situation occurs because of prescriptions of two 
different chemical entities intended to treat the same disease.  In other words, the issue is to 
devise a measure that represents clinically meaningful summary adherence by virtue of its focus 
on the disease and treatment outcomes but not on individual medication adherence estimates.  In 
their pursuit to improve quality of care, several organizations (e.g., the National Committee for 
Quality Assurance (NCQA), the Agency for Healthcare Research and Quality (AHRQ), and the 
Pharmacy Quality Alliance (PQA)) emphasize the need for developing measures including 
healthcare quality indicators.  As a result, there exist composite measures of clinical quality 
indicators (e.g., Shwartz et al., 2008).  However, the development of appropriate composite 
measures for joint adherence is still lacking.  In summary, the issue of appropriately 
operationalization of the measure of multiple medication adherence is very consistent with 
contemporary thoughts in the measurement literature (e.g., Reeves et al., 2007; Shwartz et al., 
2008) but has not been addressed yet.   
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CONCEPTUALIZATION 
Adherence to Multiple Medications 
Adherence to Multiple Medications Taken for a Single Disease 
Chronic disease management requires at least continual and effective 
pharmacotherapeutic intervention.  The patient remains always at the center of and is a crucial 
partner in disease control efforts that take place in social and physical environments.  Despite the 
advancement of knowledge and the availability of advanced pharmacotherapies, significant 
barriers to treatment appear to reside in the psychological and behavioral domains (Rosenstock, 
1985).   
Health psychologists have advanced different theoretical approaches in their attempt to 
understand various determinants of health behavior, including adherence to medications.  One of 
such approaches emphasizes on the dynamic, iterative, and reciprocal nature of such behaviors 
and adopts a system theory view that is oftentimes governed by goals or feedback processes 
(Bishop, 1991).  Fundamental to this approach is the understanding of how patients assess and 
interpret their illness.  According to the Common Sense Model of Self-Regulation (CSM) 
(Leventhal, Brissette, and Levethal, 2003), adherence behavior represents an effort on the 
patient’s end to cope with a disease that results from cognitive and emotional appraisals of 
illness.  The theory postulates that a patient is likely to exhibit adherence behavior if adherence 
makes sense within his concept of the illness, taking into account his experience with the illness 
and medications, potential outcomes of adherence behavior, and individual beliefs about the 
illness.  Indeed, as changes in cognitive pathways are accompanied by befitting coping attempts, 
medication adherence will be affected accordingly.  The CSM has been further extended to 
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incorporate medication beliefs into the cognitive mechanisms of the CSM (Horne, 2003).  The 
extended framework contends that medication adherence is related to specific beliefs about 
beneficial effects (necessity beliefs) and worries about detrimental effects (concern beliefs) of 
medications.  In addition, the extended framework includes two general beliefs: general harm 
beliefs – general mistrust about medications and general overuse beliefs, which describe a 
patient’s concern that physicians prescribe too many medications.  This framework has been 
applied to medication adherence in different chronic diseases (diabetes and cardiovascular 
diseases) (Bane, Hughes, and McElnay, 2006; Tibaldi et al., 2009).  It should be noted here that 
there is a distinction (see Helman, 1981 for a discussion) between illness and disease.  However, 
the propositions advanced by the framework seem to make sense regardless of such distinctions, 
as adherence behavior is largely patient driven and based on a determination of health status or 
perception of illness.  Empirical evidence from studies (BaneHughes, and McElnay, 2006; 
Tibaldi et al., 2009) suggest that specific necessity and concern beliefs consistently predict 
intentional medication adherence and are indeed better predictor than general beliefs.  Allen 
LaPointe et al. (2010) reported a significant association between nonpersistent use of anti-
hyperlipidemic medications and decrease in perceived necessity of cardiac medications.  Schuz 
and colleagues (2011) applied the framework in a longitudinal study to examine the role of 
beliefs about medication ‘as a whole’ without regard to specific illnesses.  Elderly patients’ 
necessity beliefs about medication were associated with intentional nonadherence and general 
overuse beliefs with unintentional nonadherence.  Interestingly, a positive association between 
number of medications and adherence was found after controlling for past adherence.  However, 
these findings are difficult to interpret adherence because of a lack of focus on illness in the 
study.  Specifically, adherence may be driven by beliefs in individual medications or subsumed 
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under overall illness beliefs to seek protections from the illness.  The later argument is consistent 
with illness perceptions under the CSM and may be relevant for understanding intra-disease 
multiple medication adherence.  In other words, it may be that cognitive perceptions or 
representations of medications along with that of the disease play a pivotal role in adherence 
behavior and affect adherence behavior to multiple medications prescribed for a disease.  Again, 
this argument is founded on a cogent theoretical rationale that is based on the role of illness 
representation in adherence behavior (Leventhal, Difenbach, and Leventhal, 1992).   
Empirically, self-regulatory perspective or illness representation has been applied to 
examine adherence in multiple chronic disease categories (e.g., hypertension, diabetes) (Meyer, 
Leventhal, and Gutmann, 1985; Gonder-Frederick and Cox, 1991).  It is important to note that it 
is unlikely for a patient to understand the necessity of individual medications within a disease 
category.  However, it is not unlikely to have distinct concerns (e.g., side effects) for individual 
medications.  As such, these concerns may be addressed appropriately (e.g., therapy 
modification, counseling, subsidence of symptoms gradually etc.) at the provider level during 
subsequent pharmacy or clinic visits.  If addressed, it may rather enhance patient convictions 
about the medications.  In addition, empirical findings suggest that compared to necessity, 
concern beliefs play a minor role in affecting adherence (Schuz et al., 2011).  This argument 
about adherence to multiple medications for a disease rests on the premise of patients’ 
knowledge of the indications of their prescription medications.  Only 13% of patients in a 
primary care practice reported not knowing the indication of at least one of their prescription 
medications, which constituted 6.3% of all prescription medications that were studied (Persell et 
al., 2004).  A small survey at an academic primary care clinic reported that patients identified a 
correct indication for nearly 80% of their medications (Marks et al., 2010).  While impressive, it 
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is important to note that the extent of understanding may vary for different diseases.  For 
example, lack of knowledge was only 3% for diabetes medications (5% for oral anti-diabetic 
medicines and none for insulin) and most prevalent for cardiovascular medications with 11% in 
hypertensive and anti-hyperlipidemic medications (Persell et al., 2004).  Another study 
conducted among dialysis patients reported that a significantly larger number of patients knew 
the indication for their antihypertensive drugs and calcitriol than for their phosphate binder 
(Cleary et al., 1995).   
Several other variables, including demography, have been examined as determinants of 
adherence.  However, as discussed previously, conclusive evidence relating demography to 
adherence does not exist.  It is not an exception even when the studies that used the self-
regulatory framework are considered.  For example, Wroe (2002) reported unintentional 
nonadherence was less strongly associated with decision balance, and more so with demography, 
age in particular.  In contrast, Schuz et al. (2011) found no association of demography with 
adherence while Horne and Weinman (1999) reported only age affecting adherence.  At a 
minimum, it can be posited that illness and medication beliefs may have an independent effect on 
joint adherence behavior that cannot be explained by other factors.  Indeed, adherence may be 
primarily driven by illness perceptions.  Therefore, the following hypotheses are presented with 
regard to adherence to multiple medications taken for a disease:   
 
H1: Overall, there will be a positive covariation between adherence behaviors related to 
two medications taken concurrently for the same chronic disease. 
H1a: Overall, the covariation of adherence between behaviors related to two medications 
taken concurrently for the same chronic disease will persist after controlling for 
gender.   
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H1b: Overall, the covariation of adherence between adherence behaviors related to two 
medications taken concurrently for the same chronic disease will persist after 
controlling for age.   
H 2: In general, patients will demonstrate a positive relationship between changes in 
adherence behaviors related to two medications taken concurrently for the same 
chronic disease over a period.  In other words, the slope of adherence to each 
medication over time will be positively related (‘association of the evolutions’).   
H2a: The ‘association of the evolutions’ will persist after controlling for gender. 
H2b: The ‘association of the evolutions’ will persist after controlling for age. 
 
Adherence to Multiple Medications Taken for Concordant Diseases 
Many patients suffer from multiple chronic diseases.  Chronic disease patients have a 
higher propensity to suffer from multiple morbidities.  For instance, according to the Medical 
Expenditure Panel Survey, most adult diabetics have at least one comorbid chronic disorder 
(Druss, 2001).  Other studies reported that as many as 40% of diabetics had more than two 
chronic diseases (Maddigan, Feeny, and Johnson, 2005; Wolff, Starfield, and Anderson, 2002).  
However, not all chronic comorbidities are necessarily similar in terms of having underlying 
relationships among them.  Piette and Kerr (2006) provided a useful yet broad typology for 
classifying chronic conditions.  They outlined three general dimensions or features of comorbid 
conditions: clinically dominant comorbid conditions, concordance of conditions, and 
symptomatic/asymptomatic conditions.  Most relevant for the purpose of this study is the 
concordance feature.  As defined by Piette and Kerr (2006), concordant diseases are those that 
“represent parts of the same overall pathophysiologic risk profile and are more likely to be the 
focus of the same disease and self-management plan” (p. 727).  In contrast, discordant 
comorbidities do not directly share either pathogenesis or management characteristics.  For 
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example, hypertension, coronary artery disease, and diabetes are considered concordant while 
diabetes and cancer or irritable bowel syndrome would be defined as discordant conditions.  
Moreover, it is thought that concordant diseases are likely to be managed by a single provider.  
Clinical practice guidelines help shape the management of chronic concordant comorbidities.  
For example, diabetes guidelines oftentimes make specific recommendations for the 
management of concordant conditions such as hyperlipidemia and hypertension (Boyd et al., 
2005).  In other cases, treatment management plans for concordant diseases follow specific 
patterns.  For example, treatment of hypertension and dyslipidemia may be initiated together or 
within a short interval of each other.  These patterns (e.g., treatment synchronization) may have a 
positive influence on adherence (Agarwal et al., 2009).   
Patients may hold different beliefs about illnesses and associated medications.  
Medication use for individual medications may vary because of differential perceived risks and 
benefits attributed to each medication (McHorney and Gadkari, 2010).  Similarly, illness 
perceptions may or may not vary depending on disease.  For instance, it was reported that while 
perceptions of diabetes were different from hyperlipidemia and hypertension, the latter two 
demonstrated similarity on many components of illness perceptions (Stack et al., 2008; 2011); 
however, self-reported intentional nonadherence did not vary between OADs, AHT, and statins 
(Stack et al., 2010).  Such a relationship between adherence and beliefs is counterintuitive.  
Methodological issues and a lack of distinction between dimensions (e.g., intentional) of 
adherence may explain some difference.  It may also be such that even if perceptions (e.g., 
necessity) vary across some diseases, patients may still demonstrate adherence to all (e.g., 
varying degrees of necessity for all) but strengths of associations between medication use may be 
attenuated.  Thus, a latent influence may be conceived that ties along concordant chronic disease 
43 
care.  While Nichol et al. (2009) reported the likelihood of transition to full adherent status over 
time of those who showed selective adherence to one drug but not the other, Ho et al. (2006b) 
reported that some patients chose to continue with only one therapy or more.  These results 
provide mixed evidence for associations of adherence across medication categories.   
Patients may possibly exhibit different behaviors across diseases when one of disease is 
symptomatic in nature.  Inferences derived from perceived symptoms play a very important role 
in patient-driven management of chronic diseases (Gonder-Frederick and Cox, 1991).  Although, 
in general, adherence to treatment regimens tends to be lower in patients whose illnesses are 
asymptomatic, contrary evidence also exists.  Symptom status did not predict adherence among 
ischemia patients (Carney et al., 1998).  Haynes, Taylor, and Sackett (1979) concluded that the 
association between symptoms and adherence was not very consistent.  However, recognition, 
interpretation, and inferences made about symptoms may influence behavior in every aspect of 
medical decision-making and disease management.  Piette and Kerr (2006) argued that 
physicians might view managing bothersome symptoms as greater concerns for patients and 
focus on treating symptoms to improve patients’ functioning and quality of life as well as 
prevent poor long-term outcomes.   
Different factors are likely to affect adherence behavior across different concordant 
diseases.  Some factors (e.g., medication-specific beliefs) may not favor associations of 
adherence across such diseases.  Another factor that has been examined in studies of adherence is 
prescription burden; however, the relationship is not very clear (Benner et al., 2002; Grant et al., 
2004).  In contrast, treatment focus or clinician priority related to concordant disease 
management during clinical encounters, if any, may alter patient perceptions about respective 
medications or illness leading to associations.  It is contended that there will be, at least weak, 
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associations of adherence across concordant diseases.  Therefore, the following hypotheses were 
proposed: 
H 3a: For patients suffering from multiple concordant chronic diseases, there will be a 
significant covariation of adherence behaviors related to medications taken 
concurrently for an index chronic disease and another asymptomatic chronic disease.   
H 3a1: For patients suffering from multiple concordant chronic diseases, there will be a 
significant covariation of adherence behaviors related to medications taken 
concurrently for an index chronic and another asymptomatic chronic disease 
regardless of disease.   
H 3b: For patients suffering from multiple concordant chronic diseases, there will be a 
significant covariation of adherence behaviors related to medications taken 
concurrently for an index chronic disease and another asymptomatic chronic disease 
even when number of chronic diseases increases.   
H 3c: For patients suffering from multiple concordant chronic diseases, there will be a 
significant covariation of adherence behaviors related to medications taken 
concurrently for an index chronic disease and another symptomatic chronic disease.   
 
Measurement of Intra-disease Multiple Medication Adherence  
While deliberating on the issue of intra-disease multiple medication adherence, an issue 
that remains is the determination or development of an appropriate composite measure of 
adherence.  Currently, several approaches are used for measuring joint adherence.  These 
measurement approaches are grounded in the definition of adherence to a single drug.  That is, a 
patient is adherent only if he is 80% (in general) or more on all simultaneously taken medications 
intended to treat a disease or some other variant of this approach.  Another way to measure 
multiple medication adherence is averaging individual medication adherence estimates of all 
simultaneously taken medications intended to treat a disease.  An assumption made by these 
approaches is that all medications are created equal.  This assumption is questionable for several 
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reasons.  First, some medications are more “forgiving” – a drug attribute, which dictates that the 
duration of action significantly exceeds the dosing interval – of poor adherence compared to 
others (Urquhart, 1998).  Thus, the impact of nonadherence is likely to differ based on this 
characteristic.  This, of course, needs to be emphasized that even the most forgiving medication 
cannot be effective if not taken for a long time.  Second, physicians intensify therapy with a 
purpose such as controlling different biomarkers representing different pathways (e.g., fasting 
serum insulin or glucose) or aggressively controlling a single end-point (e.g., blood pressure).  
The mechanistic approach of drug action dictates that there are differential effects of medications 
on individual disease markers (de Winter et al., 2006).  Indeed, medication consumption affects 
one intermediary outcome or more that are considered to cause observable outcomes such as 
hospitalizations or death.  It is sensible to think of medications in terms of preventing such 
outcomes.  This thought is consistent with clinical practice that oftentimes emphasizes achieving 
targeted intermediary outcomes (e.g., HbA1c).  Finally, pathophysiology of chronic disease is 
not yet fully understood.  However, it is generally accepted that chronic disease may progress at 
a certain rate and individual medications are likely to have different impact on that rate.  For 
example, de Winter et al. (2006) compared disease progression rates representing change in β-
cell function and change in insulin sensitivity over time in patients receiving gliclazide, 
metformin, and pioglitazone; apart from differential symptomatic short-term effects, different 
disease progression rates for each parameter were observed among these treatment groups.  In 
fact, drug treatment for a chronic disease only slows down the process, which will continue to 
progress at a specific rate.  For example, it was found that even when patients’ adherence with 
diabetic medications was nearly 100%, the disease was found to progress over time (Charbonnel 
et al., 2004; de Winter et al., 2006).  Thus, the overall impact of noncompliance may be further 
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complicated when the effect, likely to be different for individual medications, on disease 
progression rate is considered.  Although these effects cannot be accurately captured without 
pharmacokinetic-pharmacodynamic (PK-PD) modeling, potentially differential effects should be 
considered in some way while conceptualizing a summary measure of joint adherence.  One 
plausible way is to derive weights based on a medication’s comparative effectiveness with 
respect to some outcome.  Precisely, the weight represents adherence driven efficacy, 
conceptually analogous to what is termed as ‘use-effectiveness’ by Hughs and Walley (2003), as 
it is practically very difficult or infeasible to tease out pure efficacy from the impact of 
adherence.  Thus, weights can be determined by estimating the impact of adherence on 
intermediate clinical markers, composite outcomes such as QALY, or adverse consequences, 
including hospitalization.  Furthermore, weights may be based on short-term or long-term 
outcomes as deemed appropriate.   
Over the last few years, there has been an increasing emphasis on developing composite 
measures of quality indicators.  This wave has been seen in the domain of hospital and clinical 
quality indicators.  However, the definition of composite indicators varies across studies.  While 
some researchers define composite measure as weight-based average (Geppert, 2011; Shwartz et 
al., 2008), others define it as dichotomized measure (Reeves et al., 2007).  Geppert et al. (2011) 
operationalized a complex formula of AHRQ quality indicator (QI) composite measure as 
weighted average of risk-adjusted ratio and the reference population ratio from which weight is 
determined empirically.  In contrast, Reeves et al. (2007) defined ‘all or none’, conceptually 
equivalent to ‘all’ or ‘both’ measures as described previously, as composite measure.  In this 
study, the composite measure was defined in the spirit of Geppert et al. (2011).  The proposed 
new measure representing composite adherence is defined below.  The formula is presented for 
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two medications; however, it can be extended to accommodate more medications.  This is an 
empirical regression weight-based composite average measure, henceforth termed as ‘composite’ 
measure.  By definition, the composite measure allows for the benefits of individual medications 
based on partial adherence, if any. 
Adhcom=
W1.	A1+	W2.	A2
W1+	W2  
 
where Adhcom = empirical regression weight-based composite adherence estimate,  
Adhi = estimated adherence to drug i ,  
wi = outcome-based regression weight for drug i; 
• Assuming all drugs do NOT have equal effectiveness/ efficacy 
• Assuming a joint additive effect 
• Assuming trivial effects of disease progression and disease status at baseline  
As stated before, apart from developing a summary measure, there is a need to determine 
which one constitutes an appropriate method among several measurement approaches for intra-
disease multiple medication adherence.  In other words, the performance of these measurement 
approaches must be compared in order to select the most appropriate measure.  In most studies, 
adherence measures are dichotomized including categorization of an average-based measure 
(e.g., Piette et al., 2007) although wide variability occurs.  From the perspective of calibration, 
such approaches for categorization suffer from limitations and make some assumptions that do 
not appear to be grounded theoretically or empirically.  Therefore, the following objectives will 
be examined: 
1. To examine the effectiveness of the composite measure, 
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2. To compare the performance of the existing measurement approaches with the composite 
measure, 
3. To determine the optimal cut-point of the composite measure,  
4. To determine the optimal cut-point of the average measure and other continuous measures.   
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CHAPTER 3 
METHODOLOGY 
This chapter will discuss the methodology used to examine the study hypotheses and 
objectives.  The study has two major focuses: adherence behavior to multiple medications and 
multiple medication adherence measurement.  The methodology addressing the hypotheses and 
objectives associated with these two substantive areas are organized separately whenever 
appropriate.  In addition, the data analysis plan to examine the hypotheses and objectives are 
discussed.  
The study was approved by Thompson Reuters and compliant with the protocol specified 
in the Data User Agreement (DUA) between the company and The University of Mississippi.  
The study was compliant with the Health Insurance Portability and Accountability Act (U.S. 
Department of Health and Human Services).  In addition, approval was obtained from the 
Institutional Review Board (IRB) at The University of Mississippi.   
 
Research Design 
A longitudinal observational study design was employed for this study. Using 
retrospective administrative claims data, study subjects were identified.  Medication and health 
service utilization of these patients were determined as described below.  However, for the 
comparative validation and calibration of the measurement approaches a prospective study 
design was conducted utilizing the same data source.   
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Description of Data Source 
This study utilized the MarketScan® Commercial Claims and Encounters database 
(MCCED) for 2002 and 2003 from Thomson Reuters (Healthcare) Inc.  The MCCED is a large 
and comprehensive relational database that represents millions of individuals and consists of 
medical and prescription claims of private sector employees and their dependents.  This multi-
source database is constructed through submissions of health insurance data.  Collectively, the 
database incorporates data from a large number of payers, including commercial insurance 
companies, Blue Cross and Blue Shield plans, and third-party administrators (TPAs).  The fully-
integrated data can track patient information across sites, types of providers, all claims types 
including medical/surgical and outpatient pharmaceutical claims, and over a number of years.  
Rigorous validation methods, as stated by the company, ensure the completeness, accuracy, and 
reliability of data.  The data appear robust and reflect a continuum of care provided to patients 
that allows analysis of utilization patterns and the subsequent outcomes associated with medical 
care and medication use.   
The Commercial Claims and Encounters Database has the following structure: 
1. Annual Enrollment file 
2. Aggregated Populations file 
3. Medical/surgical Claims files:  
• Inpatient Admissions file 
• Inpatient Services file 
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• Facility Header file  
4. Outpatient Services file  
5. Outpatient Pharmaceutical Claims file 
The enrollment files include information about demography (e.g., age, gender, 
geographic region of residence), plan, and enrollment history.  The prescription claims files 
include national drug codes (NDC), therapeutic class, dates of purchase, quantities of medication 
dispensed, days’ supplies, refill indicator, and plan and cost related information.  The Inpatient 
Admissions files contain records that summarize information about a hospital admission.  These 
files are constructed after identifying all of the encounters or claims (service records) associated 
with an admission (e.g., claims from hospital, physician and/ or surgeon, and independent labs).  
Information in the Inpatient Admission claims files includes hospital stays, including length of 
stay, date of admission or discharge, diagnosis (ICD-9 ) and procedure codes (CPT-4 or 
HCPCS), diagnosis related group (DRG), and provider type.  The Inpatient Services files contain 
the individual facility and professional encounters and services associated with the inpatient 
admission record.  An identifier that exists in both the Inpatient Admissions and the Inpatient 
Services files identifies the individual service records that come from each admission record.  
The outpatient services claims files include services that were rendered in a doctor’s office, 
hospital outpatient facility, emergency room, or other outpatient facility.  Some of the 
information, aggregated to the level of each outpatient visit, are diagnosis codes, treatment 
procedures, place of outpatient service (e.g., emergency room, office). A few claims in the 
outpatient claims files may represent inpatient services because the claim could not be 
incorporated into an inpatient admission (e.g., no room and board charge was found); generally, 
place of service is coded as inpatient.  For the study, the Enrollment files, Inpatient Admission 
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files, Inpatient Services files, Outpatients Services files, and Outpatient Pharmaceutical claims 
files were utilized to create a longitudinal panel of observations for each subject.   
 
Disease State Selection 
Primary Disease Context of the Study 
In recent years, physicians have been found to prescribe multiple medications 
concurrently for the treatment of a single disease.  Such multiple medication regimens occur in 
many diseases, including hypertension, diabetes, heart failure, and so on.  Thus, a number of 
diseases are available, in which the objectives of this research can be studied empirically.  In 
fact, two or more diseases can be selected for empirical work.  For the sake of parsimony, 
however, only one disease was selected.  Diabetes was chosen as the primary disease state.  Such 
a selection was deemed appropriate for several reasons.   
Diabetes has been and continues to be a concern in the U.S.  The recently published 
National Diabetes Fact Sheet 2011 estimated that the number of diabetes patients including those 
undiagnosed was at 25.6 million or 11.3% of all people in the age group of 20 years or older.  
The report revealed that diagnosed and undiagnosed diabetes patients comprised 13.7% of 
individuals who were 45-64 years old and 26.9% of 60 years or older in 2010.  In addition, 
according to the fact sheet, 1.9 million new cases of diabetes were diagnosed in people aged 20 
years and older in 2010; the extent of newly diagnosed cases varied by age group.  Among 
diagnosed new cases in 2010, over one million patients were between 45 and 64 years old (CDC 
National Diabetes Fact Sheet 2011).  However, a great concern implied in the report could be 
that the number of patients estimated to have pre-diabetes (i.e., serum glucose levels higher than 
normal but not yet high enough to be classified as diabetes) was reported to be 79 million in 
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2010.  Pre-diabetes was also reported to affect patients across all ages.  Not all pre-diabetes 
individuals develop diabetes but a large proportion do over time.  Estimates provided by 
different studies widely vary depending on methods and definitions (e.g., impaired glucose 
tolerance vs. impaired fasting glucose levels, population, follow-up time) (see Nichols, Hillier, 
and Brown, 2007 for a discussion).  The Diabetes Prevention Program revealed that 11 cases per 
100 person-years progressed from pre-diabetes to type 2 diabetes over about three years of 
follow-up and many people with pre-diabetes develop type 2 diabetes within 10 years (Knowler 
et al., 2009). 
Diabetes patients often suffer from a number of comorbidities.  CDC estimates that 67% 
of adults aged 20 years or older with self-reported diabetes in 2005–2008 had high blood 
pressure or used prescription medications for hypertension. Mykkanen et al. (1993) reported that 
70% of the adults with type 2 diabetes also had hypertension or hyperlipidemia.  As such, many 
diabetes patients are prescribed multiple medicines to improve metabolic control, serum glucose 
and cholesterol level, and blood pressure (Morris, 2001; Rosenstock, 2001).  Indeed, intensive 
disease management is often advocated for diabetes patients.  The American Diabetes 
Association (2004) recommends aggressive management of hypertension in adult diabetes 
patients and the use of multiple (two or more at proper doses) medications to achieve blood 
pressure targets.  Improper or poor management of diabetes has been associated with deaths and 
several secondary complications, including heart disease, stroke, kidney disease, blindness, and 
amputation.  Diabetes was the seventh leading cause of death in 2007 and the risk for stroke is 2 
to 4 times higher among people with diabetes (CDC National Diabetes Fact Sheet 2011).  
Understandably, the cost of diabetes is enormous.  The total cost of diagnosed diabetes in the 
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United States in 2007 was estimated to be $174 billion, including $116 billion for direct medical 
costs (CDC National Diabetes Fact Sheet 2011).   
Apart from adverse outcomes that may be attributed to the fact that patients fail to 
achieve treatment goals (Saydah et al., 2004), the treatment pattern in diabetes has undergone a 
significant change over the last couple of years.  Specifically, the trend of using multiple 
medication regimens has increased considerably.  Nau, Garber, and Herman (2004) examined the 
use of multiple medication therapies in a managed care population and reported that the 
percentage of diabetes patients who were receiving multiple medications for diabetes increased 
to 43% in 2001 from 27% in 1997.  Similarly, Alexander et al. (2008) found that the average 
number of diabetes medications per treated patient increased from 1.14 in 1994 to 1.63 in 2007 
and monotherapy declined by approximately 40%.  This trend could be attributable partly to 
pharmaceutical innovation.  A number of new medication classes (e.g., TZD, DPP-4 inhibitors) 
have been introduced over the past two decades.  More importantly, a number of new medication 
classes are in the development pipeline (Nguyen et al., 2011) and expected to be introduced to 
the U.S. market in the future.  Thus, it does not appear likely that multiple medication regimens 
use for the treatment of diabetes will decrease in the future.  Conversely, the continuing trend of 
more aggressive pharmacotherapeutic management coupled with the availability of innovative 
therapies makes multiple medication therapies more likely in diabetes.  Thus, diabetes appears to 
be an appropriate disease category for examining the effect of polypharmacy on adherence and 
polypharmacy adherence on health outcomes.   
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Selection of Concordant Diseases 
Effective disease management for patients with multiple medications or chronic 
conditions may pose an overwhelming challenge to providers and patients alike.  Piette and Kerr 
(2006) provided a useful and intuitive framework that might facilitate such efforts.  The authors 
provided several examples to outline the concordant-discordant as well as the symptomatic-
asymptomatic framework.  Although the orthogonality of boundaries may be blurred, it is 
undeniable that some examples make more intuitive sense than do others.  Following the 
authors’ proposition, hypertension, dyslipidemia, and diabetes are considered concordant 
asymptomatic diseases whereas angina is considered symptomatic.  Applying the principle, 
angina can also be considered concordant with the aforementioned diseases.    
 
Identification of Study Subjects 
Selection of Multiple Medication Regimens within the Primary Disease 
As was presented previously, the major focus of the study lies on those patients who have 
been prescribed multiple medications for a disease (i.e., diabetes).  Several classes of 
medications are available for the treatment of diabetes, including sulfonylureas (SU), metformin, 
insulins, thiazolidinediones (TZD), alpha-glucosidase inhibitors, meglitinide, glucagon-like 
peptide-1 (GLP-1) analogues, and dipeptidyl peptidase-4 (DPP-4) inhibitors.  Diabetic patients 
who are prescribed multiple medications may receive two or more classes of medications 
described above.  Thus, a number of different combinations exist and some combinations of 
medications occur more frequently than do others.  For example, insulin and metformin are 
oftentimes prescribed together.  TZDs are added often to metformin or SU.  For this study, 
patients who were prescribed TZDs and SUs concurrently were included.  These two classes are 
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frequently used but not, usually, as fixed-dose combinations.  Although insulins are frequently 
used, adherence to insulin is difficult to measure from administrative claims data.  Metformin is 
widely used but oftentimes prescribed as fixed-dose combination product that restricts its 
variability in usage.  Other medications (e.g., DPP-4 inhibitors) are relatively new and their 
usage patterns are still evolving.   
 
Selection of Medications for Concordant Diseases 
Two asymptomatic diseases concordant with diabetes were considered in this study: 
dyslipidemia and hypertension.  Commonly used medications for the treatment of dyslipidemia 
include fibrates and statins.  Other classes include bile acid sequestrants (cholestyramine, 
colesevelam, and colestipol), niacin, and ezetimibe.  Two classes of anti-hyperlipidemic 
medications are seldom prescribed together and medications under the other classes are 
prescribed generally as adjunct to statins.  In instances where patients were found to be on more 
than one medication, statin adherence was considered for the sake of simplicity of calculation of 
adherence.  Many medications are available and indicated for the treatment of hypertension.  
Angiotensin II receptor blockers (ARB) or Angiotensin I converting enzyme inhibitors (ACEI), 
generally in combination with a thiazide diuretic, are considered as initial therapy for diabetic 
hypertensive patients while β-blockers and calcium channel blockers (CCB) are add-on therapies 
(Whaley-Connell and Sowers, 2005).  As such, these five classes of AHTs were considered.  
Moreover, such an approach is consistent with a previously published study of adherence to 
medications among diabetes patients suffering from multiple comorbidities (Stack et al., 2010).  
An attempt was made to confirm diagnoses of hypertension (ICD-9 codes 401 - 405) from 
medical services records.  Unlike dyslipidemia and hypertension, angina is symptomatic and 
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concordant with diabetes.  While many medication classes including antihypertensives are 
prescribed for angina pectoris, nitrates are the core pharmacotherapeutic treatment for angina 
(Parker and Parker, 1998).  In addition, past adherence/persistence research has examined 
nitrates for the treatment of angina (Grant et al., 2004; Kardas, 2004; Poluzzi et al., 2006).  Only 
di-nitrate, mono-nitrate and nitroglycerin (not sublingual) tablets and capsules were considered 
as these medications are expected to be consumed at regular intervals (at least once daily).  In 
addition, an effort was made to confirm from medical services utilization data whether they had 
any diagnosis of angina.  Consistent with past research, the ICD-9 codes 413.x (angina pectoris), 
414.0, 414.8, 414.9 (ischemic heart disease), and 786.5 (chest pain) were selected to 
operationalize “ICD angina” such that it includes all conditions most likely representing chronic 
angina (Pakhomov et al., 2007).  Medications, including those for diabetes, were selected based 
on literature (Parker and Parker, 1998; Wang, 2006) (Appendix A).   
 
 
 
 
 
 
 
Selection of Subjects and Observation Periods 
For this study, the identification of subjects occurred from January 1, 2002 through 
September 30, 2002 (Figure 3.1).  Patients who filled at least one prescription for each 
medication (i.e., SU and TZD) were identified from the prescription claims records.  Such a 
Qtr 1 2002 Qtr 2 2002 Qtr 3 2002 Qtr 4 2002 Qtr 5 2003 Qtr 6 2003 Qtr 7 2003 Qtr 8 2003 
TZD 
Eligible observation period Index date 
SU 
Identification period 
Figure 3.1: Illustration of Subject Identification to Examine Adherence 
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filling pattern would provide an indication that the patient was prescribed both medications.  
Furthermore, the earliest (or later of two initial fills) fill date indicating that patient was 
prescribed both medications served as the index date.  For example, if a patient filled a 
prescription for a SU on March 23, 2002 and a prescription for a TZD on September 29, 2002, 
the index date for the patient would be September 29, 2002.  Because of their complementary 
mechanisms of action, it was assumed that physicians were unlikely to replace one medication 
with the other even when the latest fill date for one and the earliest fill date for the other occur at 
widely-apart temporal distance.  However, the order of prescription was not considered for this 
project.  The observation period started 90 days after the index date.  The 90-day limit was 
chosen to allow for any physician-driven therapy modification.  Thus, the latest date on which an 
observation can start for a patient was January 1, 2003 and continued through December 31, 
2003.  It can be noted here that subjects were likely to have variable observation periods 
depending on respective index dates.   
 
Primary Inclusion Criteria   
Subjects identified thus far were considered for inclusion in the study if they met a set of 
additional requirements.  First, subjects were required to be 18 years or older on the index date.  
Second, they must have been continuously enrolled in MCCED with pharmacy and medical 
benefits for at least 15 months starting from their respective index date.  The 15-month period 
included 90 days (approximately, 3 months) of pre-observation period and 12 months of 
observation period.  It can be noted here that the choice of the duration is consistent with the 
literature.  A review of studies on adherence with AHT, OAD, and LIP reported that the mean 
duration of studies were 30, 18, and 15 months for LIP, OAD, and AHT, respectively (Cramer et 
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al., 2008).  Anti-diabetic prescription trends using the data source suggested that a large 
proportion of these diabetes patients were prescribed the combination of SU and TZD before 
January 1, 2002 (Cohen et al., 2003).  Thus, many patients who continued to fill during the pre-
index period had been filling the scripts for at least a year.  In addition, it was required to ensure 
that failing to refill was not driven by physician decisions.  In other words, the lack of filling was 
not due to a decision to modify therapy on the part of the prescriber.  Especially for those new to 
treatment, early modification of therapy is likely to occur because of many issues (e.g., side 
effects) within a first few months of treatment.  Third, patients must not have records of filling 
other anti-diabetic medications including insulin after the respective index date and during the 
study period; however, patients were included if they filled a prescription for insulin or other 
anti-diabetic medicines than SU and TZD only after the minimum 15-month period.  In such 
cases, patients were not followed after they had started such fills.  In other words, the period in 
which only the two study medications were filled were considered for analysis for these patients.  
Because anti-diabetic therapies are to be continued life long, this criterion together with some 
others as described above would, as best as can be determined, ensure that any lack of filling is 
because of nonadherence and not because of physician-driven treatment modifications.  Finally, 
study subjects who were less than 65 years at all time during the observation period were 
selected.  Elderly (≥ 65 years) patients suffer from multiple diseases including diabetes - the 
disease of interest for the study.  Because of their age, oftentimes a disease might have advanced 
to a point when clinician might find it a clinical necessity to prescribe multiple medications for 
the disease.  However, prescription drug coverage of all elderly may not be uniformly captured 
in the database (i.e., MCCED).  In addition, Medicare beneficiaries’ inpatient and outpatient 
medical services utilization might not be completely captured in this commercial claims database 
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and such information is very critical for examining the measurement-related objectives.  Those 
patients who met all the above criteria constituted the general pool of eligible subjects.  It is 
noted here that additional criteria are required to be met prior to examining some hypotheses and 
objectives and are discussed in appropriate sections below. 
 
 
Inclusion Criteria for Examining Inter-disease Medication Adherence 
Subjects for examining inter-disease medication adherence were selected from those 
identified as described above by imposing additional requirements.  Dyslipidemia, hypertension, 
and angina were considered as concordant diseases in conjunction with diabetes.  Statins or 
fibrates were considered for dyslipidemia, any of ACEI, ARB, CCB, diuretics, and β-blockers 
for hypertension, and nitrates (oral nitroglycerin, di-nitrates, and mono-nitrates) for ischemia.  
Patients were required to show at least two fills for medications for the respective diseases.  For 
example, patients with diabetes and dyslipidemia must be filling statins or fibrates in addition to 
a SU and a TZD; patients with diabetes, dyslipidemia, and hypertension must fill any AHT as 
described above and any anti-hyperlipidemic medications in addition to a SU and a TZD.  A 
similar process was followed for patients on angina medications.  The two fills criterion for 
concordant disease medications was consistent with that of intra-disease (diabetes) medications 
adherence.  In addition, having the subjects demonstrate that they had filled concordant disease 
medications before the observation period started ensured at least one year of observation.  
Again, this was consistent with intra-disease medications adherence criteria.   
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Inclusion Criteria for Examining Measurement Approaches 
Patients who were included for examining intra-disease multiple medication adherence 
constituted the general pool of patients.  In addition, subjects were excluded from analysis if they 
had experienced within the first 90 days of observation any adverse outcome events (i.e., 
hospitalization or ER visits) against which measures were to be compared.  This step was 
adopted to avoid measurement problems and potential confounding.  A similar exclusion 
criterion was used while examining the effect of adherence on health outcomes in diabetes 
patients (Yu, Yu, and Nichol, 2010). 
 
Variables and Measurement 
Periods of Observation 
The observation period for each patient was divided into several quarters or 90-day 
periods.  Each patient was observed for at least four quarters.  Duration of three months as the 
unit of observation was chosen because some patients might obtain their prescription 
medications from mail-order pharmacies and received 90 days’ worth of medication supply.  In 
addition, such a time period is, to an extent, consistent with reality such that chronic disease 
patients may visit a pharmacy or a physician once in three months.  Whenever a patient entered 
the study, the first quarter for the patient is started.  Thus, first quarters for different patients may 
represent different calendar time points.   
The selected patients were followed until one of the following events happened: 1) 
disenrollment; 2) patients started filling insulins or any other OADs than SUs and TZDs; or 3) 
62 
the end of the year 2003.  An additional criterion was imposed for comparing the measurement 
approaches.  Subjects were followed until the event occurred. 
 
Measurement of Adherence 
Various measures of adherence can be computed using administrative claims data.  These 
measures use different formulas to estimate adherence (see Hess et al., 2006 for a discussion).  
Mathematically, these formulas are closely related and yield similar values.  Past research has 
attempted to compare the values estimated by different measures.  Karve et al. (2008) compared 
the predictive validity of eight different measures that are generally used in studies that utilize 
administrative claims data.  The authors concluded that PDC provided the most conservative 
estimate of adherence.  Similarly, Hess et al. (2006) examined several measures and reached a 
similar conclusion.  Martin et al. (2009) compared adherence estimates measured by PDC, MPR, 
and truncated MPR (MPRt) in psychiatric disorder patients, including those who were prescribed 
multiple therapies because of therapeutic duplication; the authors recommended using PDC as 
measure of adherence.  Interestingly, the authors discussed a variant of PDC (i.e., the both 
approach) that can be considered a conservative estimate of adherence when applied in the (intra-
disease) multiple medications context such as this study.  Considering only the overlapped 
period, the ‘both’ approach inherently assumes that effects of simultaneously-prescribed 
medications occur only when taken together.  It is very likely that best plausible outcomes can be 
achieved if consumed together as deemed by prescribers.  Nonetheless, effects of individual 
medications cannot be, in general, denied regardless of whether one is taken or both are taken 
concurrently.  PDC appears to demonstrate better or equivalent predictive ability of outcomes 
when compared against other measures suitable for use in research with claims data.  For 
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example, PDC showed the highest c-statistic reflecting its superior ability of health care 
utilization in patients suffering from diabetes (Karve et al., 2008).   
 
Table 3.1: Intra-disease Multiple Medication Adherence Measurement Approaches 
Measure Operational Definition  
Composite ൤ݓ1. ܦܽݕݏݓ݅ݐℎܷܵ݅݊ܳݐݎ݅ܦܽݕݏ݅݊ܳݐݎ݅ + ݓ2.
ܦܽݕݏݓ݅ݐℎܼܶܦ݅݊ܳݐݎ݅
ܦܽݕݏ݅݊ܳݐݎ݅ ൨ /(ݓ1 + ݓ2) 
Average* ൤ܦܽݕݏݓ݅ݐℎܷܵ݅݊ܳݐݎ݅ܦܽݕݏ݅݊ܳݐݎ݅ +
ܦܽݕݏݓ݅ݐℎܼܶܦ݅݊ܳݐݎ݅
ܦܽݕݏ݅݊ܳݐݎ݅ ൨ /2 
At least 
one* ܣ݀ℎ݁ݎ݁݊ݐ݂݅ ൤
ܦܽݕݏ݅݊ܳݐݎ݅ݓ݅ݐℎ ≥ 1 ݉݁݀݅ܿܽݐ݅݋݊ܽݒ݈ܾ݈ܽ݅ܽ݁
ܦܽݕݏ݅݊ܳݐݎ݅ ൨ ≥ 80% 
Max** ൤ܦܽݕݏ݅݊ܳݐݎ݅ݓ݅ݐℎ ≥ 1 ݉݁݀݅ܿܽݐ݅݋݊ܽݒ݈ܾ݈ܽ݅ܽ݁ܦܽݕݏ݅݊ܳݐݎ݅ ൨ 
Both ܣ݀ℎ݁ݎ݁݊ݐ݂݅ ൤ܦܽݕݏ݅݊ܳݐݎ݅ݓ݅ݐℎܾ݋ݐℎ݉݁݀݅ܿܽݐ݅݋݊ݏܽݒ݈ܾ݈ܽ݅ܽ݁ܦܽݕݏ݅݊ܳݐݎ݅ ൨ ≥ 80%  
Min*** ൤ܦܽݕݏ݅݊ܳݐݎ݅ݓ݅ݐℎܾ݋ݐℎ݉݁݀݅ܿܽݐ݅݋݊ݏܽݒ݈ܾ݈ܽ݅ܽ݁ܦܽݕݏ݅݊ܳݐݎ݅ ൨ 
All* ܣ݀ℎ݁ݎ݁݊ݐ݂݅ ൤ܦܽݕݏݓ݅ݐℎܷܵ݅݊ܳݐݎ݅ܦܽݕݏ݅݊ܳݐݎ݅ X 100%൨
≥ 80% ܽ݊݀ ൤ܦܽݕݏݓ݅ݐℎܼܶܦ݅݊ܳݐݎ݅ܦܽݕݏ݅݊ܳݐݎ݅ X 100%൨ ≥ 80% 
 
Note: Qtr: quarter; SU: sulfonylureas; TZD: thiazolidinediones;  w1 and w2: weights;  
* adapted from Choudhry et al., 2009; 
** and *** continuous estimate of the ‘at least one’ and ‘both’ approaches respectively 
 
For this study, adherence was measured as PDC and estimated based on days supply for 
each patient for each class of medications in each quarter.  As noted above, days supply data 
were available in the pharmacy claims data.  The value of the days’ supply was truncated in case 
the supply extended beyond the observation period.  Thus, for some patients who were found to 
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be suffering from multiple chronic diseases, more than two PDC were calculated in some 
quarters.  Any switches between different therapeutic agents (molecules) were not carried 
forward but that between equivalent agents (e.g., different brands of the same molecule) were 
carried forward.  For instance, if a patient was switched from glyburide to glipizide, then 
glyburide on hand, if any, on the day of filling of glipizide was not carried forward for 
calculating PDC for SU.  While the assumption in case of the former was that the physician 
modified the therapy for some reasons and the patient was not supposed to consume those extra 
medications on hand, the assumption in the latter (i.e., between brands) was that the patient 
continued taking the medication from previous refills as part of the same regimen.  Similarly, in 
case of dosage modification, adjustments were made based on recommendations occurring at a 
later point in time.   
Anticipating the plausibility of multiple medications prescribed for hypertension, an a 
priori method was adopted for calculating adherence to antihypertensives after considering 
several alternative options.  One possibility was to consider each PDC separately.  However, it 
could add complexity to statistical analysis and cause potential modeling problems because of an 
increase in number of DVs.  Second, it was possible to estimate PDC in a manner analogous to 
the both approach.  If a therapy augmentation for AHT occurs after observation starts, adherence 
estimates can be weighted by days’ supply.  However, it would be difficult to distinguish 
nonadherence episodes from physician-driven switch or discontinuation for some reasons (e.g., 
side effects).  In such cases, it would further underestimate adherence of these patients.  
Therefore, it was decided that adherence to multiple antihypertensive medications would be 
measured based on the ‘at least one’ approach, i.e., proportion of days covered by at least one 
AH therapy.  This is essentially a single medication adherence estimation approach.  This was 
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thought appropriate because it consistently measured adherence for all hypertension patients 
regardless of numbers of AH medications.   
Four different measurement approaches exist in the literature for estimating adherence in 
situations of multiple medications use for a single disease.  In addition, a composite measure was 
conceived and empirically tested.  Three of these measurement methods (average-based, 
composite, and all) utilized the values of PDC estimated individually for each medication for 
diabetes.  Although the other two methods (i.e., at least one and both) of PDC estimates are 
generally dichotomized for analysis, they can be used as continuous measures as well (termed 
here as ‘max’ and ‘min’ respectively) following the operational definition described in Table 3.1.  
These seven PDC estimates of adherence to multiple medications were computed for each 
patient for each quarter for intra-disease adherence measurement comparisons.   
 
Measurement of Outcome Variable 
The outcome variable was meant to assess the potential impact of nonadherence to 
medications.  The outcome was used for assessing comparative performance of the various 
measures of intra-disease multiple medications adherence.  In other words, the variable was used 
only for examining issues related to the measurement of combined adherence.  Several clinical 
outcomes are available of which one may be chosen for the effectiveness of diabetes treatment.  
HbA1c, fasting serum insulin level, fasting plasma glucose (FPG), and post-prandial blood 
glucose (PPG) are frequently used for monitoring patients for clinical purposes.  However, these 
variables cannot be measured from administrative claims data.  Several variables have been used 
as proxy measures for clinical effectiveness in research related to adherence.  Some of them are 
quality adjusted life years (QALY) (Martinez et al., 2008) and health service utilization such as 
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hospital service utilization or ER visits (Balkrishnan et al., 2007).  Two utilization outcomes are 
generally assessed in studies on adherence to diabetes medication: 1) diabetes-related health 
services utilization (DSU), and 2) all-cause health services utilization (Balkrishnan et al., 2007; 
Karve et al., 2008; Sokol et al., 2005).  Outcomes frequently encountered by diabetes patients 
can also be considered.  Smith and Maynard (2004) reported cardiovascular hospitalizations, 
primarily coronary in origin, accounted for approximately 50% of all hospitalizations in persons 
with diabetes within VA and non-VA medical care systems. Lau and Nau (2004) reported an 
increased likelihood of a diabetes-, cardiovascular-, or cerebrovascular-related hospitalization 
among diabetes patients with poor adherence (≤ 80%).  It is easy to understand such an outcome 
(i.e., cardio- or cerebrovascular related) lies in the middle of the conceptual continuum on which 
more extreme points are occupied by any-cause hospitalization and DSU.  Yu, Yu, and Nichol 
(2010) examined the association between adherence and microvascular complications of diabetes 
using office-based diagnosis of complications.  A number of chronic complications of diabetes 
and their association with medical costs have been identified (American Diabetes Association, 
2002).  This report considered a diverse set of clinical conditions such as cardiovascular diseases, 
neurological symptoms, renal complications, endocrine/metabolic complications among others.  
In contrast, a study conducted in Europe examined eight conditions, including myocardial 
infarction, heart failure, stroke, ischemic heart diseases, while estimating diabetes-related 
hospitalization costs (Gerdtham et al., 2009).  While it may be logical to focus on macrovascular 
diseases, including heart attack, chest pain, coronary heart disease, heart failure, and stroke, as 
they are among major complications in diabetes patients (Deshpande, Harris-Hayes, and 
Schootman, 2008), diabetes-specific outcomes encompassed in past research has varied from 
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being very specific to very broad.  Even within specific events, the focus has been laid on 
microvascular complications or macrovascular events.   
Diagnoses of microvascular complications (DSU) and macrovascular events appeared as 
suitable outcome measures for this project.  Cohen et al. (2003) reported that approximately 29% 
of diabetes patient population enrolled in the MarketScan database suffered from diabetes 
complications in 2000 at which time the number of diabetes population was growing at an 
approximate rate of 10%.  Although, microvascular complications lie closer to medication 
consumption in the causal chain of medication effect, it was not selected because of possibility of 
difficulty in finding a sufficient number (expected to be about 5%) of outcome events in a 
relatively short time-frame of this study.  Similarly, it was difficult to determine if a patient had a 
preexisting diagnosis (for exclusion purposes) if they did not make a physician’s office visit 
within three months or even six months, which might leave even a shorter window for analysis.  
It is further complicated by an inherent limitation in the database that includes only two 
diagnosis options for outpatient services.  Similarly, because of the availability of only 2 years of 
data it would be difficult to find enough subjects having DSU.  Furthermore, any-cause inpatient 
hospitalizations or those occurred primarily because of medical reasons was not chosen because 
of anticipation of insufficient number of events required for a robust analysis.   
Any-cause ER service utilization (ERSU) was chosen as the primary outcome variable to 
examine the measurement issues-related objectives.  ERSU is defined as any ER visits occurring 
after at least 90 days since the beginning of observation.  Existing evidence support that any-
cause ER visits can be used as an indicator for quality of diabetes care (Stern et al., 2009).  
Although objectives in this study are different from Stern et al., yet the adaptation of the concept 
seemed reasonable.  In addition, ERSU as outcome variable may have practical implications 
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given high cost of management associated with them.  ERSU was identified from the outpatient 
services claims file used for comparing the utility of different measures.  ER service utilization 
was identified based on the procedures followed by a previously published study (Margolis et al., 
2010), which used the MarketScan data.  ERSU was dummy coded where 1 indicated occurrence 
and 0 nonoccurrence of events.   
 
Measurement of Covariates 
As discussed previously, chronic diseases often co-occur.  As such, the comorbidity 
profile of these patients was measured.  Several measures of comorbidity exist that were 
developed for different purposes and applied in different population (see de Groot et al 2003 for 
a review).  For this study, the Charlson Comorbidity Index (CCI) (Deyo, Cherkin, and Ciol, 
1992) was used as the measure of comorbidity.  The CCI demonstrates good reliability and 
validity across studies (de Groot et al., 2003).  As correlations between the CCI and adherence is 
generally weak (Sokol et al., 2005), it is less likely to cause multicollinearity.  The CCI was 
measured based on medical claims until the end of first quarters.  Patient demographic 
characteristics (age and gender) were obtained from the enrollment file.  Patients’ age as 
mentioned in the annual enrollment summary file 2002 was used in the analysis.  Other variables 
recorded for descriptive purposes include pharmacy type, insurance type, and geographic region.   
 
Data Analysis 
The study has several broad aims.  Data analysis plans for these aims are organized for 
these aims and discussed below.  Apart from hypotheses testing, descriptions of study population 
69 
and estimates of adherence for different diseases and those based on different measurement 
methods will be provided.   
 
Intra-disease Multiple Medication Adherence Behavior  
It can be recalled that the substantive points that were to be examined included 
relationship between adherence to multiple medications for a disease and that of the evolutions 
of adherence behaviors.  These relationships are outlined by hypotheses 1 through 2b (Table 
3.2).  These hypotheses were tested in the longitudinal analysis framework using a multilevel 
approach.  This analytical approach offers sophisticated modeling appropriate to the discrete-
time longitudinal structure of the data and concurs with Fitz-Simon, Bennett, and Feely (2005) 
who argued to model random effects that incorporate intra-patient variability in prescription refill 
patterns. 
 
 Table 3.2: Statement of Hypotheses 
H1: Overall, there will be a positive covariation between adherence behaviors related to 
two medications taken concurrently for the same chronic disease. 
H1a: Overall, the covariation of adherence between behaviors related to two 
medications taken concurrently for the same chronic disease will persist after 
controlling for gender.   
H1b: Overall, the covariation of adherence between adherence behaviors related to two 
medications taken concurrently for the same chronic disease will persist after 
controlling for age.   
H 2: In general, patients will demonstrate a positive relationship between changes in 
adherence behaviors related to two medications taken concurrently for the same 
chronic disease over a period.  In other words, slope of adherence to each 
medication over time will be positively related (‘association of the evolutions’).   
H2a: The ‘association of the evolutions’ will persist even after controlling for gender. 
H2b: The ‘association of the evolutions’ will persist even after controlling for age. 
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H 3a: For patients suffering from multiple concordant chronic diseases, there will be a 
significant covariation of adherence behaviors related to medications taken 
concurrently for an index chronic disease and another asymptomatic chronic 
disease.   
H 
3a1: 
For patients suffering from multiple concordant chronic diseases, there will be a 
significant covariation of adherence behaviors related to medications taken 
concurrently for an index chronic and another asymptomatic chronic disease 
regardless of disease.   
H 3b: For patients suffering from multiple concordant chronic diseases, there will be a 
significant covariation of adherence behaviors related to medications taken 
concurrently for an index chronic disease and another asymptomatic chronic 
disease even when number of chronic diseases increases.   
H 3c: For patients suffering from multiple concordant chronic diseases, there will be a 
significant covariation of adherence behaviors related to medications taken 
concurrently for an index chronic disease and another symptomatic chronic 
disease.   
 
The multilevel modeling approaches are one of the frequently employed statistical 
methods to analyze longitudinal data.  Specifically, multilevel modeling has been widely used by 
education psychologists for years to investigate contextual effects for a variety of outcomes 
including educational performance, instructional effectiveness, and change in attitudes over time 
(Fraine, Van Damme, and Onghena, 2007; Marsh, 2007).  Multilevel modeling has also been 
applied in the context of health and health behavior.  For example, researchers have examined 
the association between various contextual factors and disease morbidity rates in many diseases, 
including asthma (Juhn, 2005), coronary heart disease (Diez-Roux et at., 1997), and 
cardiovascular diseases (Leyland, 2005).  These approaches account for the hierarchical or 
clustered nature of data.  Hierarchy occurs because units are grouped or clustered at different 
levels.  Multilevel modeling considers information from all levels simultaneously and is able to 
assess the variation in a particular response attributable to each level (Goldstein, 1991).  
Certainly, for clustered data multilevel approaches may offer advantages including chance of 
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drawing correct inferences over traditional methods (Hox 2002; Snijder and Bosker, 1999) and 
allow for, most importantly, micro-level and cross-level analyses including modeling changes as 
a function of time.   
 
Table 3.3: Multilevel Approach to Longitudinal Data Analysis 
 
Unconditional Means Model 
Yij   = M0j  +  Rij, where M0jis the mean of subject j and Rij is deviation of Y for subject j at 
occasion i from the mean 
M0j  = M0  +  U0j , where U0j is deviation of subject j from the population mean M0 
 
Alternatively,  Yij = M0  +  U0j  +  Rij 
 
Unconditional Growth Model 
Yij   = M0j  +  M1j.Time  +  Rij , where M0jand M1jare the intercept  and slope (or growth rate) 
of subject j respectively and Rij is deviation of Y for subject j’s at occasion i from his or her 
true change trajectory  
M0j  = M0  +  U0j ,  where U0j is deviation of subject j from the population intercept M0 
M1j  = M1  +  U1j ,  where U1j is deviation of subject j from the population slope M1 
 
Alternatively,  Yij = M0 + M1.Time  +  U0j  +  U1j.Time +  Rij 
Variance components can be computed for each of U0j, U1j, and Rij 
 
Adapted from Singer and Willet (2003) 
 
Multilevel growth curve modeling can be extended to incorporate multiple dependent 
variables (DV) that are collected longitudinally.  Such an approach, also known as multivariate 
multilevel regression modeling (Snijder and Bosker, 1999), was used to assess the hypothesized 
relationship between the two DVs (i.e., adherence to SU and adherence to TZD) including the 
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trend parameters of them.  More specifically, the association of the evolutions (i.e., changes) 
over time was examined.  In the multivariate model that was used in the study, the dependent 
variables were nested within the measurement occasions, which were nested, in turn, within the 
subjects.  The multiple outcome variables were combined through proper specification at the 
lowest level.  Thus, the dependent variables form level 1, measurement quarters form level 2, 
and patients form level 3.   
First, the unconditional means (or, random intercept) model was fitted (Table 3.3).  It can 
be noted here that hypothesis testing (for intra-disease medication adherence) that was followed 
in the study is consistent with the approach suggested by Singer and Willet (2003) who 
recommend fitting the unconditional (i.e., without predictors) means model followed by 
unconditional growth (or, random slope) model.  The unconditional means model implies that a 
specific observed value of y (i.e., Ytj or in this analysis, a person’s PDC at a specific quarter) at a 
point t is a deviation from a person j’s true mean (i.e., Y0j) and thus, the actual individual change 
trajectory is flat as represented by person-specific mean.  In other words, under this model such 
deviations or level 2 residuals (as level 1 contains multiple DVs in this study) are within-person 
distance from respective individual means.  Thus, variance component of level 2 under 
unconditional means model is the population variability in an average person’s outcome 
estimates around his or her own mean.  Similarly, level 3 (for this study) residuals represent 
between-person deviations from the population mean because a person individual mean is a 
deviation from the population mean (Singer and Willet, 2003).  The statistical models for 
examining hypotheses associated with intra-disease multiple medication adherence were adapted 
from the literature (Fieuws and Verbeke, 2004; Snijder and Bosker, 1999) and are presented 
below.   
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Random intercept model  
Yhtj = M10.d1 + M20.d2 + U10j.d1 + U20j.d2+ R1tj.d1 + R2tj.d2  --------------- (1)  
Random intercept with fixed covariates model 
Yhtj = M10.d1 + M20.d2 + C1.d1.Cov + C2.d2.Cov + U10j.d1 + U20j.d2 + R1tj.d1 + R2tj.d2----- (2) 
Random slope model 
Yhtj = M10.d1 + M20.d2 + M11.(t-t0)d1 + M21.(t-t0).d2 + U10j.d1 + U20j.d2 + U11j.(t-t0).d1 + U21j.(t-
t0).d2 + R1tj.d1 + R2tj.d2--------------- (3)  
Random slope with fixed covariates model 
Yhtj = M10.d1 + M20.d2 + C1.d1.Cov + C2.d2.Cov + M11.(t-t0)d1 + M21.(t-t0).d2 + U10j.d1 + U20j.d2 + 
U11j.(t-t0).d1 + U21j.(t-t0).d2 + R1tj.d1 + R2tj.d2--------------- (4)  
where h=1 for adherence to SU and h=2 for adherence to TZD; 
d1=1 when h=1; d1=0 otherwise, and d2=1 when h=2; d2=0 otherwise; 
M10 and M20 are population mean for random intercepts model (eq. 1 and 2) but population 
intercepts for random slope models (eq. 3 and 4); 
M11 and M12 are population mean slope; 
Ch (h=1,2) are coefficients for fixed covariates Cov; 
Uh0j (h=1,2) are individual-dependent random components for jth individual that affect all values 
Yhtj in the same way; 
Uh1j (h=1,2) are individual-dependent random components indicating rate of change for jth 
individual where t0 is the reference point; 
Rhtj (h=1,2) are random deviations from individual mean for jth individual at time t.   
Random effects, not parameters in a statistical sense but latent variables (Snijder and 
Bosker, 1999), were the effects of interest.  Under the assumption of normal distribution, there 
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are two major estimation methods for measuring random effects: maximum likelihood (ML) and 
residual (or restricted) maximum likelihood (REML).  However, the REML method is useful for 
testing overall model fit only when two models have the same fixed parameters but differ in 
random effects.  Random intercepts or random slopes were fitted first.  Then sequentially 
covariates (gender and age) were introduced in each model to examine whether effects would 
persist after the effects of covariates were controlled.  It should be noted here that while residual 
variance components U10 and U20 (estimated from deviations U10j and U20j, respectively) for eq. 1 
and 2 represent between-person variability around grand mean, those for eq. 3 and 4 represent 
between person variability in initial estimate and U11 and U21 estimate between-person variability 
in rates of change.  Similarly, R1 and R2 (estimated from deviations R1tj and R2tj, respectively) for 
eq. 1 and 2 estimate within-person variance or the pooled scatter of each individual’s data around 
his or her individual mean and those for eq. 3 and 4 measure the scatter of each individual’s 
values around his or her linear growth trajectory (Singer and Willet, 2003).  Covariances related 
to level 3 (i.e., inter-individual) random components between two dependent variables (i.e.,U10 
and U20 for eq. 1 and 2; U11 and U21 for eq. 3 and 4) were examined for significance.  In addition, 
the goodness of fit test was conducted for covariate models.  To examine the association of the 
evolutions, methods suggested by Fieuws and Verbeke (2004) were followed.  The correlation 
between changes in adherence was given by   
ݎ = ܥ݋ݒܽݎ݅ܽ݊ܿ݁	(ܷ11	ܽ݊݀	ܷ21)ݏݐ݀. ݀݁ݒ	(ܷ11). ݏݐ݀. ݀݁ݒ	(ܷ21)	……………………(5) 
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Inter-disease Multiple Medications Adherence Behavior  
The random intercept model (described by equation 1) employed for hypothesis 1 was 
adapted to examine hypothesis 3a through 3c.  Specifically, hypertension, dyslipidemia, and 
angina medication adherence were added in the model in addition to diabetes medication 
adherence for hypothesis 3a, 3a1, and 3c, respectively, whereas adherence to anti-hyperlipidemic 
medications was added in the model for hypothesis 3a to test hypothesis 3b.  It can be understood 
that the number of DVs in each of these models are either three or four.  Thus, random intercept 
model for intra-disease adherence is extended for inter-disease adherence by addition of extra 
DVs.  Notations are extended accordingly to incorporate additional random intercept components 
due to additional DVs.  Covariances/correlations between these random intercepts were the 
effects of interest and tested for significance.   
Random Intercept Model for Inter-disease Multiple Medications Adherence 
Yhtj = ∑ Mi0.di + ∑ Ui0j.di + ∑ Ritj.di,  where h =1, 2 or 3; di=1 if i=h, otherwise di=0.---- (6)  
 
Measurement of Intra-disease Medication Adherence 
The new composite measure that was described in Chapter 2 is a weighted average-based 
measure.  Conceptually, each adherence estimate can be weighted to form a formative scale of 
composite value based on their relative contribution to patient health or treatment outcomes.  
Deriving appropriate weights is critical to the success of any composite measures.  Thus, 
important issues include but not limited to which parameters and how such weights should be 
derived.  Some directions can be provided from the medical risk assessment literature.  Several 
risk evaluation models have been proposed to stratify risks systematically (see Gale et al., 2009 
for a review).  These models estimate risk of an event based on weights of individual factors 
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derived from regression.  For example, the EMMACE risk model predicts the risk of 30-day 
mortality where age, blood pressure, heart rate are weighted (Gale et al., 2009).  Similarly, the 
TIMI risk score for the prediction of mortality in ST- elevation myocardial elevation is computed 
as the simple arithmetic sum of factors of mortality weighted according to the adjusted odds 
ratios (e.g., 1 point for 1 < OR < 2; 2 points for 2 < OR < 2.5 and so on) from logistic regression 
analysis (Morrow et al., 2000).  Calvin et al. (2000) cited the RUSH model where the risk of 
sustaining a major cardiac complication is computed as weighted average; two medication 
histories (0.85 for IV nitroglycerine required on admission and 1.34 for receiving neither β-
blocker nor CCB at admission) were weighted differentially.  Indeed, weighting individual risk 
factors by odds ratio, Calvin et al. (1995) argued, does provide a reasonable approach to risk 
stratification for major complications.   
The Cox proportional hazards model was used to derive weight estimates.  This model 
provides a semiparametric regression technique to discriminate risk factors, including those 
varying with time, associated with the occurrence of events (e.g., ER visits) during a specific 
interval (Singer and Willet, 2003).Advantages of the Cox method to model the time until an 
event of interest occurs are that it makes no assumption about the shape of the underlying hazard 
function, but identifies determinants of risks and estimates multipliers of the baseline hazard and 
the relative risks(hazard ratios) associated with the risk factors(Singer and Willet, 2003).  The 
analysis of Cox regression is based on number of events per variable (EPV), not number of 
patients or patient-years.  Thus, a sufficient number of events is required to enable accurate 
estimates. A general rule of a minimum of 10-20 EPV has been advocated for Cox regression 
(Concato et al., 1995; Peduzzi et al., 1995) although Vittinghoff and McCulloch (2007) argued 
that analysis with 5-9 EPV might be comparable with 10-16 EPV in some situations. In cases of 
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fewer events per independent variable, resampling techniques can be used to test model validity 
(Akins et al., 2008).  In the Cox model for weight derivation, ERSU was the outcome measure 
and adherence estimates were treated as time-varying covariates.  Adherence measured as PDC 
was computed for each quarter for each medication for diabetes.  Comorbidity (CCI), gender, 
and age were treated as fixed (i.e., time-invariant) covariates.  However, as mentioned before, 
patients were followed until the first occurrence of event.  This analysis strategy was consistent 
with a previous study (Yu, Yu, and Nichol, 2010) that examined the effect of adherence on 
health outcomes.  Hazard (parameter) estimates derived from Cox regression were used 
subsequently as weights.   
Following the effort of computation of weights, a series of analysis were performed to 
compare the predictive ability of medication adherence as measured by different measurement 
techniques available in the literature and the one proposed in this study.  The seven PDC 
measures of adherence (see Table 3.1) were calculated for each quarter for each patient.  The 
Cox regression analysis as described above was repeated in which ERSU was used as outcome 
measure and one of the seven adherence estimates was used as risk factor in different models 
while keeping the same covariates.  Then the next step is to characterize the performance of the 
models in which adherence was operationalized differently or measured by different 
mathematical formulas.  Two types of measures are used for such purposes while modeling 
dichotomous outcomes: calibration and discrimination (Pembina and D’Agostino, 2004).  
Calibration, as defined by the authors, describes how closely the probabilities predicted by the 
model correspond with the observed outcomes. Discrimination is a measure of a model’s ability 
to classify subjects correctly into one of the binary outcome categories (e.g., events vs. no-
events).  Although calibration and discrimination may be related, good discrimination does not 
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automatically confer the ability of good calibration and vice versa (Pencina and D’Agostino, 
2004); demonstration of a model’s ability to discriminate well should be of primary importance 
(Harrell, Lee, and Mark, 1996).   
C-statistic – equivalently, area under the Receiver Operating Characteristic (ROC) curve 
– computed from a logistic regression analysis determines the predictive accuracy or 
discrimination ability of the model and is one of the most popular measures of model 
discrimination for binary outcomes (Hanley and McNeil, 1982).  Unlike logistic regression, the 
measurement of predictive accuracy in survival analysis is more complex because of censoring.  
Harrell, Lee, and Mark (1996) introduced c-statistic as a natural extension of the ROC curve 
analysis and suggested plotting the predicted probability of surviving until each time point tj 
(j=1,2..) against the actual proportion of subjects surviving beyond tj.  An overall C index, 
conceptually based on the measure of c-statistic in logistic regression, has been proposed to 
describe the performance of a survival analysis model (D’Agostino and Nam, 2004; Pencina and 
D’Agostino, 2004). D’Agostino and colleagues outlined the steps of computation of C-index as 
follows.  From a time-to-event model, three sets of comparison groups can be identified: those 
who experience event against those who do not (event vs. non-event), those developing event 
against those also developing event (event vs. event), and event group against those censored 
(event vs. censored).  For the sake of computing C-index, event vs. event and event vs. non-event 
comparisons are considered as usable pairs; in other words, if two individuals are randomly 
drawn at least one must have an event while the other may or may not develop so.  Given all 
usable pairs, the C-index is computed based on the proportion of concordance such that a subject 
with a lower predicted probability of event experiences event later than does another with a 
higher probability or vice versa.  Several variants of this conceptualization (Gonen and Heller, 
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2005; Kremers, 2007) and implementation in statistical software exist (e.g., Liu, Forman, and 
Barton, 2009).  The modified definition advanced by Kremers (2007) was used in the study as it 
is suitable for time-dependent covariates and adjusts for ties of events, if any.  Unlike 
D’Agostino and colleagues’, Kremers’ definition is indexed by event times and counting occurs 
with respect to each event time.  For example, if an individual i experiences event at time ti, it 
counts all other individuals (Ci) except i not having event at ti but with predictor score lower than 
that of i, those with greater score at ti and no-event at ti as Di, those (Pi) with equal score but no-
event at ti, and those (i.e., ties) with event at ti as Ti.  Then Ci, Di, Pi, and Ti represent the count of 
useable pairs that can be formed with individual i at time ti and can be termed as concordant, 
discordant, tied in prediction, and tied in time, respectively.  Concordance (or, C-index) 
quantifies the proportion of all useable pairs of subjects such that a subject with the higher 
model-predicted risk of event experiences event earlier and vice versa.  Kremers’ 
conceptualization of concordance has been used in empirical studies (Fang et al., 2011; Wong et 
al., 2011b) to examine the accuracy of risk predictions and implemented in SAS by the author.  
Concordance values and their confidence intervals estimated for models with different adherence 
measures were compared.   
Analysis was undertaken to determine the optimal cut-off point for dichotomization of 
the four continuous adherence (i.e., composite, average, min, and max) measures.  Unlike data 
dependent methods (e.g., median-split), outcome-based methods for dichotomization of 
continuous variables rely on statistical criteria that best separate groups with regard to the 
outcome.  ROC curve analysis is generally used to determine the optimal threshold of continuous 
or ordinal variables that differentiates binary outcomes and is a popular method in diagnostic 
medicine (Begg et al., 2000; Hanley and McNeil, 1982; Harrell, Lee, and Mark, 1996).  Unlike 
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in logistic regression, ROC curves appear to vary as a function of time when derived from 
survival analysis (Heagerty, Lumley, and Pepe, 2000).  Therefore, deriving optimal threshold 
based on ROC curves is difficult.  Moreover, time-dependent optimal threshold may not be 
appealing conceptually.  Another approach to dichotomization is based on maximization of 
appropriate test statistics.  In the case of censored data, several statistics that are routinely 
reported by statistical software can be utilized for such purposes, including log-rank test 
(Williams et al., 2006), concordance statistic, Wald statistic, and partial likelihood ratio statistic 
(Gonen and Sima, 2008; Hollander, Sauerbrei, and Schumacher, 2001).  Mazumdar and 
Glassman (2000) outlined the steps required to derive an optimal cut-off value.  This approach, 
known as maximally selected statistic, is based on a series of two sample tests such that models 
are run with each of the potential candidate cut-off values and the cut-off value for which the 
respective model generates the maximum test statistic (or, minimum p-value) is chosen as 
optimal threshold.  In general, such models are run in a unavailable setting although 
recommendations for multivariable model also exist (Mazumdar and Glassman, 2000; 
Mazumdar, Smith, and Bacik, 2003).  In order to manage potential inflation of type I error due to 
multiple tests, several approaches have been recommended.  The methods to address such 
problems include: (1) significance level (α) adjustment (e.g., Bonferroni adjustment or some 
variants), (2) p-value adjustment based on mathematical functions or distribution (e.g., adjusted 
p-value of 0.002 is equivalent to unadjusted p = 0.05 while examining all values within the inner 
80% distribution of the variable), and (3) cross-validation/ split sample approach (Altman et al., 
1994; Faraggi and Simon, 1996; Hilsenbeck and Clark, 1996; Lausen and Schumacher, 1996; 
Mazumdar and Glassman, 2000; Mazumdar, Smith, and Bacik, 2003; Miller and Siegmand, 
1982).  In an unpublished study, Gonen and Sima (2008) contrasted the utility of five different 
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statistics in deriving optimal cut-point with censored data and the partial likelihood ratio statistic 
based method emerged as the best strategy that performed consistently.  The partial likelihood 
ratio statistic based minimum p-value approach was employed in the study.  A set of candidate 
values (65, 70, 75, 80, and 85) were chosen a priori.  These points are somewhat consistent with 
existing evidence (e.g., Karve et al., 2009; Hansen et al., 2009 for a single medication adherence) 
and clinical expert opinion and may be useful for implementation purposes.  Bonferroni-
adjustment was made for p-value and such adjustment may not result in underpowered analysis 
because of relatively small number of tests. 
Data were analyzed in SAS software, version 9.3 (SAS Institute, Inc., Cary, North 
Carolina).  Relevant SAS codes for multilevel modeling and SAS macros were obtained from the 
literature and past research (Kremers 2007; Thorp, 2007).    
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CHAPTER 4 
RESULTS 
Of all subjects whose data were available in the MarketScan 2002-2003 commercial 
claims database, 32,400 enrollees had filled at least one prescription for a SU and TZD by 
September 30, 2002.  After the application of study inclusion criteria, 6922 subjects were eligible 
for subsequent analysis.  These subjects were between18 and 62 years old as of 2002, 
continuously enrolled for at least 15 months from their index date (i.e., earliest date indicating 
filling of both SU and TZD), and either did not fill any diabetes medications other than SU and 
TZD after the respective index date or did not begin filing other diabetes medications until at 
least 15 months after their index date.   
Note on Study Subject Selection 
All prescription claims records for 2002 and 2003 of the selected subjects were extracted.  
NDCs from prescription (RX) claims files were merged with their respective active ingredient 
(or drug) name and strength using the Multum Lexicon Drug Data Table (Cerner Multum, 2011).  
Some enrollees filled nonzero quantities of a NDC more than once on one day.  As such, 
duplicate fillings occurred for both SU and TZD.  Subjects associated with duplicate fillings of 
medications were excluded from subsequent analysis.  It was observed in the dataset that some 
subjects had a record of filling multiple SU (e.g., Amaryl and glipizide) or multiple TZD and 
others filled multiple strengths of a  SU or a TZD (e.g., Avandia 2 mg, 4 mg, or 8 mg).  For 
subjects displaying prescription fillings of multiple medications or strengths of SUs or TZDs, it 
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was observed that some patients filled multiple classes or strengths somewhat regularly while 
others switched from one strength to another within a medication.  It is conceivable as to why a 
patient might be filling multiple strengths of medications.  One potential reason may be that a 
physician might advise his patient to take different strengths of medication at different times in 
order to achieve desired therapeutic outcomes (e.g., 2 mg at morning and 4 mg at night).  
However, it is difficult to differentiate instances of nonadherence from physician-driven 
medication consumption decisions in cases of lack of regular filling patterns.  Similarly, in cases 
of patients filling multiple medications, it cannot be clearly determined whether or not a change 
was made because of some legitimate medical reasons such as side effects.  Thus, it is not 
possible to determine accurately the state of adherence for a patient who filled multiple 
medications.  Because of indeterminacy a criterion was imposed for inclusion.  That is, subjects 
were restricted to any molecule switch and/or strength switch once only.  This would ensure that 
if subjects switched from one strength to another of the same medication or one medication to 
another they would not be filling two strengths or two classes of medications simultaneously as 
switches of each type were constrained to once or less.  Thus, these subjects will be on two 
diabetes medications, a SU and a TZD, at any point in time consistent with the objective of 
examining simultaneous medication adherence for two diabetes medications.   
 
Demography of Study Subjects 
A total of 6043 subjects were available for final analysis and constituted the general pool 
of study participants.  The demographic characteristics of the subjects are described in Table 4.1.  
On average, these subjects were available for observation for over 600 days.  There were 55.5% 
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male and the average age of the subjects was nearly 54 years.  The subjects were located across 
different geographic regions as determined from the enrollment summary file in 2002; however, 
the majority of the subjects came from the South and north central regions.  The subjects were 
enrolled in different types of health benefit plans.  PPO and comprehensive type of plans were 
predominantly chosen ones.  However, few subjects appeared to have changed their plan types 
over their enrollment period.  Approximately, 19% subjects filled prescriptions of SU and/or 
TZD from both community and mail order pharmacies.  However, the majority of the subjects 
appeared to patronize community pharmacies only when prescription fills for SU and TZD were 
considered jointly.   
 
Table 4.1: Demography of the Study Subject Pool 
Variable N Mean (std. dev) /Frequency % 
Age 6043 53.86 (6.67) 
Gender (male) 3356 55.54% 
Geographic Region#   
Northeast 523 8.65% 
North Central 2442 40.41% 
South 2580 42.69% 
West 488 8.08% 
Plan type   
Comprehensive 1862 27.61% 
EPO 161 2.39% 
HMO 588 8.72% 
POS 883 13.09% 
PPO 2789 41.35% 
POS with capitation 462 6.85% 
Number of Plan type   
One type 5359 88.68% 
Two or more 684 11.32% 
Pharmacy Patronage*   
Community Pharmacy only 3776 62.49% 
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Mail-order only 893 14.78% 
Either type 1135 18.78% 
Number of Days of Observation 6043 636.21 (79.01) 
Number of Comorbidities 6043 1.06 (0.31) 
Charlson Comorbidity Index (CCI) 6043 2.08 (0.42) 
 
* Based on filling patterns for SU and TZD and other medication fills were  not 
considered; # there were 10 subjects from unknown regions:  
 
INTRA-DISEASE MULTIPLE MEDICATION ADHERENCE  
Overall, the subjects demonstrated good levels of adherence (about 74%) for both SU and 
TZD and maintained consistency in adherence over time (Table 4.2).  With regard to population 
level estimates, the adherence levels of SU measured at each quarter closely followed the 
adherence levels of TZD for the respective quarters.  All subjects had 90-day observation periods 
at least until the fifth quarter but the number of available days of observation in their last quarter 
varied among subjects.  For example, if a person was observed for seven quarters, he has six 90-
day observation periods and the last (i.e., seventh) quarter with 90-days or less.  For the sake of 
estimation of last quarter PDC, two options were available: keeping the 90-day denominator for 
everyone or using subject-specific variable denominators based on availability.  For the last 
quarter, the number of available days of observation for a subject was entered in the respective 
denominator as a wide variety of available days of observation were found (e.g., less than 10 
days to 90 days).  In addition, more than 1000 subjects had a last quarter such that the number of 
days available for observation in the quarter was less than 30.  As expected, adherence rates 
continuously declined, although slightly, over time until quarter 6.  However, the rates increased 
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slightly for the last two quarters when number of patients who were available for observation 
continued to decrease.   
 
 
Table 4.2: PDC Estimates for SU and TZD 
Quarter N SU TZD 
Mean Std. dev. Mean Std. dev. 
1 6043 84.19 23.87 85.64 22.52 
2 6043 75.00 32.78 75.79 33.13 
3 6043 73.81 34.00 73.98 34.82 
4 6043 72.90 35.15 72.52 36.42 
5 6043 71.70 36.06 70.31 37.86 
6 6043* 69.76 37.79 69.04 39.38 
7 4979* 70.00 38.18 69.36 39.58 
8 3752* 72.18 38.46 70.77 40.02 
Weighted Average# 73.86 73.66 
* Numbers of days of observation in these quarters are not 90 days for all subjects  
# Weighted by N 
SU: Sulfonylureas; TZD: Thiazolidinediones  
 
Examination of Hypotheses: Intra-disease Multiple Medication Adherence 
A total of 6043 subjects were available initially for the examination of intra-disease 
multiple medication adherence (Hypotheses 1 through 2b.  Only full-quarter observations were 
included in these analyses.  For example, if a person had 7 full quarters of observations and one 
incomplete quarter, his incomplete quarter PDC was dropped when analysis was performed on 
the 8th quarter.  The number of persons available in the 6th, 7th, and 8th quarter were 4996, 3772, 
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and 447, respectively. Although random intercept models were run successfully, growth models 
could not be run on the entire set of subjects because of computation limitations when the SAS 
default method for the estimation of denominator degree of freedom (ddf) was used.  However, 
by limiting the analysis to subjects having at least 6 full quarters of observation, both models 
could be run successfully.  Another alternative option was to choose other methods for 
estimation of ddf.  Estimation of ddf is concerned primarily with fixed effect tests, which were 
not the objective of this research.  SAS offers many approximate ddf estimation methods.  The 
Kenward and Roger method (i.e., ddfm=KR on the PROC MIXED model statement) was used in 
this study.  The Kenward and Roger method requires less memory than the default method in 
SAS and is thought to perform reasonably well when complicated covariance structures are 
present, sample sizes are moderate to small, and the design is moderately balanced (Schaalje, 
McBride, and Fellingham, 2001).  Unconditional and conditional random intercept models and 
growth models using the KR method were run for examining the hypotheses.  The results are 
summarized in Table 4.3. 
 
Table 4.3: Multilevel Model Analysis – Intra-disease Multiple Medication Adherence 
Model Parameter Covariance Correlation 
Estimate Std. error Z value P  
Unc. Mns Int-SU/Int-TZD 420.71 11.7966 35.66 <.0001 0.5665 
Con. Mns1 Int-SU/Int-TZD 394.94 11.3517 34.79 <.0001 0.5509 
Con. Mns2 Int-SU/Int-TZD 416.79 11.7301 35.53 <.0001 0.5641 
Con. Mns3 Int-SU/Int-TZD 391.77 11.2982 34.68 <.0001 0.5488 
Unc. Grt Slp-SU/Slp-TZD 17.4088 0.6031 28.87 <.0001 0.6209* 
Con. Grt1 Slp-SU/Slp-TZD 17.4006 0.6030 28.86 <.0001 0.6207* 
Con. Grt2 Slp-SU/Slp-TZD 17.4111 0.6031 28.87 <.0001 0.6209* 
Con. Grt3 Slp-SU/Slp-TZD 17.4027 0.6031 28.86 <.0001 0.6207* 
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Unc. Mns: Unconditional Means model; Con. Mns: Conditional Means model; Unc. Grt: 
Unconditional Growth Model; Con. Grt: Conditional Growth Model;  
Int: Random intercept; Slp: Random slope;  
1: mean centered age as covariate; 2: gender as covariate; 3: mean centered age and gender 
as covariates; * Represents the association of evolutions   
SU: Sulfonylureas; TZD: Thiazolidinediones  
 
For the examination of hypothesis 1, a random intercept model was analyzed on quarter-
specific PDC estimates.  PDC estimates for different medications can be identified by a dummy 
variable indicating different medications (i.e., SU and TZD).  The covariation between random 
intercepts of SU and TZD was estimated at 420. 71 and it was significant (p<0.001).  Thus, H1 
was supported.  The corresponding correlation between random intercept for SU and that of TZD 
was 0.5665.  For examining Hypotheses 1a and 1b, age (mean centered) and gender was entered 
one at a time in the above model.  The effects were significant (Appendix).  After controlling for 
age and sex, the covariations remained significant at the level of 0.001.  The correlations 
between random intercepts of SU and TZD in the model with age and with gender were 0.5509 
and 0.5641, respectively, providing support for H1a and H1b were confirmed.   
Growth models were used to examine Hypotheses 2 through 2b.  Two random 
components were added to the slopes of PDC estimates for SU and TZD.  Thus, the growth 
models contained four random components – one component for the intercept and one for the 
slope for each of the two adherence estimators.  For the examination of hypothesis 2, covariation 
between random slopes was examined.  The results are described in Table 4.3.  The covariation 
between random slopes of SU and TZD was estimated at 17.41 and it was significant (p<0.001).  
Thus, H2 was confirmed.  The corresponding correlation (i.e., the association of evolutions) 
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between random slopes for SU and that of TZD was found to 0.62.  When Hypotheses 2a and 2b, 
age (mean centered) and gender was entered respectively in the model specified for H2.  After 
controlling for the effect of age and gender, the covariation remained significant at the level of 
0.001.  The associations of evolutions of SU and TZD in the model with age and with gender 
were 0.62.  Thus, the results supported H2a and H2b, respectively. 
 
INTER-DISEASE MULTIPLE MEDICATION ADHERENCE  
In addition to using multiple diabetes medications, diabetes patients may use medications 
for the treatment of one or more different chronic disorders.  Hypotheses 3a through 3c were 
meant to examine simultaneous adherence behaviors for medications prescribed for different 
additional chronic diseases.  Subjects were selected from the general pool with an additional 
restriction that subjects must have at least four full quarters of observation beginning from the 
inter-disease index date.  The index date for inter-disease medication adherence may be different 
from index date for intra-disease medication adherence.  Inter-disease index date was determined 
by the first fill for a medication intended for the asymptomatic chronic disease of interest; the 
inter-disease index date could occur on or later than the index date.  For example, in case of 
examining adherence relationships between diabetes medications and an anti-hyperlipidemic 
medication (asymptomatic chronic disorder), if a patient filled an anti-hyperlipidemic medication 
before his index date for SU and TZD, the inter-disease index date took the value of the diabetes 
index date.  Similarly, for a patient on two diabetes medications, antihypertensives, and anti-
hyperlipidemic medications the earliest date indicating the patient filled all requisite medications 
at least once was considered as the index date for subsequent analysis.  Four inter-disease index 
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dates were computed for a patient who was eligible for inclusion in all analyses associated with 
Hypotheses 3a through 3c.  Only those patients who demonstrated at least one prescription fill 
for chronic disease of interest and had at least four quarters of observation following respective 
inter-disease index dates were included in hypotheses testing.   
 
 
Table 4.4: Demography of the Inter-disease Multiple Medication Adherence Subjects 
Analysis Variable N* Mean (std. dev) /Frequency (%) 
SU + TZD + LIP 
(H3a) 
Age 
2360 
 
54.92 (6.02) 
Gender (male) 1387 (58.77) 
Number of Days of 
Observation 
609.95 (92.38) 
SU + TZD + 
AHT (H3a1) 
Age 
2444 
 
53.70 (6.57) 
Gender (male) 1316(53.85) 
Number of Days of 
Observation 
578.57 (162.81) 
SU + TZD + LIP  
+ AHT (H3b) 
Age 
860 
54.60 (94.15) 
Gender (male) 462 (55.66) 
Number of Days of 
Observation 
601.87 (6.13) 
SU + TZD + 
ANG (H3c) 
Age 
300 
56.46 (4.73) 
Gender (male) 187 (62.33) 
Number of Days of 
Observation 
559.92 (101.74) 
* Subjects who had at least four 90-day quarters of availability starting from analysis-specific 
index dates  
SU: Sulfonylureas; TZD: Thiazolidinediones; LIP: anti-hyperlipidemic medications; AHT: 
hypertension medications; ANG: Anti-anginal medications   
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Table 4.4 describes the demographic profile of the subjects included in inter-disease 
multiple medication adherence analyses.  Subjects were about 55 year old and had, on average, 
560 days of observation following the start of the analysis-specific (e.g., SU + TZD + AHT + 
LIP for H3b) index date.  With regard to gender, subjects consuming multiple asymptomatic 
chronic disorder medications were evenly split except for those having angina in which 62% 
were male.   
 
PDC Estimates for Different Chronic Diseases 
The population PDC estimates for different asymptomatic chronic disorders were about 
70% (Table 4.5).  Subjects may have had incomplete observation periods from quarter 5 onward.  
The PDC denominator for any incomplete quarters was based on available days of observation.  
Patients receiving anti-hyperlipidemic medications had slightly lower average adherence rates on 
those medications than their PDC for their diabetes medications.  In contrast, those subjects 
receiving antihypertensives showed slightly higher adherence rates when compared to their 
diabetes medications.  Higher adherence rates for antihypertensives, although small, persisted 
even in subjects receiving four medications: SU, TZD, anti-hyperlipidemic medications agents, 
and antihypertensives.  Interestingly, adherence rates to nitrates were lower substantially.  
Additionally, adherence rates in the last two quarters showed an increasing trend regardless of 
the nature of disease. 
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Table 4.5: PDC Estimates for Subjects on Medications for Multiple Chronic 
Disorders 
Model Param Qtr 1 Qtr 2 Qtr 3 Qtr 4 Qtr 5 Qtr 6 Qtr 7 Qtr 8
SU+TZD+
LIP 
Mean 
(SU) 
85.20 77.31 76.38 75.44 74.46 72.36 72.49 74.17 
Std. Dev 23.76 31.92 33.17 34.53 35.28 37.16 37.79 38.74 
Mean 
(TZD) 
86.22 79.02 77.21 75.53 73.07 72.38 72.98 74.99 
Std. Dev 22.76 31.20 33.61 34.91 36.90 38.48 38.43 38.54 
Mean 
(LIP) 
84.05 74.02 72.01 69.98 68.79 67.36 70.09 71.46 
Std. Dev 24.42 34.05 36.27 37.89 38.65 40.47 39.22 39.59 
N 2360 2360 2360 2360 2357 2234 1748 1233 
SU+TZD+
AHT 
Mean 
(SU) 
84.47 75.76 74.87 73.92 72.23 70.58 70.32 73.55 
Std. Dev 23.85 32.36 33.42 34.46 35.59 37.50 37.97 37.80 
Mean 
(TZD) 
85.26 76.76 74.66 73.67 71.57 70.84 70.82 71.99 
Std. Dev 23.26 32.99 34.77 35.91 37.34 38.44 38.96 39.79 
Mean 
(AHT) 
86.07 78.72 77.56 76.71 75.45 74.82 76.31 77.58 
Std. Dev 22.71 31.34 32.40 34.06 35.12 36.21 35.05 35.70 
N 2212 2212 2212 2212 2212 2145 1734 1276 
SU+TZD+
LIP+AHT 
Mean 
(SU) 
85.46 78.02 76.87 75.74 74.56 72.48 72.65 75.09 
Std. Dev 24.01 31.94 33.14 34.74 35.30 37.22 37.65 38.61 
Mean 
(TZD) 
85.88 79.50 78.05 77.32 74.90 73.88 74.74 76.38 
Std. Dev 22.71 31.34 33.24 33.79 35.80 37.79 37.63 38.23 
Mean 
(LIP) 
82.78 74.90 72.66 72.11 68.68 67.25 71.09 71.56 
Std. Dev 25.23 33.73 35.99 36.70 38.00 40.42 38.83 39.92 
Mean 
(AHT) 
86.40 81.75 80.42 79.50 78.03 77.79 79.89 80.19 
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Std. Dev 23.27 29.29 31.04 33.23 33.74 35.22 33.64 34.82 
N 830 830 830 830 830 775 593 408 
SU+TZD+
ANG 
Mean 
(SU) 
79.84 75.53 75.41 73.37 72.13 69.57 69.36 77.01 
 
Std. Dev 28.94 34.27 34.89 36.34 37.38 40.27 39.47 36.87 
Mean 
(TZD) 
80.90 71.09 69.57 70.12 68.09 69.00 69.87 71.45 
Std. Dev 29.18 37.28 38.96 38.86 39.93 40.97 40.32 42.07 
Mean 
(ANG) 
37.99 25.76 25.73 24.69 24.43 25.38 31.41 36.05 
Std. Dev 37.07 40.48 40.12 38.38 39.10 39.50 42.38 44.80 
N 300 300 300 300 299 253 166 88 
Param: Parameters; Qtr: Quarter;  
Subjects may have incomplete quarters from quarter 5 onward and PDC denominator for 
any incomplete quarters was based on available days of observation  
SU: Sulfonylureas; TZD: Thiazolidinediones; LIP: anti-hyperlipidemic medications; 
AHT: hypertension medications; ANG: Anti-anginal medications  
 
 
Table 4.6: Number of Subjects for Inter-disease Multiple Medication Adherence  
Quarter Number of subjects with medications for multiple chronic diseases 
SU+TZD+LIP SU+TZD+AHT SU+TZD+LIP+AHT SU+TZD+ANG
1 2360 2212 830 300 
2 2360 2212 830 300 
3 2360 2212 830 300 
4 2360 2212 830 300 
5 2235 2145 776 253 
6 1752 1736 594 167 
7 1240 1284 410 88 
8 92 87 19 6 
SU: Sulfonylureas; TZD: Thiazolidinediones; LIP: anti-hyperlipidemic medications; 
AHT: hypertension medications; ANG: Anti-anginal medications   
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Examination of Hypotheses: Inter-disease Multiple Medication Adherence 
Multi-level modeling analyses were used to examine Hypotheses 3a through 3c.  
Specifically, multivariate unconditional random intercept models were analyzed in which 
quarter-specific PDC estimates for each medication were analyzed.  Consistent with the 
approach used to examine intra-disease multiple medication adherence hypotheses, a subject was 
included in a quarter only if he had a full quarter of observation.  Random effects were modeled 
from data using the unstructured option in SAS and subject-specific random error was modeled 
using the variance component option in SAS.  It is noted that number of subjects in the following 
analyses continued to decrease after the fourth quarter.  The numbers of subjects available for 
each analysis in each quarter appear in Table 4.6.   
 
Table 4.7: Multilevel Model Analysis – Inter-disease Multiple Medication Adherence 
Model Parameter Covariance Correlation 
Estimate Std. error Z value P  
Unc. Mns 1 Int-SU/Int-TZD 379.31 17.4716 21.71 <.0001 0.5524 
Unc. Mns 1 Int-SU/Int-LIP 376.26 18.3807 20.47 <.0001 0.6239 
Unc. Mns 1 Int-LIP/Int-TZD 467.59 19.5534 23.91 <.0001 0.5136 
Unc. Mns 2 Int-SU/Int-TZD 402.97 19.0566 21.15 <.0001 0.5524 
Unc. Mns2 Int-SU/Int-AHT 371.98 17.8122 20.88 <.0001 0.5436 
Unc. Mns2 Int-AHT/Int-TZD 452.80 19.4428 23.29 <.0001 0.6208 
Unc. Mns 3 Int-SU/Int-TZD 371.46 29.1893 12.73 <.0001 0.5428 
Unc. Mns 3 Int-SU/Int-LIP 318.59 27.1611 11.73 <.0001 0.4909 
Unc. Mns 3 Int-LIP/Int-TZD 410.15 28.6394 14.32 <.0001 0.6293 
Unc. Mns 3 Int-SU/Int-AHT 348.81 30.5863 11.40 <.0001 0.4753 
Unc. Mns 3 Int-AHT/Int-TZD 457.90 32.3164 14.17 <.0001 0.6213 
Unc. Mns 3 Int-LIP/Int-AHT 439.85 30.7196 14.32 <.0001 0.6294 
Unc. Mns 4 Int-SU/Int-TZD 341.21 59.4130 5.74 <.0001 0.3837 
Unc. Mns 4 Int-SU/Int-ANG 78.2794 63.7770 1.23 0.2197 0.0753 
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Unc. Mns 4 Int-ANG/Int-TZD 164.53 68.0516 2.42 0.0156 0.1498 
Unc. Mns: Unconditional means model;  Int: Random intercept;  
1: PDCs for SU, TZD, LIP; 2: PDCs for SU, TZD, AHT; 3: PDCs for SU, TZD, LIP, AHT; 
4: PDCs for SU, TZD, ANG 
SU: Sulfonylureas; TZD: Thiazolidinediones; LIP: anti-hyperlipidemic medications; AHT: 
hypertension medications; ANG: Anti-anginal medications   
 
A total of 2360 subjects were available for analysis initially (i.e., until the fourth quarter) 
and the number reduced to 1240 at the seventh quarter and only 92 in the eighth quarter.  The 
results of these analyses are summarized in Table 4.7.  Covariation of random intercepts between 
SU and anti-hyperlipidemic medications and that of TZD and anti-hyperlipidemic medications 
were significant (p<0.001).  Thus, H3a was supported.  The correlation between random 
intercepts for diabetes medications was 0.55.  The correlation between random intercepts for SU 
and that of anti-hyperlipidemic medications was 0.62 and that of TZD and anti-hyperlipidemic 
medications was 0.51.   
The above analysis was repeated to examine H3a1 in which subjects were on 
antihypertensive medications instead of anti-hyperlipidemic medications.  Initially, 2212 persons 
were available.  Covariation of random intercepts between SU and antihypertensives and that of 
TZD and antihypertensive medications were significant (p<0.001).  Thus, H3a1 was supported.  
The correlation between random intercepts for SU and that of antihypertensive medications was 
estimated at 0.54 (Table 4.7) and that of TZD and antihypertensives was 0.62.   
To examine H3b, multivariate multilevel analysis was performed on subjects receiving 
antihypertensive medications and anti-hyperlipidemic medications in addition to two diabetes 
medications.  Unlike the subjects in the aforementioned analyses, the subjects in the present 
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analysis were on at least one additional medication.  All covariations between cross-disease 
medications were examined.  Covariation of random intercepts between SU and 
antihypertensives and that of TZD and antihypertensive medications were significant (p<0.001).  
Covariation of random intercepts between SU and anti-hyperlipidemic medications and that of 
TZD and anti-hyperlipidemic medications were significant (p<0.001).  Finally, covariation of 
random intercepts between anti-hyperlipidemic medications and hypertension medications were 
significant (p<0.001).  Thus, H3b was supported.  The correlations of random intercepts for SU 
and hypertension medication, for SU and cholesterol medication, for TZD and cholesterol 
medication, for TZD and hypertension medication, and for hypertension and cholesterol 
medication were estimated at 0.48, 0.49, 0.63, 0.62, and 0.63, respectively.   
For the examination of H3c, in which subjects were on anti-anginal medications in 
addition to diabetes medications, 300 persons were available initially.  The covariation of 
random intercepts between SU and angina medications was not significant (p=0.075) whereas 
that of TZD and angina medications was significant (p=0.016).  Thus, H3c was partially 
supported.  However, the correlation between random intercepts for SU and TZD was estimated 
at 0.38 (Table 4.7) and significant (p<0.001).   
 
Table 4.8: Associations of Evolutions for Inter-disease Multiple Medication 
Adherence 
Model Parameter Correlation P 
Con. Grt 1 Slp-SU Slp -TZD 0.6437 <0.0001 
Con. Grt 1 Slp -SU/ Slp -LIP 0.6084 <0.0001 
Con. Grt 1 Slp -LIP/ Slp-TZD 0.6897 <0.0001 
Con. Grt 2 Slp -SU/ Slp -TZD 0.6390 <0.0001 
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Con. Grt2 Slp -SU/ Slp -AHT 0.7086 <0.0001 
Con. Grt2 Slp -AHT/ Slp -TZD 0.6881 <0.0001 
Con. Grt 3 Slp -SU/ Slp -TZD 0.7283 <0.0001 
Con. Grt 3 Slp -SU/ Slp -LIP 0.7215 <0.0001 
Con. Grt 3 Slp -LIP/ Slp -TZD 0.7131 <0.0001 
Con. Grt 3 Slp -SU/ Slp -AHT 0.6280 <0.0001 
Con. Grt 3 Slp -AHT/ Slp -TZD 0.7699 <0.0001 
Con. Grt 3 Slp -LIP/ Slp -AHT 0.7123 <0.0001 
Con. Grt 4 Slp -SU/ Slp -TZD 0.5913 <0.0001 
Con. Grt 4 Slp -SU/ Slp -ANG 0.1472 0.1233 
Con. Grt 4 Slp -ANG/ Slp -TZD 0.2093 0.0406 
Con. Grt.: conditional growth model with mean centered age and gender as covariates  
1: PDCs for SU, TZD, LIP; 2: PDCs for SU, TZD, AHT; 3: PDCs for SU, TZD, LIP, 
AHT; 4: PDCs for SU, TZD, ANG 
SU: Sulfonylureas; TZD: Thiazolidinediones; LIP: anti-hyperlipidemic medications; 
AHT: hypertension medications; ANG: Anti-anginal medications   
 
Following the intra-disease multiple medication adherence analysis, additional analyses 
were undertaken to examine the relationship between random growth patterns of inter-disease 
medication adherence over time.  Specifically, the relationships between random slopes for 
adherence to two medications (i.e., associations of evolutions) were examined.  The results of the 
analyses are presented in Table 4.8.  In general, associations of evolutions are strong and 
significant at the level of 0.001.  After controlling for the effects of age and gender, such 
associations ranged from 0.61 to 0.76 for people who are on either anti-hyperlipidemic 
medications or antihypertensive medications or both in addition to two diabetes medications.  
However, the association of evolutions between SU and anti-anginal medications was poor and 
not significant (p>0.1) whereas that of TZD and anti-anginal medications were week (0.21) but 
significant (p<0.05).  The association of evolutions of SU and TZD measured in patients taking 
angina medications was estimated at 0.59 and significant (p<0.001).   
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MEASUREMENT OF INTRA-DISEASE MULTIPLE MEDICATION ADHERENCE  
PDC Estimates 
It is known that single estimates of PDC for multiple medications can be computed using 
different algorithms.  Table 4.9 provides quarter specific and cumulative PDC estimates as 
calculated by the continuous measure-based approaches.  Cumulative PDC estimates were 
calculated by proportion of days on medications out of all days until the end of quarter or 
observation. Thus, subjects may or may not have a complete last quarter.  Individual or 
population estimates of PDC varied widely depending on types of measures used.  For example, 
population PDC estimates for the fifth quarter in which all had a 90-day observation period were 
82.78%, 59.22%, and 71% based on maximum (i.e., availability of any medications on a day), 
minimum (i.e., availability of all medications on a day), and average approaches, respectively.  
Similarly, cumulative PDC estimates differed; cumulative PDC estimates for the eighth quarter 
with subject-specific variable observation period were 87.40%, 67.29%, 71.47% when PDC was 
calculated by maximum, minimum, and average based approaches, respectively.  Variations in 
estimates based on the minimum measurement were generally more than those of the other two 
approaches.   
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Table 4.9: PDC estimates by Different Continuous Measures 
Approach Quarter N 
Quarter–specific Cumulative 
Mean Std Dev Mean Std Dev 
Maximum 
1 6043 93.30 14.88 93.30 14.88 
2 6043 86.73 24.86 90.02 18.07 
3 6043 85.45 26.79 88.49 19.52 
4 6043 84.39 28.51 87.47 20.62 
5 6043 82.78 30.26 86.53 21.46 
6 6043 81.40 32.19 85.76 22.09 
7 4979 81.63 32.32 86.47 21.26 
8 3752 83.05 32.19 87.40 20.49 
Minimum 
1 6043 76.54 28.28 76.54 28.28 
2 6043 64.06 37.26 70.30 29.88 
3 6043 62.34 38.31 67.65 30.62 
4 6043 61.03 39.48 65.99 31.15 
5 6043 59.22 40.21 64.64 31.52 
6 6043 57.40 41.54 63.52 31.80 
7 4979 57.74 41.99 64.89 31.04 
8 3752 59.90 42.75 67.29 29.97 
Average 
1 6043 84.92 19.33 84.92 19.33 
2 6043 75.40 27.96 75.40 27.96 
3 6043 73.90 29.36 73.90 29.36 
4 6043 72.71 30.66 72.71 30.66 
5 6043 71.00 31.88 71.00 31.88 
6 6043 69.40 33.38 69.40 33.38 
7 4979 69.68 33.55 69.68 33.55 
8 3752 71.47 33.72 71.47 33.72 
 
Single measures of multiple medication adherence were computed based on a 
dichotomous scale where a cut-point of 80% was used to classify patients as adherent.  There 
was considerable variability in estimates measured by the ‘at least one’ (i.e., whether or not 80% 
days on at least one medication), ‘both’ (i.e., whether or not 80% days on both medications), and 
‘all’ (i.e., whether or not 80% days on each medication measured separately) approaches.  PDC 
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estimates varied from 88% at quarter 1 to 78% at quarter 8 when measured by the ‘at least 1’ 
approach.  Similar estimates for ‘both’ were from 61% to 51%, and for ‘all’ 63% to 52%.  A 
detailed description of all estimates has been provided in Appendix.  Thus, the both approach 
consistently provided lowest estimates.   The all-based estimates were slightly smaller but 
closely followed the estimates measured by the both approach.   
 
Table 4.10: Measure of Discrepancy 
Quarter Quarter-specific 
N % 
1 1630 30.6 
2 1778 36.71 
3 1815 38.21 
4 1769 37.74 
5 1735 37.9 
6 1697 37.71 
7 1366 36.47 
8 1011 34.55 
Number of subjects who were rated adherent by one or two dichotomous measures 
but not by all three approaches.   
 
Using dichotomous measures of adherence, a subject can be classified as adherent or 
nonadherent.  Thus, a person can be classified as adherent by only one composite dichotomous 
measure, two measures, or all three.  An analysis was performed to examine the discrepancy in 
classification provided by different dichotomy-based approaches.  The analysis was run on 
quarter-specific PDC for subjects who were rated adherent by at least one of the approaches.  
Table 4.10 describes the rate of discrepancy across different quarters.  It was found that at least 
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30% subjects were differentially classified.  In other words, about one third population will be 
rated as adherent based on an approach but nonadherent based on another approach.  
Interestingly, the rates of such differential classification were even higher (35-38%) in later 
quarters.    
 
Kaplan-Meier analysis (Figure 4.1) was performed to compare how different categorical 
composite measures classified population persistence estimates.  PDC was measured 
cumulatively until last full quarter of observation and patients were followed until they became 
Figure 4.1: Persistency Estimates as Measured by Different Categorical Single Measures
1 
2 
3 
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nonadherent (i.e., cumulative adherence <80%) for the first time or censored at the end of last 
full quarter.  As can be understood, ‘at least one’ identified more subjects as persistent and 
showed a much slower decline than did the all or both approaches both of which closely 
followed each other.  In addition, the gap widened over time.  The log-rank test (adjusted) 
revealed that statistics produced by all three approaches were significantly (p<0.005) different 
from one another.  Thus, choice of measurement approach does matter.   
 
EFFECTIVENESS OF MEASURES OF MULTIPLE MEDICATION ADHERENCE  
PDC estimates for multiple medications based on different approaches varied.  Apart 
from six measures as above, a weighted-average measure of multiple medication adherence was 
conceived as part of the objectives of the study.  The analyses that follow address the selection of 
the most effective measurement paradigm.  Specifically, the analysis aims are to compare 
different measures and offer an optimal cut point for adherence classification.   
Different outcome measures may be used for answering the substantive issue described 
above.  Among them are emergency room (ER) visits, inpatient stays, and a combined indicator 
of any ER or inpatient hospitalization, whichever occurring first.  Additionally, outcomes may be 
any cause, primarily diabetes related, or any diabetes-related utilization.  Thus, it was possible to 
choose from nine different outcome measures.  The sample of study population demonstrated 
high rates of censoring.  It was more so for some types of events (e.g., primarily diabetes related 
utilization).  Thus, it was necessary to pay attention to focus on the selection of an outcome that 
would be theoretically and practically meaningful and yet had a reasonable number of events for 
survival analysis to run successfully.   
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Table 4.11: Event Distribution Across Quarters 
Quarter AC_ER Diab_ER AC_cmb Diab_cmb 
 N (%) N (%) N (%) N (%) 
2 313 (22.06) 55 (16.92) 379 (22.47) 107 (16.77) 
3 279 (19.66) 49 (15.08) 338 (20.04) 100 (15.67) 
4 299 (21.07) 51 (15.69) 355 (21.04) 118 (18.5) 
5 235 (16.56) 69 (21.23) 268 (15.89) 141 (22.1) 
6 169 (11.91) 58 (17.85) 193 (11.44) 95 (14.89) 
7 107 (7.54) 37 (11.38) 133 (7.88) 66 (10.34) 
8 17 (1.2) 6 (1.85) 21 (1.24) 11 (1.72) 
Total* 1419 325 1687 638 
AC_ER: all cause emergency room (ER) visits; Diab_ER: any diabetes related 
ER; AC_cmb: all cause ER or inpatient hospitalization (IP), whichever 
occurring first; Diab_cmb: any diabetes related ER or IP, whichever occurring 
first 
* Events occurring only in any fully observed quarters included  
 
Event Distribution Analysis  
A total of 1419 subjects had an all cause ER event.  It is noted here that there were a few 
more events when all observations were considered regardless of whether or not events occurred 
in any fully observed period.  Thus, an event that occurred during a subject’s last quarter, which 
was shorter than 90 days, was not counted as the person was followed only until the last full 
quarter, which preceded the occurrence of event.  Such events were not concentrated in any 
quarter and rather spread across quarters (Table 4.11).  However, few events were observed 
during quarter 8.  There are other event types that can be utilized to examine the issue of 
measurement effectiveness.  Some have been presented in Table 4.11.  Any diabetes related 
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utilization was considered conceptually meaningful and proximal to the causal relationship 
between event and medication use.  Similarly, any diabetes related ER or inpatient 
hospitalization events (i.e., Diab_cmb in Table 4.11) capture those with which diabetes has been 
explicitly associated.  These outcomes not only appear theoretically appealing but also hold 
practical implications.  A total of 325 and 638 events were observed, respectively.  However, 
only the former category was used in this study for unbiased and consistent analysis because the 
latter category may include planned inpatient admissions (e.g., surgical procedures such as 
CABG) for which medication adherence may not be directly related.  For this study, any diabetes 
related ER utilization was considered in addition to any cause ER.  
 
Measurement of PDC for Survival Analysis  
For all PDC calculations associated with this dissertation study a duration of 90 days (i.e., 
90-day quarter) was used.  However, several issues arose that needed additional consideration 
with regard to the measurement of PDC.  A large number of participants had an incomplete 
observation period in their last quarter.  In the examination of multiple medication adherence, 
these incomplete observations (i.e., incomplete quarters) were ignored.  However, the adoption 
of a similar strategy for survival analysis may not be appropriate.  A total of 1240 subjects had a 
last quarter with 30 days or less and about 5500 had fewer than 90 days of observation.  
Moreover, events may have occurred in some of these incomplete reporting periods.  As such, 
ignoring all incomplete 90-day quarters will result in a loss of events and, in turn, an increase in 
censoring, the rate of which is already somewhat high.  Because of excessive censoring, the 
survival analysis may become underpowered.  As such, it was believed that shortening of 
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measurement period to 30-day periods might alleviate the problem of losing events and would 
allow the inclusion of full-length observations.  In addition, it was thought that shortening the 
length of measurement period of PDC would bring closer the period of event measurement, 
which was measured as day, to the PDC measurement period.  If these periods are closer to each 
other then there will be less error associated with any probable overestimation of PDC, 
especially for PDC measured over the post-event period or any increase in post-event PDC.  
Another consideration is that the primary outcome measure (i.e., all cause ER) chosen for this 
analysis may require a short measurement period in order for capturing the effect of 
nonadherence.  Episodes of nonadherence within a short period may lead to hyperglycemia, 
which may represent an underlying contributing factor for an acute event such as all cause ER.  
In contrast to the above period-specific temporal measurement approach, the disease progression 
paradigm posits that a patient’s adherence behavior over a period of time would represent his 
propensity of having an event.  Thus, the analyses for this part of the project will present the 
results for 30-day and 90-day PDC period-specific measures as well as cumulative monthly and 
cumulative quarter-specific measures.  Only observations that represented a complete reporting 
period were included.  Subjects were censored at the of their last full observation period or after 
an event, whichever occurred earlier.   
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Weighted Average Adherence Measure 
Survival analysis was performed to estimate drug-specific weights (Ws) required to 
estimate weighted average adherence measure.  By definition, the composite measure reflects the 
benefits of individual medications based on partial adherence, if any. 
Adhcom=
W1.	A1+	W2.	A2
W1+	W2  
 
 
Table 4.12:Hazard Estimates for Predictors of Adverse Events  
Parameter DF Parameter
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard
Ratio 
Age 1 -0.00160 0.00405 0.1550 0.6938 0.998 
Gender 
(male) 
1 -0.28755 0.05328 29.1282 <0.0001 0.750 
CCI 1 0.35141 0.04240 68.7027 <0.0001 1.421 
PDC (SU) 1 -0.00095 0.00085 1.2507 0.2634 0.999 
PDC (TZD) 1 -0.00215 0.00082 6.9825 0.0082 0.998 
Outcome: all cause ER; PDC is measured at each quarter 
 
Weights were to be represented by medication-specific hazard estimates.  Survival 
analysis was performed with all cause ER visits as the outcome.  Several models were run with 
different PDC estimates based on the period lengths.  Adherence estimates were calculated as 
PDC measured over a period of 30 days and 90 days for each quarter and PDC measured 
cumulatively at each quarter.  When 90-day quarter-specific PDC was used, only PDC for TZD 
was significant at the level of 0.05 (Table 4.12).  However, when 90-day cumulative PDC 
estimates were used, none of them were significant at a level of 0.05.  In this instance, PDC for 
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SU was significant at the level of 0.01 (Table 4.13).  A similar trend was observed when PDC 
measurement period was changed to 30 days.  In other words, period-specific PDC for TZD was 
significant (p=0.008) (Table 4.14), but cumulative PDC for SU was significant (p=0.028) (Table 
4.15).   
There was no difference between parameter estimates of individual 90-day quarter-
specific PDCs (Chi square 0.725, p=0.39).  A similar result (p=0.97) was observed when 
cumulative 90-day PDCs were entered into the survival analysis.  Results did not differ for 
PDCs, both period-specific and cumulative, measured over a 30 period.  Although all individual 
hazard estimates were in the right direction and some were significant, there were no differences 
in the hazard ratios.  Under this situation, weights could not be estimated that were nontrivial and 
different from each other.  Thus, it was not possible to calculate a weighted average measure of 
PDC.   
 
 
Table 4.13:Hazard Estimates for Predictors of Adverse Events  
Parameter DF Parameter
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard
Ratio 
Age 1 -0.00166 0.00407 0.1668 0.6829 0.998
Gender (male) 1 -0.28968 0.05331 29.5281 <0.0001 0.749
CCI 1 0.35082 0.04243 68.3703 <0.0001 1.420
PDC (SU) 1 -0.00183 0.00110 2.7725 0.0959 0.998
PDC (TZD) 1 -0.00175 0.00109 2.5576 0.1098 0.998
Outcome: all cause ER; PDC is measured cumulatively over quarters 
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Table 4.14:Hazard Estimates for Predictors of Adverse Events  
Parameter DF Parameter
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard
Ratio 
Age 1 -0.00070 0.00397 0.0315 0.8592 0.999
Gender 
(male) 
1 -0.27109 0.05204 27.1320 <0.0001 0.763
CCI 1 0.34317 0.04279 64.3337 <0.0001 1.409
PDC (SU) 1 -0.00093 0.00073 1.5925 0.2070 0.999
PDC (TZD) 1 -0.00190 0.00072 6.9829 0.0082 0.998
Outcome: all cause ER; PDC is measured at each 30-day period  
 
 
Table 4.15:Hazard Estimates for Predictors of Adverse Events  
Parameter DF Parameter
Estimate 
Standard 
Error 
Chi-
Square 
Pr > 
ChiSq 
Hazard
Ratio 
Age 1 -0.00042 0.00399 0.0111 0.9160 1.000
Gender 
(male) 
1 -0.27231 0.05209 27.3289 <0.0001 0.762
CCI 1 0.34038 0.04288 63.0147 <0.0001 1.405
PDC (SU) 1 -0.00236 0.00107 4.8133 0.0282 0.998
PDC 
(TZD) 
1 -0.00150 0.00108 1.9347 0.1642 0.998
Outcome: all cause ER; PDC is measured cumulatively over 30-day periods 
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Comparison of the Adherence Measures: Predictive Power  
As a weighted average-based composite model could not be computed, multiple survival 
analyses were performed with the six different PDC estimates as described before.  Analyses 
were run using both a univariable and a multivariable framework.  The results from survival 
analysis with the six different PDC measures are presented in Table 4.16.  Medication adherence 
was significantly (p<0.001) associated with the adverse outcomes of interest.  Indeed, 
nonadherence to diabetes medications as measured by all different single estimates predicted 
hazards of adverse events.  However, hazard estimates as given by different single measures of 
adherence widely varied.  Hazard ratios for adherence, measured temporally over a 30-day 
period, varied from 0.784 to 0.997.  Although some hazards estimates were nearly 1.0, all were 
statistically significant (p<0.005).  Hazard estimates were slightly lower under the univariable 
analysis for adherence measured over each 30-day period by the all, at least one, and both 
approaches.  Such differences were not observed when continuous measures of PDC were used.   
As proposed, the analyses were rerun with PDC estimated at each quarter (i.e., 90 days).  
Adherence was associated significantly with lower hazards of all-cause ER visits.  For example, 
the hazard of having any all-cause ER visit was 0.787 when adherence was measured over each 
quarter following the both approach.  Measures using dichotomous approaches provided slightly 
lower hazard ratios when only PDC was used as the independent variable.  The hazard estimates 
for at least one-based PDC measured over 90 days were 0.785 and 0.807 in a univariable and 
multivariable setting, respectively (Table 4.16).  Mostly, the at least one approach among all 
different measures appeared to provide lower hazard estimates regardless of measurement 
period.   
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Table 4.16: Hazard Estimates for Different PDC Measurements  
Measurement 
Period Model Approach
Parameter 
estimate Std. Err P 
Hazard 
Ratio  
30 days 
 
Uni 
All -0.2536 0.05192 <.0001 0.776 
Atlst1 -0.2437 0.06193 0.0001 0.784 
Avg -0.0033 0.00075 <.0001 0.997 
Both -0.2538 0.05192 <.0001 0.776 
Max -0.0027 0.00078 0.0007 0.997 
Min -0.0025 0.0006 <.0001 0.997 
Mul 
All -0.2189 0.05253 <.0001 0.803 
Atlst1 -0.2205 0.06296 0.0005 0.802 
Avg -0.0028 0.00077 0.0002 0.997 
Both -0.2186 0.05254 <.0001 0.804 
Max -0.0024 0.0008 0.0202 0.998 
Min -0.0021 0.0006 0.0005 0.998 
90 days 
Uni 
All -0.2129 0.05321 <.0001 0.808 
Atlst1 -0.2421 0.06114 0.0001 0.785 
Avg -0.0038 0.00084 <.0001 0.996 
Both -0.2392 0.0534 <.0001 0.787 
Max -0.0031 0.00088 0.0006 0.997 
Min -0.003 0.00067 <.0001 0.997 
Mul 
All -0.1689 0.05399 0.0018 0.845 
Atlst1 -0.2147 0.06233 0.0006 0.807 
Avg -0.0031 0.00086 0.0003 0.997 
Both -0.1965 0.05417 0.0003 0.822 
Max -0.0027 0.0009 0.0033 0.997 
Min -0.0024 0.00068 0.0005 0.998 
 
Outcome: all cause ER; Uni: univariable; Mul: Multivariable; PDC measured for each 
period 
Atlst1: At least one approach; Avg: Average approach; Max: Maximum approach; Min: 
Minimum approach  
111 
 
Table 4.17: Hazard Estimates for Different Cumulative PDC Measurements 
Measurement 
Period Model Approach
Parameter 
estimate Std. Err P 
Hazard 
Ratio 
30 days 
 
Uni 
All -0.2279 0.05198 <.0001 0.796 
Atlst1 -0.1918 0.06376 0.0032 0.825 
Avg -0.0033 0.00075 <.0001 0.997 
Both -0.2098 0.05221 <.0001 0.811 
Max -0.0041 0.00123 0.0011 0.996 
Min -0.0036 0.00083 <.0001 0.996 
Mul 
All -0.1897 0.05276 0.0003 0.827 
Atlst1 -0.1638 0.06511 0.0119 0.849 
Avg -0.0028 0.00077 0.0002 0.997 
Both -0.169 0.05302 0.0014 0.845 
Max -0.0036 0.00126 0.0045 0.996 
Min -0.0028 0.00084 0.0009 0.997 
90 days 
Uni 
All -0.2279 0.05321 <.0001 0.796 
Atlst1 -0.1988 0.0646 0.0025 0.82 
Avg -0.0038 0.00084 <.0001 0.996 
Both -0.2185 0.05351 <.0001 0.804 
Max -0.0039 0.00124 0.0022 0.996 
Min -0.0035 0.00084 <.0001 0.996 
Mul 
All -0.1857 0.05401 0.0006 0.83 
Atlst1 -0.1658 0.06602 0.012 0.847 
Avg -0.0031 0.00086 0.0003 0.997 
Both -0.1725 0.05438 0.0015 0.842 
Max -0.0033 0.00128 0.011 0.997 
Min -0.0027 0.00086 0.0021 0.997 
 
Outcome: all cause ER; Uni: univariable; Mul: Multivariable; PDC measured 
cumulatively up to a period 
Atlst1: At least one approach; Avg: Average approach; Max: Maximum approach; Min: 
Minimum approach  
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In general, medication adherence is measured over a period of 6 months or greater.  
Cumulative PDC measurements are thought to capture patient behavior over a longer period of 
time than do by period-specific measures.  Adherence was measured cumulatively at each 30 day 
period or 90-day quarter.  Hazard of having an all cause event was significantly (p <0.05) 
associated with medication adherence.  Hazards estimates (Table 4.17) ranged from a low of 
0.796 to almost 1 (0.997) for dichotomous measures and continuous PDC estimated cumulatively 
over a 30-day period or 90-day period, respectively.  The all approach revealed consistently 
lowest hazards of having an all cause ER event regardless of whether a univariable model or 
multivariable model was used or a measurement period of 30 or 90 days was used.   
A subset of all cause events is any diabetes related event.  Analyses were repeated with 
diabetes-related ER as the outcome for adherence measured at each temporal period and 
cumulatively at each period.  The hazard estimates (Appendix) for PDC measured over each 30-
day period varied from 0.66 to 0.75 for the at least one, all, both approaches while continuous 
measures indicated a hazard slightly less, although statistically significant, than one.  The 
corresponding results for dichotomous measures were between 0.54 and 0.71 when PDC 
measurement period was 90 days.   The at least one approach provided the lowest hazard 
estimates that ranged from 0.54 to 0.69.  When PDC was measured cumulatively, the hazard 
estimates for the three said categorical approaches ranged for 0.56 to 0.68.   
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Comparison of the Adherence Measures: Discriminatory Power  
Nonadherence was found to be a consistent predictor of events of interest regardless of 
measurement approach used or measurement period considered.  However, the extent of 
predictive power differed depending on the approach used.  Analyses were performed to examine 
how different measurement approaches discriminated subjects having events from those not 
experiencing an event.  Concordance statistics were computed with each PDC measurement 
approach.  Analyses were run in both a univariable and a multivariable framework.  All the 
approaches resulted in concordance statistics that lay very close to one another (Table 4.18).  The 
average based approach resulted in the highest mean value of 0.5391 under the univariable 
setting.  The mean value of other continuous measures were 0.5380 (min) and 0.5360 (max).  
Dichotomous approaches resulted in slightly lower c-statistics than for analyses using continuous 
adherence measures.  Among dichotomy-based measures, the at least one approach showed the 
lowest mean of 0.5228.  Table 4.18 reports the values and confidence intervals of all 
concordance statistics.  Under the multivariable analysis, the mean values of all concordance 
statistics improved from their respective univariable estimate.  Among all, the average approach 
showed the highest values of 0.5648 and at least one the lowest value of 0.5584.  Although 
indicating poor discrimination, all these concordance statistics were greater than 0.50 (p<0.05).  
In addition, confidence intervals from all concordance statistics overlapped one another 
indicating a lack of statistical significance.   
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Table 4.18: Concordance Statistics for Different Adherence Measurement Approaches 
Measure-
ment 
Period 
Model Approach
All cause ER  Diabetes ER  
C-
statistic CI 
C-
statistic CI 
30 days 
 
Uni 
All 0.5330 0.5201-0.5460 0.5404 0.5137-0.5672
Atlst1 0.5224 0.5115-0.5333 0.5385 0.5146-0.5624
Avg 0.5426 0.5282-0.5570 0.5637 0.5340-0.5933
Both 0.5329 0.5199-0.5458 0.5410 0.5142-0.5677
Max 0.5355 0.5225-0.5485 0.5483 0.5208-0.5757
Min 0.5394 0.5252-0.5535 0.5572 0.5284-0.5860
Mul 
All 0.5606 0.5453-0.5759 0.5643 0.5328-0.5958
Atlst1 0.5564 0.5411-0.5718 0.5664 0.5349-0.5979
Avg 0.5645 0.5494-0.5796 0.5698 0.5386-0.6009
Both 0.5602 0.5449-0.5755 0.5639 0.5322-0.5955
Max 0.5622 0.5470-0.5774 0.5659 0.5350-0.5968
Min 0.5627 0.5476-0.5779 0.5649 0.5340-0.5959
90 days 
Uni 
All 0.5290 0.5158-0.5422 0.5484 0.5212-0.5757
Atlst1 0.5228 0.5114-0.5342 0.5614 0.5353-0.5876
Avg 0.5391 0.5240-0.5542 0.5597 0.5270-0.5923
Both 0.5324 0.5192-0.5455 0.5475 0.5204-0.5746
Max 0.5360 0.5216-0.5504 0.5599 0.5288-0.5910
Min 0.5380 0.5230-0.5531 0.5530 0.5209-0.5850
Mul 
All 0.5612 0.5456-0.5768 0.5687 0.5360-0.6014
Atlst1 0.5584 0.5428-0.5739 0.5820 0.5494-0.6146
Avg 0.5648 0.5493-0.5804 0.5725 0.5395-0.6054
Both 0.5628 0.5472-0.5783 0.5679 0.5351-0.6006
Max 0.5621 0.5465-0.5777 0.5759 0.5436-0.6082
Min 0.5636 0.5481-0.5792 0.5663 0.5334-0.5991
C-statistic: Concordance statistic (CT from Kremers); CI: confidence interval of C-statistic; 
Uni: univariable; Mul: Multivariable; PDC measured at each quarter   
Atlst1: At least one approach; Avg: Average approach; Max: Maximum approach; Min: 
Minimum approach 
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Table 4.19: Concordance Statistics for Different Cumulative Adherence Measurement 
Approaches 
Measure-
ment 
Period 
Model Approach 
All cause ER  Diabetes ER  
C-
statistic CI 
C-
statistic CI 
30 days 
 
Uni 
All 0.5276 0.5146-0.5406 0.5515 0.5249-0.5780 
Atlst1 0.5157 0.5053-0.5261 0.5531 0.5288-0.5775 
Avg 0.5426 0.5282-0.5570 0.5637 0.5340-0.5933 
Both 0.5253 0.5124-0.5382 0.5529 0.5268-0.5789 
Max 0.5216 0.5068-0.5364 0.5475 0.5153-0.5798 
Min 0.5338 0.5188-0.5487 0.5587 0.5278-0.5896 
Mul 
All 0.5582 0.5429-0.5734 0.5690 0.5371-0.6008 
Atlst1 0.5535 0.5383-0.5687 0.5728 0.5410-0.6045 
Avg 0.5645 0.5494-0.5796 0.5698 0.5386-0.6009 
Both 0.5572 0.5419-0.5725 0.5710 0.5395-0.6025 
Max 0.5569 0.5416-0.5722 0.5646 0.5328-0.5963 
Min 0.5599 0.5446-0.5751 0.5665 0.5349-0.5982 
90 days 
Uni 
All 0.5290 0.5157-0.5422 0.5460 0.5186-0.5733 
Atlst1 0.5169 0.5061-0.5277 0.5457 0.5208-0.5706 
Avg 0.5391 0.5240-0.5542 0.5597 0.5270-0.5923 
Both 0.5281 0.5149-0.5413 0.5489 0.5221-0.5758 
Max 0.5258 0.5107-0.5410 0.5493 0.5161-0.5825 
Min 0.5358 0.5206-0.5510 0.5542 0.5223-0.5861 
Mul 
All 0.5612 0.5456-0.5767 0.5660 0.5330-0.5989 
Atlst1 0.5570 0.5415-0.5725 0.5672 0.5344-0.6000 
Avg 0.5648 0.5493-0.5804 0.5725 0.5395-0.6054 
Both 0.5607 0.5451-0.5763 0.5683 0.5356-0.6011 
Max 0.5593 0.5437-0.5749 0.5670 0.5341-0.5998 
Min 0.5626 0.5470-0.5782 0.5648 0.5320-0.5975 
 
C-statistic: Concordance statistic (CT from Kremers); CI: confidence interval of C-statistic; 
Uni: univariable; Mul: Multivariable; PDC measured cumulatively at each quarter   
Atlst1: At least one approach; Avg: Average approach; Max: Maximum approach; Min: 
Minimum approach 
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The concordance statistics for different measurement approaches were computed for PDC 
estimated over 30-day periods.  The concordance statistics measured in the univariable setting 
ranged from 0.5426 to 0.5224 (Table 4.18) with statistic for ‘average’ being the largest among 
all.  Like statistics for PDC measured over 90 days, multivariable concordance statistics for 
adherence estimated in each 30-day period were higher than their univariable counterpart.  
Again, the at least one approach resulted in lowest mean concordance statistics in both 
multivariable and univariable analyses.  Most of 30-day mean values are slightly higher than 
their corresponding 90-day values.   
Additional analyses were performed using the cumulative PDC measurement approach.  
That is, adherence measured cumulatively at a specific period (i.e., 30 or 90 days) was entered in 
survival analysis.  For the 30-day based cumulative measures, the average and minimum 
approaches showed two highest concordance statistics.  The univariable and multivariable mean 
values for the average approach were 0.5426 and 0.5645, respectively (Table 4.19) and for the 
minimum-based approach, the corresponding statistics were 0.5338 and 0.5599, respectively.  
When the 90-day measurement period was used, the estimates closely followed that of 30-day 
cumulative analysis.  For example, concordance statistics were 0.5391 and 0.5648 in the 
univariable and multivariable analysis, respectively.  Interestingly, the lower bounds of the at 
least one based approach and its continuous version (i.e., maximum) lay barely above 0.5 in the 
univariable analyses regardless of cumulative measurement period.   
Analyses were repeated using any diabetes-related event as the outcome measure for 
adherence measured at each period and cumulatively at each period. Table 4.18 and Table 4.19 
present the results.  Concordance estimates for PDC measured over each 30-day period varied 
from 0.5385 (at least one) to 0. 5637 (average) under the univariable analysis and remained 
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literally constant in the multivariable models for all approaches (Table 4.18).  When period of 
measurement was 90 days, concordance estimates ranged from 0.5475 (both) to 0.5646 (average) 
in univariable models (Table 4.18).  In the multivariable analysis, the at least one had the highest 
estimate of 0.5820 and its continuous counterpart (minimum) has the lowest estimate of 0.5663.  
When cumulative measures were used, the mean concordance varied from 0.5457 to 0.5728 
(Table 4.19).  The average approach resulted in the highest estimate in all analyses except for the 
30-day multivariable model in which the at least one approach had the highest mean concordance 
statistic of 0.5728 (Table 4.19).  Confidence intervals of all concordance statistics were above 
0.5. 
 
Examination of Optimal Cut-points of Measures of Multiple Medication Adherence  
There are three single measures of multiple medication adherence that measure adherence 
on a continuous scale.  These are based on the average, maximum, and minimum algorithms and 
can be converted into categorical measures.  Cut point analyses were performed on these 
continuous PDC measures and results from both multivariable and univariable survival analysis 
are presented in Table 4.20.  In the case of multivariable analysis, likelihood difference 
contributed by PDC was considered.  That is, the differences in log likelihood of a survival 
analysis model containing all variables (age, gender, CCI, and PDC) and that of a model with all 
variables except PDC were computed.  Additional dichotomous PDC variables were created 
from the respective continuous measures by applying different cut points for dichotomization.  
Five cut points were chosen for dichotomization: 65, 70, 75, 80, and 85.  Maximum Chi square 
statistics that were significant at p=0.05/15 (Bonferroni adjusted) were identified.  Any values 
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that were above 8.6154 were considered significant at a level of p=0.05/15 (approximately, 
0.003).  As above, analyses were performed using cumulative and period-specific PDC measured 
over 90 days or 30 days.   
 
Table 4.20: Optimality of Cut Point Analysis with Different Adherence Measures  
Measure-
ment Model Approach PDC  65 PDC-70 PDC-75 PDC-80 PDC-85 
Cumulative 
90-day 
Quarter 
Mul 
Average 7.0462 3.9441 6.4148 9.3322 11.227 
Maximum 5.0143 3.8126 6.7254 6.125 2.7552 
Minimum 9.4119 8.4991 14.401 10.107 11.284 
Uni 
Average 12.487 8.3871 11.314 14.915 18.259 
Maximum 7.1239 6.0205 9.5342 9.1097 5.1445 
Minimum 15.524 14.799 22.259 16.789 17.904 
90-day 
Quarter 
Mul 
Average 8.7781 8.468 8.048 9.9933 12.409 
Maximum 5.9385 10.912 12.115 11.465 10.812 
Minimum 9.5463 9.4438 12.106 13.223 11.887 
Uni 
Average 13.974 13.938 13.278 16.268 19.359 
Maximum 8.0635 14.232 15.73 15.037 14.893 
Minimum 15.399 15.904 19.018 20.18 18.44 
Outcome variable: all cause ER visits; Uni: univariable; Mul: Multivariable; bold cells are 
maximum chi square values among respective row values and are significant at p=0.05/15.   
Numbers were obtained from chi square statistics from the Survival analysis 
 
First, survival analyses were performed on all cause ER visits as outcome measure.  
When PDC was measured cumulatively over 90 days, maximal Chi square statistics were 
identified when dichotomization occurred at 85% in both multivariable and univariable analysis 
(Table 4.20).  Thus, statistics for average-based dichotomization analyses were significant.  In 
case of maximum and minimum algorithms, similar analyses showed that maximization occurred 
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at 75%.  However, statistic for maximum in the multivariable model was not significant at p = 
0.003.  When the PDC measure was based on each quarter, the maximization of average-based 
dichotomization occurred at 85% in both univariable and multivariable models in which chi 
square statistics were significant (p<0.003).  For the maximum based approach, maximum values 
were found at 75% and were significant (p<0.003).  For minimum-based dichotomization, 
maximizations occurred at 80% in both multivariable and univariable models.   
 
Table 4.21: Optimality of Cut Point Analysis with Different Adherence Measures 
Measurement Model Approach PDC  65 PDC-70 PDC-75 PDC-80 PDC-85
Cumulative 
30-day Period 
Mul 
Average 5.2231 6.8647 7.6926 9.7486 13.277 
Maximum 6.4368 6.2179 8.6639 6.1458 4.0449 
Minimum 9.7597 11.011 16.019 10.196 9.7981 
Uni 
Average 9.6211 11.914 12.568 15.195 19.98 
Maximum 8.6173 8.5361 11.381 8.7115 6.4434 
Minimum 15.754 17.486 23.36 16.23 15.484 
30-day Period 
Mul 
Average 7.4047 8.8584 9.2459 8.0082 14.139 
Maximum 8.6901 9.8615 9.5206 11.803 21.378 
Minimum 11.919 11.323 15.285 17.281 23.137 
Uni 
Average 11.925 13.673 14.375 12.927 20.274 
Maximum 11.286 12.559 12.184 14.786 25.587 
Minimum 17.648 16.832 21.398 23.857 30.723 
Outcome variable: all cause ER visits; Uni: univariable; Mul: Multivariable; colored cells are 
maximum chi square values among respective row values and bold ones are significant at 
p=0.05/15.   
Numbers were obtained from chi square statistics from the Survival analysis 
 
Above analyses on all cause ER visit were repeated with PDC measured over a 30-day 
period.  Table 4.21 presents the results of the analyses.  When PDC was measured cumulatively 
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or at each period over 30 days, the maximization of the average approach based dichotomization 
occurred at 85% in both univariable and multivariable models.  Similarly, maximizations were 
noted for the maximum and minimum based approaches at 85% when PDC was measured at 
each 30-day period in multivariable or univariable analysis.  In contrast, dichotomization 
analysis on these two approaches demonstrated that the maximized values were found to occur at 
75% when PDC was measured cumulatively.   
 
Table 4.22: Cut Point Analysis with Different Adherence Measures  
Measure-
ment Model Approach PDC  65 PDC-70 PDC-75 PDC-80 PDC-85 
Cumulative 
90-day 
Quarter 
Mul 
Average 7.070 8.521 11.783 13.766 11.221 
Maximum 3.455 7.464 12.105 12.094 9.549 
Minimum 8.885 8.712 13.235 11.048 9.641 
Uni 
Average 10.080 10.906 14.400 15.521 12.066 
Maximum 9.395 11.023 18.319 22.031 19.952 
Minimum 8.990 8.185 9.596 9.3371 9.184 
90-day 
Quarter 
Mul 
Average 9.698 11.381 14.956 17.135 14.345 
Maximum 5.114 9.860 15.038 15.21 12.52 
Minimum 11.613 11.419 16.386 13.879 12.268 
Uni 
Average 12.826 13.768 17.57 18.809 15.045 
Maximum 11.806 13.786 21.716 25.721 23.724 
Minimum 11.475 10.640 12.207 11.887 11.704 
Outcome variable: any diabetes ER visits; bold cells are maximum chi square values among 
respective row values and significant at p=0.05/15.   
Numbers were obtained from chi square statistics from the Survival analysis 
 
Next, optimal dichotomization analyses were performed using any diabetes related ER 
visits as outcome measure.  When PDC was measured cumulatively over 90-day quarters, 
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maximal partial likelihood statistics occurred for dichotomization at 80% in both multivariable 
and univariable analysis (Table 4.22).  Similar results were observed for PDC measured at each 
quarter.  In case of minimum based algorithms, maximizations of partial likelihood statistics 
occurred when PDC was dichotomized at 75%  and these results held true for both multivariable 
and univariable analysis.  When analyses were run on the maximum based approaches, 
maximization of statistic occurred for PDC dichotomized at 80% except for the case of 
multivariable analysis with PDC measured cumulatively.  In the latter case, the maximum value 
was found at 75%.  Statistics for all the above analyses were significant (p< 0.003).   
 
Table 4.23: Optimality of Cut Point Analysis with Different Adherence Measures 
Measure-
ment Model Approach PDC  65 PDC-70 PDC-75 PDC-80 PDC-85
Cumulative 
30-day 
Period 
Mul 
Average 9.4571 12.758 14.643 15.281 12.669 
Maximum 4.3559 6.4868 11.369 18.242 11.067 
Minimum 12.223 13.581 17 14.18 10.945 
Uni 
Average 12.705 16.438 18.483 19.145 16.237 
Maximum 6.4359 9.0358 14.642 22.376 14.582 
Minimum 15.591 17.101 20.746 17.619 13.956 
30-day 
Period 
Mul 
Average 5.4106 4.7225 4.9703 6.9607 8.245 
Maximum 4.4476 5.7976 7.1672 8.4171 8.383 
Minimum 6.2205 6.8583 5.5575 7.0427 10.764 
Uni 
Average 7.5734 6.7659 7.0906 9.3951 10.884 
Maximum 6.4519 8.0648 9.6847 11.136 11.188 
Minimum 8.4399 9.1793 7.6826 9.4027 13.586 
Outcome variable: any diabetes ER visits; bold cells are maximum chi square values 
among respective row values and significant at p=0.05/15.   
Numbers were obtained from chi square statistics from the Survival analysis 
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The above analyses on any diabetes related ER visit were repeated with PDC measured 
over a 30-day period.  Table 4.23 presents the results of the analyses.  For PDC measured 
cumulatively over 30 days, the maximization of statistic for the average approach based 
dichotomization occurred at 80% in both univariable and multivariable models.  Similarly, 
maximizations were observed at 80% for the maximum based approach when PDC was 
measured cumulatively over a 30-day period in multivariable or univariable analysis.  In 
contrast, dichotomization analysis on the minimum approach showed the maximization at 75% 
in both multivariable and univariable models.  When analysis was performed on PDC measured 
at each 30-day period, the maximization occurred at 85% in all cases except for the maximum-
based multivariable analysis in which the statistic was maximized at 80% but not significant.   
The above discussions on dichotomization have so far focused on the maximization of 
partial likelihood statistic.  However, in true sense, maximization was not found to occur for 
some multivariable analysis.  For example, in case of PDC measured cumulatively at 30-day 
periods, partial likelihood statistic for average based dichotomization increased monotonously 
(5.2231, 6.8647, 7.6926, 9.7486, and 13.277) before being maximized at 85%.  Similarly, for the 
PDC measure based on average at every 30 days, the partial statistics increased almost 
monotonously (7.4047, 8.8584, 9.2459, 8.0082, and 14.139) before showing the highest value at 
85%.  In the latter case, all values except the first one (i.e., 65%) lie above 8.615, which is the 
chi square value of the Bonferroni adjusted p value of 0.05.  In other cases, maximization 
occurred in true sense but statistics on either sides of the maximized one were significant.  For 
example, the results from analysis on diabetes-related ER based on average-based dichotomized 
PDC measured cumulatively over 30 days demonstrated maximization at 75% (17) and values 
around 75% (12.223, 13.581, 14.18, 10.945) were significant (p<0.0033) as well.    
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Concordance Analysis between Results of Concordance Statistics and Maximization 
Statistics 
While computing concordance statistics, analyses were run with PDC measurement 
approaches such as at least one and both.  These two approaches had some equivalent formats in 
the maximization analysis.  These equivalent formats occurred when corresponding continuous 
PDC was dichotomized at 80% (i.e., dichotomization performed on maximum and minimum 
based estimates).  Comparisons were made between statistics obtained from concordance 
statistics analysis and maximization analysis.  The results from analysis on all-cause ER visits 
were presented in Table 4.24 in which C-stat represents concordance statistic for at least one or 
both-based PDC and partial likelihood statistic contributed by maximum and minimum based 
PDC dichotomized at 80%.  Perfect correspondence was noted between concordance statistic and 
partial likelihood statistic regardless of measurement period and multivariable or univariable 
analysis.  In other words, when C-statistic increased, so did partial likelihood.  For example, 
when PDC was measured cumulatively over quarters both concordance statistic and partial 
likelihood statistic were lower for ‘at least one’ than those were for the both-based approach.   
Because maximization analysis was performed on 5 cut points (65% through 85% at 5% 
intervals), for each row (i.e., PDC measurement) in Table 4.24 contained a respective maximum 
statistic that could range from 75% through 85%.  The maximization column in Table 4.24 
reports the maximum values associated with analysis performed on all-cause ER visit.  The 
concordance column reports whether maximum values are 80% or not.  Of the 16 different ways 
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in which PDC were measured in the study, maximization occurred at 80% only in 2 (12.5%) 
cases.   
Table 4.24: Concordance Analysis on Optimality of Cut-off Points 
Measurement Model Approach C-stat/ PL80 Max Concordance 
Cumulative 
90 day 
Multivar 
At least one/ 
max 80 
0.557/6.125 75%* no 
Both/min 80 0.5607/10.107 75% no 
Univar 
At least 
one/max 80 
0.5169/9.1097 75% no 
Both/min 80 0.5281/16.789 75% no 
90 day 
Multivar 
At least one/ 
max 80 
0.5228/11.465 75% no 
Both/min 80 0.5324/15.037 80% yes 
Univar 
At least one/ 
max 80 
0.5584/13.223 75% no 
Both/min 80 0.5628/20.18 80% yes 
Cumulative 
30 day 
Multivar 
At least one 
/max 80 
0.5535/6.1458 75% no 
Both/min 80 0.5572/10.196 75% no 
Univar 
At least one/ 
max 80 
0.5157/8.7115 75% no 
Both/min 80 0.5253/16.23 75% no 
30 day 
Multivar 
At least one/ 
max 80 
0.5224/11.803 85% no 
Both/min 80 0.5329/17.281 85% no 
Univar 
At least one/ 
max 80 
0.5564/14.786 85% no 
Both/min 80 0.5602/23.857 85% no 
 
Max: Maximization cut point; Outcome variable: All-cause ER;  C-stat: Concordance 
statistics (CT from Kremers);  PL80: partial likelihood statistic of PDC dichotomized at 
80%;  Multivar: multivariable model;  Univar: univariable model;  Max 80: dichotomization 
of maximum approach at 80%;  Min 80: dichotomization of minimum approach at 80%  
* statistic not significant at p=0.0033  
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Concordance analysis was performed on any diabetes related event as outcome variable.  
A total of six of eight of maximum-based PDC dichotomized at 80% yielded highest values 
among all respective maximum-based PDC measure dichotomized at different cut points 
(Appendix).  The two that were not maximized at 80% were the ones when PDC was measured 
cumulatively over 90 days in a multivariable model and when PDC was measured at every 30 
days in a univariable model.  Thus, the at least one based approach showed high concordance 
with the maximization of partial likelihood statistic-based approach when analysis was run on 
any diabetes related event.  All of both-based PDC – alternatively, minimum-based PDC 
dichotomized at 80% – were maximized either at 75% or at 85%.   
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CHAPTER 5  
DISCUSSION 
Using the MarketScan 2002-2003 commercial claims database, this dissertation examined 
intra-disease and inter-disease multiple medication adherence and issues associated with intra-
disease multiple medication adherence.  A number of inclusion and exclusion criteria were 
imposed for the selection of study subjects; such methods resulted in a smaller pool of subjects 
receiving two oral diabetes medications (SU and TZD) but they were thought to ensure 
consistency in measurement and unbiased results.  On average, this pool of older adults 
demonstrated good levels of adherence for both SU and TZD over time although rates continued 
to decline over time; these findings were consistent with past research.   
 
Intra-disease Multiple Medication Adherence 
A total of 6043 subjects were available initially for examining intra-disease multiple 
medication adherence; however, the number of subjects declined to 4996, 3772, and 447 in the 
6th, 7th, and 8th quarter, respectively.  A series of multivariate multilevel random intercept and 
growth models with and without covariates were undertaken to examine multiple medication 
adherence. It was expected that a positive covariation between adherence behaviors related to 
two medications taken concurrently for the same chronic disease would exist; consequently, a 
significant correlation of 0.57 between the random components of adherence to the two 
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medications was observed.  The strength of the relationship persisted after controlling for age 
and gender.  To an extent, these results can be anticipated from the patterns of population 
adherence estimates (Table 4.2) of the two diabetes medications under investigation.  Thus, even 
if there were variations in adherence at different times to individual medications prescribed for a 
disease, the relationship between means measured at the individual level appear to be related.  
More precisely, factors that are affecting the overall medication adherence behaviors for two 
medications appear to have strong relationship.  Many reasons can be speculated in support of 
such results, including synchronization and scheduling (Choudhry et al., 2011); however, a 
conceptually plausible reason may include the patient’s overall disease beliefs as a driver of 
adherence behavior as supported by studies based on psychosocial factors affecting adherence 
(Stack et al., 2011).  The latter may be further supported by the subgroup analysis, which 
included community pharmacy patrons only, that demonstrated a strong correlation between the 
random effects (Appendix).  In general, medications obtained from community pharmacies are 
not refilled automatically; thus, community patrons generally make conscious decisions about 
getting their prescriptions filled and continuing them over time. 
Multivariate growth models were run to examine the relationships between changes in an 
individual’s adherence behaviors to two medications taken concurrently for a chronic disease.  In 
other words, relationships between the random slopes for each medication adherence were 
analyzed.  The correlations (i.e., the association of evolutions) between random slope for SU and 
that of TZD were greater than 0.62 regardless of whether or not the effects of age and gender 
were controlled for.  Thus, it appears that factors that affect adherence behaviors for multiple 
medications over time are strongly related.  Subgroup analysis on community patrons also 
replicated strong relationships as described above.  It is interesting to note that correlations of 
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random slopes from the growth model analyses were stronger than correlations from means (i.e., 
random intercept) model analyses.  Among a host of potential reasons, one is that underlying 
factors driving the growth of individual medication adherence behaviors change in a more 
closely coordinated manner than do those representing overall behaviors.   
To a patient receiving treatment, medications may have a symbolic meaning for disease 
state.  It is possible that when a patient is put on an additional medication for the treatment of a 
disease, he will start perceiving the disease more seriously.  Thus, disease beliefs may be driving 
the state of adherence for each medication for that disease at every point in time and ensure 
similarities in the pattern of consumption variations.  In contrast, mean model correlation 
estimations may be affected by differential initial states of adherence as prescriptions are likely 
to be not initiated simultaneously more often than not.  However, the effect of statistical 
modeling (i.e., use of random intercept vs. growth model) cannot be ruled out when a variable 
such chronic medication adherence is truly time-dependent.   
 
Inter-disease Multiple Medication Adherence 
Because so many patients suffer from multiple chronic diseases, this study explored the 
adherence behaviors of diabetes patients for medications prescribed for other diseases in addition 
to adherence to two diabetes medications.  In order to investigate inter-disease multiple 
medication adherence, diabetes patients who were prescribed two oral diabetes medications were 
evaluated as to their use of medications to treat hypertension, hyperlipidemia, or angina.  Over 
2300 patients were taking medications for either hypertension or cholesterol, 860 were on 
prescriptions for both hypertension and cholesterol.  Additionally, many were prescribed anti-
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anginal medications.  It should be noted here that these numbers are not estimates of percent of 
diabetes patients suffering from the aforementioned chronic diseases; it is very likely that the 
number of diabetes patients suffering from other chronic diseases has been underestimated 
because of the selective medication filling-based selection criterion used in the study.  The 
subjects for the analyses of inter-disease multiple medication adherence were observed, on 
average, for over one and a half years and slightly dominated by male.   
 As such, there were four sets of patients on which analyses related to inter-disease 
multiple medication adherence were performed.  While the statistical modeling strategy was the 
same as that of the intra-disease multiple medication adherence analysis, the number response 
variables was 3 or 4; thus, the number of random effect correlations were always 3 or greater.  
Adherence rates for individual medications for all four subgroups of patients were estimated 
(Table 4.5) for each quarter.  Adherence rates for diabetes medications of these groups of 
patients as presented in Table 4.5 were slightly different from actual adherence estimates of the 
same because different index dates for intra-disease and inter-disease medication adherence 
might have been used for some patients.   
Diabetes Patients with One Additional Asymptomatic Chronic Disease  
Chronic diseases may be related to one another based on disease patho-physiologic 
profile leading to concordance or lack of that with another chronic disease.  There were two 
groups of diabetes patients who were suffering from concordant diseases and prescribed 
medications (hypertension or hyperlipidemia).  The average quarter-specific PDC estimates for 
concordant disease medications trailed the corresponding PDC estimates for SU and TZD except 
for that of hypertension medications, which were slightly above their respective diabetes 
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medications estimates.  However, the results for hypertension medications may have occurred 
because of a liberal methodology adopted for estimation (i.e., possession of any medications on a 
day) of PDC for hypertension medications.  The average population adherence estimates for 
cholesterol medications were about 70% in all quarters and that for hypertension were slightly 
greater than 70% in all quarters.   
Similar to intra-disease multiple medication adherence analyses, the multivariate multi-
level models for inter-disease multiple medications adherence were run on quarter-specific PDC 
estimates for each medication on those subjects that had a full quarter of observation and the 
strategy led to decline in number of subjects in later quarters.  The results of unconditional 
random intercept models analyses revealed strong correlations (greater than 0.5) among all 
medications, including those for cholesterol and hypertension.  Thus, when patients suffered 
from multiple concordant chronic diseases, significant correlations were observed with regard to 
within-patient adherence to medications taken concurrently for an index chronic disease (i.e., 
diabetes) and another asymptomatic chronic disease regardless of disease state (i.e., hypertension 
or hypercholesterolemia).  Interestingly, correlation estimates of inter-disease multiple 
medication adherence (i.e., between SU and anti-hyperlipidemic medications and between 
hypertension medications and TZD) were stronger than that for intra-disease correlation.  It is 
difficult to explain such findings definitively.  However, a few reasons can be speculated to have 
caused such results including simultaneous initiation or synchronization of refills of those 
specific medications.  Alternatively, patients demonstrated selective medication adherence (e.g., 
Wogen et al. (2003) noted adherence to specific medication class; McHorney and Gadkari (2010) 
found differential beliefs to medications patients chose to persist compared to ones patients did 
not) that are tied to one medication for each disease.  Additional analyses using conditional 
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growth models showed that there were significant correlations between random slopes of 
medication-specific adherence over time.  Thus, it appears that a patient’s changes in adherence 
behavior over time related to each chronic disease medication are strongly related even after 
controlling for age and gender.  Interestingly, the results of means model analyses are replicated 
qualitatively in growth model analyses in that some inter-disease association of evolutions 
estimates were higher than their intra-disease counterparts although association of evolutions 
estimates were much greater than estimates of association of means.  In sum, consistency and 
strength in relationships that were observed for inter-disease multiple medication adherence is 
interesting; indeed, it may provide evidence of a higher order construct affecting patients’ health 
behavior decisions, specifically as it relates to medication consumption.  This is consistent with a 
recent work that found that a pharmacist-provided counseling program improved adherence to 
target and nontarget chronic medications (Taitel et al., 2012).  
Diabetes Patients with More than One Additional Asymptomatic Chronic Disease  
Many diabetes patients suffer from more than one chronic disease (e.g., hypertension and 
hypercholesterolemia).  This study found that for these patients the average adherence estimates 
in all quarters were consistently highest for hypertension medications and lowest for cholesterol 
medications.  The average adherence rates for hypertension medications were about 80% in all 
quarters whereas other rates were suboptimal (based on the ≥80% criterion).  The unconditional 
random intercept models were run to examine six correlations: five for cross-disease medications 
and one for within-disease medications.  All random intercept correlations were significant and 
were above 0.5 except for two between SU and anti-hyperlipidemic medications (0.49) and SU 
and hypertension medications (0.47).  Thus, when patients suffered from multiple concordant 
chronic diseases, significant correlations were observed with regard to within-patient adherence 
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to medications taken concurrently for an index chronic disease (i.e., diabetes in this case) and 
another asymptomatic chronic disease even when number of chronic diseases increased.  
Conditional growth model analyses in which age and gender were controlled for showed that 
there were significant correlations between random slopes of medication-specific adherence over 
time with the correlation between TZD and hypertension medications and that of TZD and SU 
being the highest (0.77) and lowest (0.6), respectively.  Although these patients are a subset of 
the group with one asymptomatic chronic disease and not different from the later concerning 
their demographic profile and mean adherence estimates, such high correlations in random 
slopes appear interesting and need further investigation.  At the present time, it can be suggested 
that factors affecting their adherence that may include disease or medication beliefs are strong 
and consistent.  Alternatively, it is likely that these subjects are very health conscious and 
maintain healthy behaviors.  It should be noted here that there were very few subjects left in the 
last quarter in the analysis reported above.  However, the result did not differ when the 1st or 8th 
quarter was dropped from the analysis (Appendix).   
Diabetes Patients with an Additional Symptomatic Chronic Disease  
Chronic diseases may be symptomatic or asymptomatic in addition to being concordant 
with another chronic disease.  Angina is symptomatic and considered concordant with diabetes.  
Angina patient selection was limited to those filling only tablet or capsule forms of nitroglycerin.  
Although necessary, this inclusion criterion resulted in about 300 subjects being available for 
analysis and this number declined sharply in the last two quarters.  The average population 
adherence estimates for nitrates were substantially lower in all quarters in comparison with 
corresponding rates for diabetes medications although it showed small improvement in the last 
two quarters with smaller numbers of patients.  Given that this group was not very different in 
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the overall follow up time and demographic profile from those with only asymptomatic diseases, 
such low rates are hard to explain and may lie in methodological artifacts (e.g., SOS 
prescriptions).  Alternatively, low adherence may reflect by patients’ decision that they can find 
a rescue medication (e.g., sublingual nitrates) to treat the disease when needed.  The correlations 
of random intercepts between SU and TZD and between TZD and nitrates were statistically 
significant (p<0.05) while that for SU and nitrates was not.  Thus, the relationship between 
adherence to concordant chronic symptomatic and asymptomatic disease medications was not 
clear.  It is interesting to note that the correlation estimate (0.38) between random intercepts of 
SU and TZD is much lower than the corresponding ones observed in intra-disease or other inter-
disease analyses.  Similarly, there was a poor correlation (0.15; p=0.016) between TZD and 
nitrates.  Like other analyses, the association of evolutions estimates were higher than random 
intercepts model estimates; however, the association of evolutions of SU and nitrates were not 
significant while that of TZD and nitrates was poor but significant (0.21; p<0.05) and that of SU 
and TZD was strong (0.59; p<0.001).  When the models were rerun excluding the last 2 and 3 
quarters, no significant changes in results were observed.  Although the analyses may be 
constrained by smaller sample size especially in the last few quarters, it is encouraging to note 
that the intra-disease random intercepts and growth model correlation estimates were consistent 
with the results from all other analyses.  Contrary to popular beliefs about higher adherence to 
symptomatic disease, lower adherence to angina medications was little surprising.  
 
Measurement of Intra-disease Multiple Medication Adherence  
Based on existing methods that were identified from the literature, a single composite 
estimate of adherence for multiple medications for a disease can be computed using six different 
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methods: three each for continuous and categorical measures.  The means of (single) continuous 
PDC estimates of multiple medication adherence varied widely depending on the type of 
measurement used.  Both average and minimum-based approaches yielded suboptimal (per 
≥80% criterion) adherence rates.  These differences were present when PDCs were calculated at 
each quarter or estimated cumulatively up to each quarter.  It can be expected that variations in 
estimates of PDC based on a restrictive methodology (e.g., requiring patients to take both 
medications or minimum approach) became large and would continue to grow in populations in 
which overall adherence rates are lower than the population used in the study or in instances 
where a patient is followed for a longer time (i.e., >8 quarters).   
When single measures of multiple medication adherence based on a dichotomy (i.e., 
adherent vs. nonadherent) with a cut-point of 80% PDC were used, similar to the results for 
continuous measure-based estimates, there was a considerable variability in estimates based on 
the approach used and adherence estimates can be considered suboptimal based on measurement 
method selected.  The all-based estimates were slightly smaller but closely followed the 
estimates measured by the both approach, which provided the lowest estimates.  Thus, it is 
understood that not every composite dichotomous measure will classify patients consistently as 
adherent or nonadherent unless a patient shows high adherence rates.  Interestingly, it was found 
that the extent of discrepancy in classification of patients who were rated adherent at least by one 
approach could be as high as 38%.  Thus, this can be concluded that such discrepancy, which is 
indeed high in the study population, will become more apparent if overall population adherence 
rates become poor or when a longer observation period is considered.   
Different composite measures of PDC estimates for multiple medications were compared. 
In addition, a weighted average-based composite measure was conceptualized and proposed to 
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be compared against other composite measures.  All-cause and any diabetes related ER visits 
were chosen to derive weights and compare the performance of measurement approaches.  The 
decisions to choose outcome measures were based on theoretically and practically meaningful 
and statistical modeling rationales.  In analyses related to measurement, an additional time unit 
(i.e., 30-day periods) of measurement was considered.  This decision was partly driven by the 
fact that episodes of nonadherence within a short period might lead to hyperglycemia that might 
lead to an acute ER event.  In addition, shorter measurement unit may prevent excluding subjects 
due to incomplete reporting periods and thus, to some extent, might alleviate the problem of high 
censoring rate or fewer events.  Although small, the number of events was not particularly 
concentrated on any specific quarters except that the last quarter had the fewest events.   
In order for deriving weights for the proposed weighted average-based composite 
measure, survival analysis was performed.  Although individual hazard estimates were in the 
right direction, hazard estimates for both SU and TZD were not significant simultaneously.  In 
some analyses, hazard estimates for SU were significant but not that of TZD or vice versa.  Such 
results were repeated regardless of whether PDC was measured using 30-day periods or 90-day 
periods or cumulatively over those periods.  As strong relationships between adherence to SU 
and TZD were noted consistently in the multiple medication adherence analyses, it is believed 
that strong multicolinearity may have caused such results.  Thus, any outcome-based weights and 
weighted average-based composite measure of intra-disease multiple medication adherence 
could not be computed.  Most studies in adherence do not differentiate specific medications with 
regard to their impact of health outcome.  In the light of evidence gained in this study, the 
assumption that all medications have the same health impact cannot be ruled out.  Indeed, this 
study provides evidence for averaging out adherence values for multiple medications.   
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Comparisons of Measures of Multiple Medication Adherence: Predictive power  
A series of survival analyses were performed to compare the six different composite 
measures of intra-disease multiple medication adherence.  All composite measures of adherence 
to diabetes medications significantly predicted hazards of all-cause adverse events; however, 
hazard estimates yielded by different composite measures varied depending on whether 
continuous or dichotomous measures were used.  Hazards estimates of all continuous measures 
approached one regardless of whether or not PDC was measured at 30-day or 90-day periods or 
cumulatively, all were statistically significant (p<0.005).  As such, findings that even a small 
improvement in adherence will result in lower hazards of adverse events are encouraging for 
healthcare providers for whom adherence improvement is a focus of their patient care activities.  
The hazard ratios of dichotomous composite measures differed on the basis of the method used 
to compute adherence estimate; while the at least one method showed slightly superior (i.e., 
lower) hazards when adherence was computed over 90-day periods, the all measure consistently 
revealed the lowest hazards regardless of adherence being computed cumulatively over 30-day 
periods or 90-day periods.  Interestingly, the hazard ratios in multivariable models were slightly 
higher than those in the corresponding univariable models for all dichotomous measures.  As age 
and comorbidity are strong and consistent predictors of health outcomes, the effect of adherence 
is less pronounced in the multivariable models.   
When analysis was performed on any diabetes related ER events, a clear trend emerged.  
Similar to the results from all-cause analysis, hazard estimates on any diabetes-related ER visits 
were significant (p<0.05) but nearly one for all continuous composite PDC measured over 30-
day periods or 90-day periods or cumulatively.  In cases of dichotomous composite measures, the 
at least one measure consistently demonstrated the lowest estimates regardless of period specific 
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or cumulative PDC or the length of PDC measurement period used; hazards estimates were 
slightly wide apart and 90-day based measures yielded lower hazards whereas 30-day based 
cumulative measures showed lower hazards.  Thus, the results appear to suggest that 30-day 
based measures show enough power if considered cumulatively whereas 90-day based measures 
is strong enough to predict an event in a period when patients are nonadherent.  Compared to all-
cause hazard ratios as estimated by composite PDC measures, all of the respective diabetes-
related hazard estimates were much lower.  This is intuitive in that diabetes medication 
adherence should be a better predictor of diabetes-related ER events than it would be for all-
cause ER events.  In sum, consistent with other studies (Balkrishnan et al., 2003; Sokol et al., 
2005), nonadherence measured by any composite measure was a consistent predictor of adverse 
healthcare events regardless of adherence measurement approach or period.  However, 
significant relationships do not state anything about a model’s overall prognostic or explanatory 
power.   
 
Comparison of the Adherence Measures: Discriminatory Power  
One attribute of a good measure is its ability to discriminate well between groups that are 
different on outcome potential.  In other words, a measure should have the ability of classifying 
subjects into appropriate groups to which they actually belong.  A concordance statistic was 
computed for each adherence measurement approach to determine how well each method 
classifies subjects into groups of those having events and those having none.  All the approaches 
resulted in statistically significant concordance statistics.  With regard to all-cause analyses, the 
average based approach consistently demonstrated highest concordance statistics regardless of 
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30-day or 90-day measurement periods or cumulative period measurement. Among categorical 
composite measures ‘all’ (especially, when measured cumulatively) or ‘both’ showed slightly 
higher values than did ‘at least one’.  When diabetes-related outcomes were analyzed, no clear 
trends emerged; the average and at least one approaches appeared to perform better than others.  
Regardless of outcome selected, the multivariable models resulted in improved concordance 
statistics compared to their respective univariable model-based values.  Although some 
performance-related trends were observed, concordance statistics generated by the different 
measurement methods were not statistically different from one another as reflected by their 
overlapping confidence intervals.  In addition, the value of concordance statistics were slightly 
greater than 0.5 implying poor discriminatory power.  However, comparable values of 
discriminatory index (i.e., c-statistics) were observed in a previous study of comparison of 
measures of adherence to a single medication or medications for a disease (Karve et al., 2009).   
 
Examination of Optimal Cut-points of Measures of Multiple Medication Adherence  
Apart from the average approach, the two other continuous composite approaches 
evaluated were the maximum and minimum algorithms.  These two showed comparable 
estimates of concordance statistics while the average-based estimates were slightly better than 
those estimated by the minimum and maximum approach.  Cut point analysis was performed on 
these continuous composite PDC measures.  Five cut points were chosen for dichotomization: 
65, 70, 75, 80, and 85.  The dichotomization point that resulted in an adjusted significant 
maximization of likelihood statistics was examined.  Analysis on all-cause ER revealed that if 
the average measure is dichotomized at 85% with PDC being measured at each period or 
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cumulatively over 90 days, the likelihood statistics maximized.  For the more restrictive 
minimum approach, such results were observed at 75% or 80%, while it is interesting to note that 
the more liberal minimum approach indicated maximization at 75%.  More clear trends emerged 
when PDC was measured over 30 days such that almost all maximization occurred at 85%.  
When the analyses were repeated on diabetes-related outcomes with measurement period being 
at 90 days or cumulative 90 days, maximization occurred at 80% for average, 75% for minimum, 
and 80% or 75% for maximum. When the measurement period was cumulative 30 days, above 
results were replicated.  However, when the measurement was done at every 30 days, higher 
value (85%) of optimal adherence was observed.  Thus, based on the study findings it can be 
suggested that, in general, the 80% cut-point paradigm holds in the context of multiple 
medication adherence; however, providers should encourage their patients to bring their 
adherence level slightly higher for more effective disease management and for avoiding 
unnecessary health events.   
Several points deserve attention in light of the above discussion.  In a true sense, it may 
not be appropriate to describe some phenomena as maximization if it had occurred at 85% as no 
higher values were examined.  That said, as the other maximum points also lie below 85% and 
conventional wisdom advocating 80%, it can be suggested that increment in benefit of improving 
adherence will be declining sharply above 85% or maximum occurs at 85% even if higher values 
are examined.  It was apparent that from a measurement standpoint, the optimality of cut point 
was related to what methods were used to measure multiple medication adherence.  This makes 
sense because some measurements are more restrictive than others in their rationale on disease 
management and control process.  Another interesting observation can be made from the results 
such that when diabetes medication adherence is used for its ability to predict global events the 
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bar that indicates that adverse events are unlikely should be raised.  Similarly, if there is an 
imminent chance of event, higher standard of medication consumption behavior may be required 
considering that the maximization values were 85% in most 30-day period analyses.  Finally, the 
maximization analysis provided a valuable insight.  The at least one, all, and both approaches 
were operationalized with a cut point at 80%, which may not always be appropriate as 
maximization did not occur at that level for most cases.  Those measurement algorithms may still 
be useful, but the issue of cut point may need to be revisited to generate more clear insight.   
 
Limitations  
The study has several limitations, which should be considered while the results of the 
study are interpreted.  The study was conducted in a population that is enrolled in employer 
provided insurance programs.  This population has several attributes that might have affected 
study results.  For example, this population consists of relatively younger adults and, on average, 
is 10 years younger than the Medicare population.  Age is a well-known risk factor for disease 
outcomes.  Indeed, in this study, age has been found to be a significant predictor in all analyses.  
The results of this study (i.e., associations of evolutions or cut-point estimates) may or may not 
hold in other populations that differ with respect to age.  Similarly, this population may be 
different from general population with regard to other socio-economic variables (e.g., income, 
life style, dietary habits, etc.) that may play a role in disease progression, health outcomes, and 
health behavior including medication adherence.   
Chronic disease management, by definition, is a long term process.  In this study, the 
mean observation time was little over one and a half years.  Although not short, the observation 
period may not reflect long-term patient behavior or capture health outcomes that are likely to 
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occur as a result of poor medication adherence for a longer period of time.  In fact, some patients 
were available for observation for less than a year for survival analysis or just a little over a year 
for the analysis of multiple medication adherence association.  The results may not be 
appropriate when the goal is to study or predict long term behavior or events.   
This study primarily focused on diabetes patients who were on two medications.  If 
adherence behavior is rooted in specific medications then the study results may not be 
generalizable to other medications.  For many patients, different medication formulations are 
currently prescribed concurrently for the treatment of diabetes.  As both of the study medications 
were tablets, findings based on tablet formulation may not be applicable to other formulation 
types or a combination of different formulation types.  Similarly, it may not be generalizable to 
situations where primary disease state is not diabetes.  Existing evidence (Cramer et al., 2008) 
suggests that adherence rates may be different in difference diseases and failure to adhere to 
prescribed regimen may result in adverse outcomes that might occur at different times dependent 
on disease.  If such underlying dynamics are at play, it would limit the findings of this study.   
For analyzing the optimality of cut point for dichotomization of medication adherence, 
patient comorbidity (i.e., CCI) was calculated based on only two quarters.  While it was 
consistent for all subjects, comorbidity may not have measured optimally by the method 
followed in the study.  For example, if a patient does not visit a physician in six months under 
consideration for CCI calculation, CCI will be underestimated for the patient.  Similarly, if a 
patient does not have any in-patient hospitalizations during the period under consideration his 
CCI score may likely to be underestimated compared to one having a hospitalization (e.g., 
increased options for reporting ICD-9 codes that may result in higher likelihood of reporting 
multiple diagnoses compared to ones that may occur in an outpatient setting).  It is not known 
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what the impact would be on the study findings had CCI been measured over a year or longer.  
As CCI has been consistently found as a significant predictor in all analyses related to 
measurement issues, it is speculated that appropriate measurement of CCI would likely improve 
concordance statistics.   
This study was able to include only a relatively small number of subjects.  The inclusion 
and exclusion criteria that led to small sample size were based on the objective of deriving an 
unbiased result.  In general, studies that use claims data methodology include a larger number of 
subjects compared to the number of subjects included in this study.  However, precedence also 
exists in which a small sample size was used including studies on medication adherence (e.g., 
Balkrishnan et al., 2003).  That said, a relatively smaller sample size should be recognized as a 
limitation, especially when it is known that millions of subjects in the US suffer from diabetes or 
other chronic diseases.   
The outcome events that were analyzed in this study deserve a note.  Two types of events 
were analyzed: all-cause ER visits and any diabetes-related ER visits.  Other types of outcome 
events that are analyzed in claim-based studies include in-patient hospitalization or primary-
cause events. Naturally, extending the results of measures being able to predict outcomes beyond 
the ones used in the study or comparing measures in any contexts of outcomes beyond these ones 
are limited.  In addition, patients were not followed once they had an event.  Thus, results cannot 
be extended to situations in which the goal is to identify patients susceptible to readmission or 
repeated adverse events.   
The methodology adopted to estimate adherence could limit the results of the study.  
Many patients included in the study had an incomplete period of observation.  Such patients (i.e., 
those having less than 30 days for 30-day periods or less than 90 days for 90-day quarters) were 
143 
not included while calculating period-specific adherence rates for multi-level model or survival 
analyses.  Thus, adherence estimates or association between adherence estimates could have 
been different had these people been included.  This problem may be further aggravated for 
inter-disease multiple medication adherence estimates as the number of observation periods 
further declined.  Furthermore, if there was any significant nonlinearity in patient adherence 
behavior, associations of evolutions estimated in this study will not represent true estimates.  As 
many of the subjects were not included in later time-periods, number of subjects continued to 
decline in later periods that may have affected the results related to survival analysis in several 
ways including reducing statistical power or introducing some biases.   
Finally, the results should be interpreted with caution because of the statistical techniques 
that were used in the study.  Several approaches have been proposed in the statistical literature 
for computing discriminatory index (i.e., concordance statistic) for a survival analysis model; 
however, there is a limited guidance in the literature as to which approach performs better.  In 
addition, this question becomes further complicated for analyzing a time dependent variable and 
in presence of a high rate of censoring.  Similar issues exist for choosing a method for 
determining an optimal cut point.  As the method adopted in this study was based on an 
unpublished scholastic work and failed to demonstrate a consistent and meaningful trend in some 
analyses (e.g., for ‘at least one’), such limitations should be recognized while interpreting the 
results.   
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Future Research 
This study opens up several opportunities for future investigation.  First, although the 
hypothesized multiple medication adherence relationships were founded upon the Common 
Sense Model it was not possible to conclude about association of actual beliefs.  Future research 
should focus on the collection of information on actual beliefs about two or more different 
medications and how these beliefs evolve over a period of time.  Actual measures of theory-
based adherence beliefs will help us further understand multiple medication adherence behavior.  
Second, it is important to understand the multiple medication adherence construct.  If beliefs 
drive adherence behavior, it will be insightful to understand how beliefs are structured or nested.  
For example, intra-disease multiple medication adherence may be driven by beliefs in individual 
medications or it may be subsumed under disease beliefs.  From the results of the study it can be 
speculated that there may be a higher order construct in which part of individual medication 
beliefs are nested as reflected by high correlation.  In other words, disease beliefs may influence 
individual medication beliefs and adherence.  If so, how distinct are individual medications 
beliefs from disease beliefs?  Are there any contextual effects where one might be more 
important than the other?  Are there different antecedents to each of these belief types?  Third, as 
the current literature on medication adherence provides no conceptualization of multiple 
medication adherence, understanding of the theoretical structure of multiple medication 
adherence begs further attention.  In the future, studies should be undertaken to understand 
whether or not multiple medication adherence is a complex construct and is distinct from single 
therapy adherence.  In particular, its complexity increases further for inter-disease multiple 
medication adherence.  Presently, it leaves us with no understanding of what roles are played by 
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disease beliefs and individual medication beliefs within the context of inter-disease multiple 
medication adherence.   
Medication adherence is a complex behavior.  A multitude of factors are thought to affect 
medication adherence.  Previous studies of medication adherence have found that disease state 
(Briesacher et al., 2008), severity (DiMatteo, Haskard, and Williams, 2007), cormorbid 
conditions (Rozenfeld et al., 2008; Wogen et al., 2003), cost (Briesacher, Gurwitz, and 
Soumerai, 2005), and medication burden (Benner et al., 2009; Ren et al., 2002) affect medication 
adherence (i.e., adherence to a single medication).  While comorbidity was controlled for when 
analyzing measurement issues, it was not included in the analyses related to intra- and inter-
disease multiple medication adherence.  Additional analysis (Appendix), consistent with past 
work (Ho et al., 2006b), shows that patients behave differently after an adverse event that affects 
disease state.  Fourth, in the future, the effects of variables found to have significant relationships 
with adherence, including disease state, comorbidity, cost, and number of medications need to be 
investigated in the context of multiple medication adherence.   
Multiple prescriptions are likely to occur more naturally in elderly than others.  Fifth, in 
future studies of multiple medication adherence the Medicare population should be included.  
Especially, in light of emphasis on outcome-based reimbursement by the Centers for Medicare 
and Medicaid Services (CMS), as reflected by higher weight on medication adherence based 
measures, multiple medication adherence in the Medicare population assumes increased 
relevance.   
Sixth, future studies should be designed such that a large number of patients can be 
observed for a longer duration.  A few past studies of adherence have followed patients over a 
couple of years (e.g., Nichol et al. (2009) followed patients for 6 years), and found adherence 
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rates generally declining, thus, it will be interesting to know how associations of evolutions 
evolve over years.  While increasing sample size and duration of observation will certainly 
increase power and have the potential to provide better concordance statistic estimates and 
stronger evidence of maximization (as opposed to trends that were observed for some cut-point 
analyses in the study), yet empirical evidence is required before any conclusion can be made.   
Seventh, it may be useful to validate the results in different disease states.  Past research 
on optimality of cut point for medication adherence has been replicated in different disease states 
(e.g., Karve et al., 2009); however, disease state was not related to cut-point estimates.  A similar 
analysis related to multiple medication adherence will be useful for at least two reasons: 1) it 
may make results more generalizable in terms of identifying the measure demonstrating 
consistent and superior predictive and discriminatory power and 2) it will improve the strength of 
evidence.  In addition, it will be enlightening to know if any clarity of and differences in cut-
points emerge in such studies.   
Finally, this study proposed a novel (weighted) composite measure of multiple 
medication adherence.  Although the measure was theoretically appealing, it was not possible to 
test the measure empirically because of multicollinearity.  Future studies should employ an 
appropriate methodology (e.g., analysis on split sample, matched sample analysis with one 
medication) such that the weighted composite measure can be compared against other 
measurement approaches discussed in this dissertation.   
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Contribution 
This dissertation makes several contributions to the literature and enriches the existing 
knowledge base.  First, this study generates baseline information on multiple medication 
adherence. Unlike prior studies that either looked at a single medication or did not differentiate 
medications for a disease, this research provides temporal adherence (population) estimates for 
individual medications when patients are advised two medications simultaneously for a disease.  
Similarly, it provides temporal adherence estimates for patients who are on multiple medications 
for different chronic disorders.  Although adherence estimates are high for some medications, 
they are not at an acceptable level of appropriate adherence target and may be utilized for 
intervention decisions.   
Second, recently efforts have been made to understand medication adherence for two 
distinct diseases (e.g., Chapman et al., 2005).  This study is the first to extend the work by 
focusing on diseases that have different types of relationships.  This work identifies the fact that 
many patients may be suffering from two or more chronic concordant symptomatic and 
asymptomatic diseases and attempts to estimate adherence rates for the subgroup of patients who 
are on multiple medications for different chronic diseases.   
Third, this study extends the generalizability of past work that focused on other 
population (e.g., Nichol et al., 2009) examined multiple medication adherence for two diseases in 
the Medicaid population.  Although the commercially-insured older adult population may be 
perceived to be adherent because of higher ability to afford costs or better access to healthcare, 
empirical evidence shows they may not reflect an ideal behavior.   
Fourth, multiple medication adherence has strong futuristic implications given the way 
the science of drug development and medical treatment are evolving.  This is the first study that 
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draws an explicit attention to intra-disease multiple medication adherence.  Indeed, it strives to 
differentiate multiple medication adherence into distinct phenomena: intra-disease multiple 
medication adherence and inter-disease multiple medication adherence by comparing and 
contrasting these two types of adherence behaviors.   
Fifth, measurement of adherence is the first step before any intervention decisions can be 
made.  This research highlights how the selection of a measurement paradigm can result in 
inconsistency in classification of a patient’s adherence status; it provides an estimation of 
inconsistency in patient classification that occurred based on the different measurement 
paradigms chosen.  It is noted that the issue of inconsistency may become more important when 
the population average PDC estimates are not as high as was observed in this study.   
Finally, the academic community has always wrestled over the issue of choosing an 
appropriate adherence measure.  Past work has compared and contrasted different measurement 
approaches for measuring adherence (e.g., Hess et al., 2006).  This work complements the 
previous work by generating evidence regarding the selection of an appropriate measure of intra-
disease multiple medication adherence and toward formalizing an operational definition of 
multiple medication adherence.  A categorical measure of adherence is very frequently employed 
by researchers.  To serve the need in the context of multiple medication adherence, this work 
attempted to derive an optimal cut-point that was not based on the concept of adherence to a 
single medication.   
This study has two primary methodological contributions to the field.  First, many 
individual-level factors (e.g., attitude, intentions, self-efficacy) may not be temporally stable and 
time-dependent values of these factors may affect outcomes.  Medication adherence is 
potentially one of such variables because of the possibility that changes in factors that may affect 
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adherence.  These factors may be manifested as within-patient random variables.  This research 
utilized the multilevel modeling technique to explicitly model intra-patient variation or random 
effects modeling.  There are other approaches that can be utilized for multiple medication 
adherence.  For example, latent growth curve modeling is a powerful and flexible technique to 
analyze the interrelationships among multiple dependent variables such as nested longitudinal 
adherence measures (Appendix).  However, multilevel modeling offers advantages when there 
are incomplete observations that may have little influence on mixed models (Gao et al., 2009; 
Littell et al., 1996). In addition, it adopted the concept of association of evolutions from the 
statistics literature to introduce in the adherence research.   
Second, adherence has traditionally been treated as a non-time varying variable in the 
literature.  This research treated adherence as a time-dependent variable and thus, it emphasizes 
examining not only events but also the proximity of event or time to event.  Such a consideration 
is more meaningful practically and similar to an operationalization followed in a recent 
published study of relationship between adherence and health outcomes (Yu, Yu, and Nichol, 
2010).  This dissertation work has operationalized adherence in its true sense such that values 
that change over time are captured adequately while examining the measurement of adherence 
itself.   
 
Implications 
The importance of medication adherence cannot be overstated.  Any work that improves 
adherence or deepens the understanding of adherence holds strong implications.  This study 
focused on patient behavior under a specific treatment pattern (i.e., use of multiple medications 
for better management).  Within such a disease management context, it brings insight about how 
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medication adherence behavior evolves for patients who are advised to consume multiple 
prescriptions.  As the practice is likely to grow in the future because of advancement in 
knowledge and technology, findings of the study appear to have strong implications for future 
disease management practice.  Furthermore, these results will become more valuable because of 
the declining age of onset of chronic disease and increasing life expectancy both of which affect 
cost and management strategies. 
Interventions are made to improve patient adherence.  Many factors may affect the 
effectiveness of intervention or adherence.  Although much is not known about their potential 
effect on multiple medication adherence, the study results suggest that there may be some higher 
order constructs (e.g., disease belief or trait) that may drive the joint behavior.  If interventions 
are designed effectively around such factors, there may be a spillover effect of any success in 
one disease into others with respect to medication consumption.  Period-specific changes in 
adherence demonstrated a stronger relationship in patient adherence behavior than overall mean 
associations.  Thus, it can be suggested that interventions focused on factors that may change 
periodically may be more effective.  Similarly, intervention decisions should be tailored to the 
goal of achieving a desired outcome or preventing outcome of interest.  This is implied by the 
variability in cut-points in predicting health outcomes or predicting outcomes that may occur at 
differential temporal points.   
Measurement of adherence to multiple medications is an important issue.  This study 
brought to light several issues including the potential chance of misclassification and the utility 
of existing measurement approaches.  The study results may help toward formulating a 
consistent operational definition of multiple medication adherence and serve to identify an 
appropriate and effective measurement algorithm.   
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Conclusion  
Medication adherence is critical to managing a rising burden of chronic diseases.  This 
research investigated medication adherence that would occur in a particular segment of patients 
due to the pressing need to manage the disease process more effectively or aggressively.  Intra-
disease multiple medication adherence and inter-disease multiple medication adherence were 
clearly discussed, distinguished, and defined and examined in the working older adult population 
that might be increasingly inflicted given onset age decreasing and life span increasing.  
Although this population demonstrated good adherence, the adherence rates cannot be termed 
optimal by a much-accepted norm of 80% based on the single medication adherence.  Applying 
the concepts from the biostatistics literature, it was observed that there were significant 
relationships in the growth pattern in intra-patient adherence behavior to multiple medications 
intended to treat a single chronic disease or multiple chronic diseases that are related to one 
another with regard to the patho-physiology of disease or disease management.  Consistent with 
existing knowledge (Steiner et al., 2009), this study found that demographic variables alone may 
not explain adherence well as reflected in the fact that random effect correlations remained 
strong after controlling for covariates.  Additional analyses in a subset of patients (i.e., 
community patrons) supported the theoretical justifications and interpretation of results.  
Compared to the association of overall means, a stronger relationship between period-specific 
changes in adherence implies that factors that may change periodically may be stronger 
determinants of long-term adherence to multiple medications.   
This dissertation assembled different approaches from the literature that can be applied to 
measure intra-disease multiple medication adherence and compared and contrasted the 
measurement approaches in the context.  This is consistent with past scholastic work on the issue 
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of choosing an appropriate adherence measure.  In spite of statistical power issues and 
methodological constraints, the study found that all measurement approaches significantly 
predicted outcomes and discriminated subjects.  However, there were no clear trends in 
superiority in predictive and discriminatory power of one approach over others.  That said, the 
average (continuous) and all (dichotomous) approaches appear to have edge over others due to 
some empirical support observed in the study or merely for the ease of measurement.  The 
efficacy of a measure may also be tied to outcome of interest as differences in predictive or 
discriminatory power or the optimality of cut points were observed depending on outcome event 
(i.e., diabetes vs. all-cause ER) analyzed.  Diabetes outcomes may have theoretical justification 
because of diabetes medication adherence being measured and more proximity to underlying 
causes leading to adverse events; however, it may also suffer from the lack of measurement 
validity because of the way a physician chooses ICD-9 codes or due to limited options of coding 
in the outpatient setting.  In addition, other issues of substantive interest include whether or not 
the objective is to prevent any undue adverse events or design interventions to prevent any 
versus diabetes-specific events.  Study findings should be interpreted and utilized with these 
issues in mind.   
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Table D: List of Medications Used in the Study 
Disease Medication Class Medication (Brand) 
Diabetes Sulfonylurea (SU) Acetohexamide, chlorpropamide, 
glimepiride, glipizide, glyburide, 
tolazamide, tolbutamide 
Thiazolidinediones (TZD) Pioglitazone, rosiglitazone  
Hypertension Angiotensin Receptor Blockers 
(ARB) 
Candesartan, eprosartan, 
irbesartan, losartan, olmesartan, 
telmisartan, valsartan 
Angiotensin-Converting Enzyme 
(ACE) inhibitors 
Benazepril, captopril, enalapril, 
fosinopril, lisinopril, moexipril, 
perindopril, quinapril, ramipril, 
trandolapril 
Calcium Channel Blockers(CCB) Amlodipine, diltiazem, felodipine, 
isradipine, nicardipine, nifedipine , 
nisoldipine, verapamil 
β-blockers  Acebutolol, atenolol, betaxolol, 
bisoprolol, carvedilol, labetolol, 
metoprolol, nadolol, pindolol, 
propranolol, sotalol 
Diuretics Hydroclorothiazide, chlorthiazide, 
indapamide, methyclothiazide, 
metolazone, bumetanide, 
ethacrinic acid, furosemide, 
torsemide, amiloride, 
spironolactone, triamterene  
Dislipidemia Statins Atorvastatin, fluvastatin, 
lovastatin, pravastatin, simvastatin, 
rosuvastatin  
Fibrates Gemfibrozil, fenofibrate  
Angina  Nitrates (oral) Isosorbide dinitrate, isosorbide-5-
mononitrate, nitroglycerin 
Adapted from Parker and Parker, 1998; Wang, 2006  
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Table A1: PDC Estimates by Different Dichotomous Measures 
Approach Qtr N 
Quarter –specific Cumulative 
Nonadh Adh Nonadh Adh 
At least 
one 
1 6043 716  (11.85) 5327 (88.15) 716 (11.85) 5327 (88.15) 
2 6043 1199 (19.84) 4844 (80.16) 967 (16) 5076 (84) 
3 6043 1293 (21.4) 4750 (78.6) 1156 (19.13) 4887 (80.87) 
4 6043 1356 (22.44)  4687 (77.56) 1209 (20.01) 4834 (79.99) 
5 6043 1465 (24.24) 4578 (75.76) 1275 (21.1) 4768 (78.9) 
6 6043 1543 (25.53) 4500 (74.47) 1393 (23.05) 4650 (76.95) 
7 4979 1233 (24.76) 3746 (75.24) 1091 (21.91) 3888 (78.09) 
8 3752 826 (22.01) 2926 (77.99) 777 (20.71) 2975 (79.29) 
Both 
1 6043 2346 (38.82) 3697 (61.18) 2346 (38.82) 3697 (61.18) 
2 6043 2977 (49.26) 3066 (50.74) 2868 (47.46) 3175 (42.54) 
3 6043 3108 (51.43) 2935 (48.57) 3132 (51.83) 2911 (48.17) 
4 6043 3125 (51.71) 2918 (48.29) 3253 (53.83) 2790 (46.17) 
5 6043 3200 (52.95) 2843 (47.05) 3345 (55.35) 2698 (44.65) 
6 6043 3240 (53.62) 2803 (46.38) 3423 (56.64) 2620 (43.36) 
7 4979 2599 (52.2) 2380 (47.8) 2766 (55.55) 2213 (44.45) 
8 3752 1837 (48.96) 1915 (51.04) 1999 (53.28) 1753 (46.72) 
 
All 
1 6043 2241 (37.08) 3802 (62.92) 2241 (37.08) 3802 (62.92) 
2 6043 2868 (47.46) 3175 (52.54) 2681 (44.37) 3362 (55.63) 
3 6043 3004 (49.71) 3039 (50.29) 2952 (48.85) 3091 (51.15) 
4 6043 3029 (50.12) 3014 (49.88) 3037 (50.26) 3006 (49.74) 
5 6043 3112 (51.5) 2931 (48.5) 3085 (51.05) 2958 (48.95) 
6 6043 3161 (52.31) 2882 (47.69) 3201 (52.97) 2842 (47.03) 
7 4979 2549 (51.2) 2430 (48.8) 2579 (51.8) 2400 (48.2) 
8 3752 1805 (48.11) 1947 (51.89) 1847 (49.23) 1905 (50.77) 
 
Qtr: Quarter; Nonadh: Nonadherent; Adh: Adherent (based on the 80% rule)  
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Table A2: Intra-disease Multiple Medication Adherence: Fixed Effects for 
Unconditional Growth Models 
Effect Med Estimate Standard Error DF t Value Pr > |t|
med SU 80.3023 0.3425 5988 234.46 <0.0001
med TZ 81.6592 0.3389 5976 240.98 <0.0001
qtr_cont  -2.8469 0.0853 5537 -33.36 <0.0001
qtr_cont*med SU 0.5825 0.0903 5310 6.45 <0.0001
qtr_cont*med TZ 0 . . . .
   
 
 
 
 
 
 
 
Table A3: Intra-disease Multiple Medication Adherence: Fixed Effects for Conditional 
Growth Models 
Effect med Estimate Standard Error DF t Value Pr > |t|
med SU 80.2982 0.3391 5985 236.78 <0.0001
med TZ 81.6541 0.3351 5972 243.64 <0.0001
qtr_cont  -2.8435 0.0853 5537 -33.32 <0.0001
age_mc  0.6348 0.0495 6029 12.82 <0.0001
qtr_cont*med SU 0.5818 0.0903 5310 6.44 <0.0001
qtr_cont*med TZ 0 . . . .
age_mc*med SU -0.0199 0.0511 6036 -0.39 0.6975
age_mc*med TZ 0 . . . 
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Table A4: Intra-disease Multiple Medication Adherence: Fixed Effects for Conditional 
Growth Models 
Effect med Gender of Patient Estimate Standard Error DF t Value Pr > |t|
med SU 79.0280 0.5036 6236 156.92 <.0001
med TZ 79.5628 0.5034 6092 158.04 <.0001
qtr_cont -2.8463 0.08534 5537 -33.35 <.0001
SEX 1 3.7732 0.6713 6019 5.62 <.0001
SEX 2 0 . . . .
qtr_cont*med SU 0.5824 0.09031 5310 6.45 <.0001
qtr_cont*med TZ 0 . . . .
med*SEX SU 1 -1.4798 0.6861 6035 -2.16 0.0310
med*SEX SU 2 0 . . . .
med*SEX TZ 1 0 . . . .
med*SEX TZ 2 0 . . . .
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Table A5: Intra-disease Multiple Medication Adherence: Fixed Effects for Conditional 
Growth Models 
Effect med Gender 
of Patient 
Estimate Standard Error DF t Value Pr > |t|
med SU  79.1823 0.4982 6251 158.93 <0.0001
med TZ  79.7204 0.4977 6104 160.18 <0.0001
qtr_cont   -2.8430 0.0853 5537 -33.31 <0.0001
age_mc   0.6257 0.0494 6028 12.66 <0.0001
SEX  1 3.4805 0.6633 6020 5.25 <0.0001
SEX  2 0 . . . .
qtr_cont*med SU  0.5817 0.0903 5310 6.44 <0.0001
qtr_cont*med TZ  0 . . . .
age_mc*med SU  -0.0160 0.0512 6035 -0.31 0.7541
age_mc*med TZ  0 . . . .
med*SEX SU 1 -1.4721 0.6866 6034 -2.14 0.0321
med*SEX SU 2 0 . . . .
med*SEX TZ 1 0 . . . .
med*SEX TZ 2 0 . . . 
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Table A6: Inter-disease Multiple Medication Adherence: Fixed Effects for Conditional 
Growth Models 
Effect med Gender 
 
Estimate Std Error DF t Value Pr > |t|
med LP  77.3629 0.8466 2389 91.39 <0.0001
med SU  81.1535 0.8028 2438 101.09 <0.0001
med TZ  81.6540 0.7947 2392 102.75 <0.0001
qtr_cont   -2.6842 0.1411 2124 -19.03 <0.0001
age_mc   0.5144 0.0840 2347 6.12 <0.0001
SEX  1 3.5604 1.0270 2345 3.47 0.0005
SEX  2 0 . . . .
qtr_cont*med LP  -0.1847 0.1469 1923 -1.26 0.2087
qtr_cont*med SU  0.5191 0.1478 2056 3.51 0.0005
qtr_cont*med TZ  0 . . . .
age_mc*med LP  0.1696 0.0871 2353 1.95 0.0516
age_mc*med SU  0.09593 0.0896 2354 1.07 0.2842
age_mc*med TZ  0 . . . .
med*SEX LP 1 0.5763 1.0653 2353 0.54 0.5886
med*SEX LP 2 0 . . . .
med*SEX SU 1 -1.8462 1.0951 2354 -1.69 0.0919
med*SEX SU 2 0 . . . .
med*SEX TZ 1 0 . . . .
med*SEX TZ 2 0 . . . 
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Table A7: Inter-disease Multiple Medication Adherence: Fixed Effects for Conditional 
Growth Models 
Effect med Gender 
 
Estimate Standard Error DF t Value Pr > |t|
med AH  82.6801 0.7647 2243 108.13 <0.0001
med SU  80.2791 0.7904 2300 101.57 <0.0001
med TZ  80.4139 0.8061 2222 99.75 <0.0001
qtr_cont   -2.7314 0.1385 1985 -19.72 <0.0001
age_mc   0.5930 0.0858 2205 6.91 <0.0001
SEX  1 3.0248 1.0988 2200 2.75 0.0060
SEX  2 0 . . . .
qtr_cont*med AH  0.7580 0.1383 1878 5.48 <0.0001
qtr_cont*med SU  0.3826 0.1485 1951 2.58 0.0100
qtr_cont*med TZ  0 . . . .
age_mc*med AH  -0.0653 0.0830 2207 -0.79 0.4312
age_mc*med SU  0.00234 0.0898 2208 0.03 0.9792
age_mc*med TZ  0 . . . .
med*SEX AH 1 -2.3466 1.0629 2205 -2.21 0.0274
med*SEX AH 2 0 . . . .
med*SEX SU 1 -1.4841 1.1504 2206 -1.29 0.1971
med*SEX SU 2 0 . . . .
med*SEX TZ 1 0 . . . .
med*SEX TZ 2 0 . . . 
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Table A8: Inter-disease Multiple Medication Adherence: Fixed Effects for Conditional 
Growth Models 
Effect med Gender Estimate Standard Error DF t Value Pr > |t|
med AH  76.7130 1.4053 847 54.59 <0.0001
med LP  85.1435 1.2428 850 68.51 <0.0001
med SU  82.3388 1.3236 852 62.21 <0.0001
med TZ  82.3879 1.2834 840 64.20 <0.0001
qtr_cont   -2.3323 0.2326 741 -10.03 <0.0001
age_mc   0.5198 0.1384 823 3.75 0.0002
SEX  1 2.5503 1.7063 822 1.49 0.1354
SEX  2 0 . . . .
qtr_cont*med AH  -0.3392 0.2315 619 -1.47 0.1434
qtr_cont*med LP  0.7163 0.2276 686 3.15 0.0017
qtr_cont*med SU  0.0291 0.2334 705 0.12 0.9009
qtr_cont*med TZ  0 . . . .
age_mc*med AH  0.0232 0.1469 824 0.16 0.8745
age_mc*med LP  -0.0261 0.1347 825 -0.19 0.8463
age_mc*med SU  0.0501 0.1515 825 0.33 0.7411
age_mc*med TZ  0 . . . .
med*SEX AH 1 2.9325 1.8106 824 1.62 0.1057
med*SEX AH 2 0 . . . .
med*SEX LP 1 -3.5545 1.6601 825 -2.14 0.0326
med*SEX LP 2 0 . . . .
med*SEX SU 1 -1.7493 1.8680 826 -0.94 0.3493
med*SEX SU 2 0 . . . .
med*SEX TZ 1 0 . . . .
med*SEX TZ 2 0 . . . .
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Table A9: Inter-disease Multiple Medication Adherence: Fixed Effects for Conditional 
Growth Models 
Effect med Gender 
 
Estimate Standard 
Error
DF t 
Value 
Pr > |t|
med AG  36.4003 3.5094 305 10.37 <0.0001
med SU  74.9576 2.7807 311 26.96 <0.0001
med TZ  73.8889 2.9722 306 24.86 <0.0001
qtr_cont   -2.3166 0.4521 258 -5.12 <0.0001
age_mc   0.1489 0.3842 297 0.39 0.6987
SEX  1 4.7621 3.7399 297 1.27 0.2039
SEX  2 0 . . . .
qtr_cont*med AG  -0.1099 0.5178 243 -0.21 0.8321
qtr_cont*med SU  0.4843 0.4927 256 0.98 0.3265
qtr_cont*med TZ  0 . . . .
age_mc*med AG  0.4364 0.5464 297 0.80 0.4251
age_mc*med SU  0.1908 0.4262 297 0.45 0.6547
age_mc*med TZ  0 . . . .
med*SEX AG 1 -10.5834 5.3200 297 -1.99 0.0476
med*SEX AG 2 0 . . . .
med*SEX SU 1 1.5000 4.1498 297 0.36 0.7180
med*SEX SU 2 0 . . . .
med*SEX TZ 1 0 . . . .
med*SEX TZ 2 0 . . . .
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Table A10: Additional Analysis on Groups of Subjects or Specific Quarters 
Model Patrons First five5 Q Five Q from 2nd 
onward 
Conditional means model: 
random intercepts 
All 0.5466 0.5383 
Conditional growth model: ae 
(SU and TZ) 
All 0.6581 0.6347 
Conditional means model: 
random intercepts 
Community 0.5520 0.5491 
Conditional growth model: ae 
(SU and TZ) 
Community 0.5949 0.5842 
Conditional: covariates sex and age included in the model; Q: quarter; ae: association of 
evolutions; SU: Sulfonylurea; TZD: thiazolidinediones   
 
 
Table A11: Survival Analysis (Analysis of Maximum Likelihood Estimates)  
Parameter  DF Parameter
Estimate
Standard
Error
Chi-Square Pr > ChiSq Hazard
Ratio
AGE  1 -0.01009 0.00813 1.5419 0.2143 0.990
SEX 1 1 -0.02412 0.11178 0.0466 0.8292 0.976
cci  1 0.19789 0.09127 4.7008 0.0301 1.219
pdcs  1 0.0008417 0.00174 0.2344 0.6283 1.001
pdct  1 -0.00648 0.00159 16.5827 <.0001 0.994
Difference in PDC test statistic: 6.5447 (p=0.0105); Outcome variable: Diabetes ER; pdcs: 
PDC for sulfonylurea; pdct: PDC for thiazolidinediones 
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Table A12: Survival Analysis (Analysis of Maximum Likelihood Estimates)  
Parameter  DF Parameter
Estimate
Standard
Error
Chi-Square Pr > ChiSq Hazard
Ratio
AGE  1 -0.01016 0.00815 1.5511 0.2130 0.990
SEX 1 1 -0.02674 0.11183 0.0572 0.8110 0.974
cci  1 0.20215 0.09158 4.8722 0.0273 1.224
pdcs_c  1 0.0005078 0.00232 0.0478 0.8269 1.001
pdct_c  1 -0.00710 0.00215 10.9314 0.0009 0.993
Difference in cumulative PDC test statistic: 3.8774 (p=0.0489); Outcome variable: Diabetes 
ER pdcs_c: cumulative PDC for sulfonylurea; pdct_c: cumulative PDC for thiazolidinediones 
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Table A13: Survival Analysis Hazard Estimates  
Measurement 
Period Model Approach
Parameter 
estimate Std. Err P 
Hazard 
Ratio  
30 days 
 
Uni 
All -0.3257 0.10831 0.0026 0.722 
Atlst1 -0.4188 0.12117 0.0008 0.658 
Avg -0.0053 0.00149 0.0005 0.995 
Both -0.3318 0.10845 0.0022 0.718 
Max -0.0045 0.0015 0.004 0.996 
Min -0.004 0.00122 0.0011 0.996 
Mul 
All -0.2851 0.10979 0.0094 0.752 
Atlst1 -0.3688 0.12367 0.0029 0.692 
Avg -0.0046 0.00153 0.0024 0.995 
Both -0.2911 0.10993 0.0081 0.747 
Max -0.0038 0.00153 0.0125 0.996 
Min -0.0035 0.00124 0.0043 0.996 
90 days 
Uni 
All -0.3969 0.11286 0.0004 0.672 
Atlst1 -0.6151 0.1168 <0.0001 0.541 
Avg -0.0066 0.00165 0.0001 0.993 
Both -0.387 0.11342 0.0006 0.679 
Max -0.0058 0.00166 0.0009 0.994 
Min -0.005 0.00136 0.0002 0.995 
Mul 
All -0.3588 0.11458 0.0017 0.699 
Atlst1 -0.5796 0.1195 <0.0001 0.56 
Avg -0.0059 0.00169 0.0005 0.994 
Both -0.3487 0.11511 0.0025 0.706 
Max -0.0051 0.00171 0.0027 0.995 
Min -0.0045 0.00138 0.0011 0.995 
Outcome: any diabetes related ER; Uni: univariable; Mul: Multivariable; PDC measured 
for each period 
Atlst1: At least one approach; Avg: Average approach; Max: Maximum approach; Min: 
Minimum approach 
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Table A14: Survival Analysis Hazard Estimates 
Measurement 
Period Model Approach
Parameter 
estimate Std. Err P 
Hazard 
Ratio 
30 days 
 
Uni 
All -0.4485 0.11012 <.0001 0.639 
Atlst1 -0.5847 0.11832 <.0001 0.557 
Avg -0.0053 0.00149 0.0005 0.995 
Both -0.4632 0.11217 <.0001 0.629 
Max -0.0077 0.00229 0.0015 0.992 
Min -0.0064 0.00167 0.0002 0.994 
Mul 
All -0.4081 0.11191 0.0003 0.665 
Atlst1 -0.5386 0.12158 <.0001 0.584 
Avg -0.0046 0.00153 0.0024 0.995 
Both -0.423 0.11391 0.0002 0.655 
Max -0.0066 0.00238 0.0056 0.993 
Min -0.0057 0.00171 0.001 0.994 
90 days 
Uni 
All -0.3993 0.11268 0.0004 0.671 
Atlst1 -0.4999 0.12328 <.0001 0.607 
Avg -0.0066 0.00165 0.0001 0.993 
Both -0.4214 0.11471 0.0002 0.656 
Max -0.0074 0.00234 0.0026 0.993 
Min -0.0058 0.00172 0.001 0.994 
Mul 
All -0.3601 0.11456 0.0017 0.698 
Atlst1 -0.4547 0.12659 0.0003 0.635 
Avg -0.0059 0.00169 0.0005 0.994 
Both -0.3828 0.11654 0.001 0.682 
Max -0.0064 0.00243 0.0083 0.994 
Min -0.005 0.00176 0.0042 0.995 
Outcome: any diabetes related ER; Uni: univariable; Mul: Multivariable; PDC measured 
cumulatively up to a period  
Atlst1: At least one approach; Avg: Average approach; Max: Maximum approach; Min: 
Minimum approach  
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Table A15: Concordance Analysis on Optimal Cut-off 
 
Measurement Model Approach C-stat/ PL80 Maximization Concordance 
Cumulative 90 
day 
Multivar 
At least one/ 
max 80 
0.5672/12.094 75% no 
Both/min 80 0.5683/11.048 75% no 
Univar 
At least 
one/max 80 
0.5457/22.031 80% yes 
Both/min 80 0.5489/9.3371 75% no 
90 day 
Multivar 
At least one/ 
max 80 
0.582/15.2100 80% yes 
Both/min 80 
0.5679/13.879
0 
75% no 
Univar 
At least one/ 
max 80 
0.5614/25.721
0 
80% yes 
Both/min 80 
0.5475/11.887
0 
75% no 
Cumulative 30 
day 
Multivar 
At least one 
/max 80 
0.5728/18.242 80% yes 
Both/min 80 0.571/14.18 75% no 
Univar 
At least one/ 
max 80 
0.5531/22.376 80% yes 
Both/min 80 0.5529/17.619 75% no 
30 day 
Multivar 
At least one/ 
max 80 
0.5664/8.4171 80% yes 
Both/min 80 0.5639/7.0427 85% no 
Univar 
At least one/ 
max 80 
0.5385/11.136 85% no 
Both/min 80 0.541/9.4027 85% no 
Outcome variable: Any diabetes ER;  C-stat: Concordance statistics (CT from Kremers);  
PL80: partial likelihood statistic of PDC dichotomized at 80%;  Multivar: multivariable 
model;  Univar: univariable model;  Max 80: dichotomization of maximum approach at 80%;  
Min 80: dichotomization of minimum approach at 80%  
* statistic not significant at p=0.0033  
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Table A16: Comparison Pre-ER and Post-ER Adherence 
Variable N* Mean Std Dev Minimum Maximum 
pdcs_e1 525 76.08 30.56 0 100 
pdcs_e2 801 74.27 32.26 0 100 
pdcs_e3 801 73.09 34.35 0 100 
pdcs_e4 801 71.80 34.25 0 100 
pdcs_e5 801 68.66 36.49 0 100 
pdcs_e6 546 69.75 36.47 0 100 
pdct_e1 525 78.37 30.79 0 100 
pdct_e2 801 75.84 32.61 0 100 
pdct_e3 801 71.39 35.96 0 100 
pdct_e4 801 70.01 36.68 0 100 
pdct_e5 801 67.13 38.95 0 100 
pdct_e6 546 66.28 39.45 0 100 
pdcs_b 801 76.68 26.48 0 100 
pdcs_a 801 68.40 33.75 0 99.81 
pdct_b 801 77.39 26.98 0 100 
pdct_a 801 65.77 35.71 0 99.81 
 
Pdcs_ex: PDC for SU at quarter x; Pdct_ex: PDC for TZD at quarter x; Pre-ER and 
post-ER quarters are 1 through 3 and 4 through 6, respectively;  
Pdcx_b: Average PDC for SU/TZD estimated on all available days before ER  
Pdcx_a: Average PDC for SU/TZD estimated on all available days after ER 
*Subjects were available for observation for at least 180 days preceding and 
following an all-cause ER event.  
 
 
 
Table A17: Paired t-test Between Pre-ER and Post-ER Adherence 
Medication N* Mean** Std Dev 95% CI t-statistic p-value 
SU 801 -8.28 24.20 -9.96, -6.60 -9.68 <0.0001 
TZD 801 -11.6205 24.98 -13.35, -9.89 -13.1 <0.0001 
 
**Difference between average pre-ER and post-ER PDC for SU/TZD estimated on all 
available days before ER  
*Subjects were available for observation for at least 180 days preceding and following 
an all-cause ER event.  
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Table A18: Latent Growth Curve Modeling Analysis of Multiple Medication 
Adherence 
Model N* Parameter Correlation P-value 
Uncon. Grt 1 3772 
Int-SU Int -TZD 0.6099 <0.0001 
Slp -SU/ Slp -TZD 0.5975 <0.0001 
Uncon. Grt.: unconditional growth model with mean centered age and gender as 
covariates  
Int: Intercept; Slp: Slope 
SU: Sulfonylureas; TZD: Thiazolidinediones;  
*Subjects were available for 7 quarters of observation and all 7 quarters were included 
in the analysis. 
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APPENDIX: ADDITIONAL FIGURES 
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Y-axis: Partial likelihood estimate; X-axis: PDC dichotomization points at 65%, 70%, 75%, 
80%, and 85% 
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Figure A1: Quarter-wise Analysis on All-cause ER Visit
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Y-axis: Partial likelihood estimate; X-axis: PDC dichotomization points 
 
 
 
2
7
12
17
22
27
PDC  65 PDC-70 PDC-75 PDC-80 PDC-85
Figure A2: Quarter-wise Analysis on Any Diabetes ER Visit
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Y-axis: Partial likelihood estimate; X-axis: PDC dichotomization points 
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Figure A3: Month-wise Analysis on All-cause ER Visit
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Y-axis: Partial likelihood estimate; X-axis: PDC dichotomization points 
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Figure A4: Month-wise Analysis on Any Diabetes ER Visit
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